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-SUMMARY.
The oxidative metabolism of both drugs and steroids 
occurs mainly as a consequence of utilising the hepatic 
monooxygenase system (Kuntzman et al, 1964). It has been 
shown that the activities of various hepatic enzymes are not 
constant, but are subject to regulation by the endocrine 
system, and also by hormones. The main classes of hormones 
which have been implicated in the regulation of hepatic 
metabolism are; (a) androgens, as extensively reviewed by 
Skett & Gustafsson (1979) and Gustafsson and coworkers 
(1980); (b) the pituitary hormones, including prolactin 
(Colby et al, 1974) and growth hormone (Colby et al, 1974; 
Mode et al, 1981); and (c) the pancreatic hormones, 
particularly insulin (Kato & Gillette, 1965; Kato et al, 
1970).
As the different hormonal pathways within the body are 
subject to complex interactions, and since some hormones 
have different secretion profiles in male and female 
animals, the precise mechanism by which hormones act to 
regulate the activity of hepatic enzymes has not yet been 
fully elucidated.
One mechanism by which hormones can produce their 
intracellular effects is by stimulating the hydrolysis of 
membrane-bound phospholipids. The consequence of this 
hydrolysis is that two intracellular second messengers are 
produced, inositol-1,4,5-trisphosphate, which causes an 
elevation in intracellular free calcium levels, and 
1,2-diacylglycerol, which interacts with phosphatidylserine 
and calcium to activate the phosphorylating enzyme, protein
kinase C. Activation of protein kinase C by receptor- 
mediated inositol phospholipid hydrolysis, relays 
information across the cell membrane to regulate a variety 
of intracellular processes, and hormonal activation of 
protein kinase C in the liver has been reported.
Vasopressin is known to affect hepatic enzymes, such as 
glycogen synthetase (Blackmore et al, 1986a; Ahmad et al, 
1984) and glycogen phosphorylase (Barritt et al, 1988), and 
vasopressin also has general effects upon hepatic events, 
especially ax-mediated adrenergic effects (Garcia-Sainz et 
al, 1986). Angiotensin II has also been reported to have 
hepatic effects mediated through activation of protein 
kinase C (Garcia-Sainz et al, 1986; Garcia-Sainz & 
Hernandez-Sotomayor, 1987). Recently, some actions of 
insulin have also been attributed to protein kinase C 
activation (Acevedo-Duncan et al, 1989; Cooper et al, 1987; 
Gomez et al, 1988), although evidence implicating hepatic 
effects of insulin through protein kinsae C are still 
contradictory.
Recently, it has been demonstrated that, in a 
reconstituted microsomal membrane system, protein kinase C, 
and protein kinase A, are capable of phosphorylating 
cytochrome P450, the terminal oxidase in hepatic mono­
oxygenases (Pyerin et al, 1983; Pyerin et al, 1987).
It seemed possible, therefore, that stimulation of 
inositol phospholipid hydrolysis, and therefore of protein 
kinase C and subsequent phosphorylation of cytochrome P450, 
or other proteinaceous components, may be one mechanism by 
which hepatic monooxygenase activity could be regulated by
xx i
hormones.
The proposed aim of the present study was to try to 
determine whether or not activation of protein kinase C in 
the rat liver could influence the activity of hepatic 
monooxygenases, and to try to elucidate the underlying 
mechanism of any effect which was observed. This study was 
conducted using isolated rat hepatocytes in an attempt to 
avoid complex hormonal interactions, and to try to represent 
a more physiological situation than is often encountered 
during in vitro studies.
To activate protein kinase C directly, tumor-promoting 
phorbol esters and synthethic diacylglycerols were used. 
Phorbol esters are reported to act solely through protein 
kinase C (Niedel et al, 1983; Castagna et al, 1982) and they 
are convenient probes of protein kinase C activity in 
isolated cell systems. Hormonal activation of protein 
kinase C, via stimulation of inositol phospholipid 
hydrolysis, was investigated with vasopressin and 
angiotensin II, and the role of elevating intracellular 
calcium was investigated by the use of the ionophore A23187. 
The effect of activating protein kinase C upon the 
metabolism of the endogenous steroid 4-androstene-3,17-dione 
was ascertained after various times of incubation with the 
different compounds.
It was found that activation of protein kinase C with 
all of the compounds, except angiotensin II, produced a 
time-dependent inhibition in the activity of all of the 
enzymes metabolising 4-androstene-3,17-dione. This 
inhibition of enzymes activity was not sex-dependent, males
xxi i
and female were both affected to the same extent. With 
vasopressin, a biphasic pattern of enzymes inhibition was 
observed, an effect which implies a dependency on 
diacylglycerol initially, with the later effect being more 
dependent upon calcium.
Angiotensin-II failed to show any inhibition of enzyme 
activity, and in contrast showed a stimulation of enzyme 
activity. Angiotensin II is known to affect both protein 
kinase C and protein kinase A and the stimulation seen with 
angiotensin II is possibly a reflection of some complex, but 
poorly understood, interaction between the two cascade 
systems.
Inhibition of enzyme activity appeared to be solely 
dependent upon the activation of protein kinase C. Using 
kinase inhibitors, as originally described by Kase and his 
group (Kase et al, 1986; Kase et al, 1987), we determined 
that only the specific protein kinase C inhibitor, K252b, 
was capable of preventing inhibition of enzyme activity in 
the presence of phorbol esters. The involvement of protein 
kinase C was further implicated by the results of the 
protein kinase C translocation assay, a recognised method 
for implying protein kinase C in a biological phenomenon.
We found that protein kinase C could be translocated from 
the cytosol to the plasma membrane in the presence of 
phorbol esters, which are reported to have protein kinase C 
as their intracellular receptor (Niedel et al, 1983).
By using the protein synthesis inhibitor cycloheximide, 
it became further apparent that the inhibition of enzyme 
activity also had a requirement for protein synthesis.
The possibility that -the effects of protein kinase C 
upon enzyme activity were due to the phosphorylation of 
cytochrome P450, as had been reported previously in in vitro 
studies (Pyerin et al, 1987), was also examined. We were 
unable to detect any incorporation of 32P into either 
immunoprecipitated cytochrome P4502c (P450IIC11), a 
constitutive enzyme thought to be responsible for up to 90% 
of hydroxylation of 4-androstene-3,17-dione at the 16a 
position (Waxman, 1984), immunoprecipitated cytochrome 
P450PB3a (P450IIB1), the major phenobarbital-inducible 
enzyme, immunoprecipitated cytochrome P450MC-lb (P450IA1), 
the major 3-methylcholantherene-inducible isozyme, or 
immunoprecipitated cytochrome P450UT-1 (P450IIA1), the 
steroid 7a-hydroxylase, following incubation with 50nM 4p- 
phorbol-12-myristate-13-acetate. This implies that 
phosphorylation of cytochrome P450 may not be a 
physiological effect of activting protein kinase C.
Further investigation into the role of the 
NADPH-cytochrome P450 enzyme system in protein kinase 
C-dependent effects revealed that, the inhibition of steroid 
metabolising enzyme activity by protein kinase C was not 
dependent upon either the availability or rate of loss of 
the cofactor NADPH, or the activity of cytochrome c (P450) 
reductase.
Further phosphorylation studies failed to reveal any 
specific protein which may have been responsible for the 
actions of protein kinase C upon enzyme activity.
In conclusion, the results of this study revealed that 
activation of the phosphorylating enzyme, protein kinase C,
in the isolated rat hepatocyte caused a sex-independent, 
time-dependent inhibition of the activity of the enzymes 
metabolising the steroid substrate, 4-androstene-3,17-dione. 
This effect was apparently independent of the 
phosphorylation of cytochrome P450, and independent of any 
effect on a specific component of the cytochrome P450 enzyme 
system. The precise mechanism of action of protein kinase C, 
although not fully elucidated in this study, appears to have 
a requirement for gene expression and de novo protein 
synthesis. We propose that inositol phospholipid hydrolysis 
and activation of protein kinase C may be one mechanism 
through which the activity of hepatic monooxygenases are 
regulated.
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INTRODUCTION
1Introduction.
1.1 Historical Background
1.1(a) Discovery of hepatic metabolism.
During the last century, it became apparent that 
foreign chemicals which were taken into the body of an 
animal were subsequently excreted in the urine and faeces. 
The first metabolic pathway to be elucidated in mammals was 
the formation of hippuric acid, which was found to be the 
glycine conjugate of ingested benzoic acid and was excreted 
from the body in the urine (Keller, 1842).
The early ideas about the detoxification of compounds
were proposed by Baumann (1876), although the concept of
detoxifying a parent compound to produce less harmful
metabolites was not developed for another twenty years (Lang 
1894; Neumeister, 1895).
It became apparent that the body possessed a variety of 
protective measures which it could employ to aid the 
entrance of foreign compounds (xenobiotics) into the 
systemic circulation, and once these compounds had entered 
the systemic circulation, hepatic metabolism came into play 
in order to dispose of the xenobiotics from the body.
The original work upon metabolism was concerned with 
the metabolism of chemicals and ingested drugs, and 
extensive work by Williams (1959; 1967) led to the 
determination of detailed pathways of the routes of 
metabolism for many different xenobiotics.
Eventually, it was discovered that hormones such as 
testosterone, could also be metabolised in the liver (Conney 
& Klutch, 1963) and it was postulated that steroid
2metabolism and xenobiotic metabolism could be performed by 
the same enzymes within the body (Kuntzman et al, 1964).
Metabolism of xenobiotics in the body can be broadly 
described by two phases, as described by Williams (1959).
The first type is Phase 1 metabolism and this is principally 
concerned with the oxidation, reduction, hydration or 
hydrolysis of a parent compound. After Phase 1 metabolism, 
Phase 2 metabolism subsequently occurs and the principle of 
a Phase 2 reaction is that metabolites are combined with 
hydrophobic endogenous compounds, in a process commonly 
referred to as conjugation. Conjugation of a compound 
greatly facilitates the excretion of the compound in the 
urine, as it makes the compound more water soluble. Phase 1 
and 2 reactions can occur simultaneously, the function of 
Phase 1 metabolism being to transform a parent compound into 
a form which can be readily conjugated by Phase 2 (Caldwell, 
1982). Phase 1 and 2 processes, although they have clearly 
distinct functions, are part of one overall process and it 
is important that they are considered in this context.
Phase 2 conjugation reactions will not be considered in 
this thesis, although they have been extensively reviewed 
(Williams, 1967; Caldwell, 1982).
1.1(b) Discovery of hepatic microsomal metabolism.
In the 1940s, intensive study into hepatic drug 
metabolism began, when it was realised that rat liver 
homogenates could biotransform compounds which had 
carcinogenic properties. Mueller and Miller (1949) observed
that the reductive cleavage of the carcinogenic dye 
4-dimethylaminoazobenzene yielded dimethylphenyldiamine and 
aniline as products in a microsomal fraction of liver 
homogenates. The same group later showed (Mueller & Miller, 
1953) that in order for hepatic microsomal systems to 
function optimally, molecular oxygen, reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) and reduced 
nicotinamide adenine nucleotide (NADH) had to be present.
Several years later, Brodie and coworkers (1955) 
characterized a virtually identical system to that of 
Mueller and Miller, in rabbit microsomes. This system had 
identical requirements for oxygen, NADPH and NADH in order 
to act optimally and through a variety of metabolic 
pathways, the system could perform a range of metabolic 
reactions.
The requirement of microsomal drug metabolising enzymes 
for both molecular oxygen and a reducing agent (NADPH) were 
enigmatical, until it was shown independently (Mason, 1957; 
Hayaishi, 1964) that certain oxidases transfer one atom of 
molecular oxygen to the substrate to form a hydroxylated 
product, while the other oxygen atom undergoes two 
equivalent reductions to form a molecule of water. Mason 
(1957) designated the enzymes the mixed function oxidases, 
while Hayaishi (1964) referred to the enzymes as the mono­
oxygenases. Posner and his group (1961), by using 
radiolabelled molecular oxygen, proved that the oxygen 
utilised in metabolic pathways was derived from molecular 
oxygen and not cellular water.
1.1(c) Discovery of cytochrome P450.
A reduced pigment in rat hepatic microsomes, that had 
an absorption band with a maximum wavelength at 450nm after 
binding to carbon monoxide, was first identified 
independently by both Klingenberg and Garfinkel in 1958.
This pigment was further characterized as a P450 hemoprotein 
in 1964 by Omura and Sato. They presented evidence that the 
cytochrome contained an integral heavy metal, which was iron 
(1964a), and after solubilisation, purification and studies 
as to the properties of this cytochrome (1964b), they named 
the pigment cytochrome P450 (pigment 450). The role of 
cytochrome P450 in microsomal mixed function oxidase systems 
was also established at this time (Cooper et al, 1965) and 
over the next twenty years it became apparent that multiple 
forms of cytochrome P450 can exist in mammals and other 
species.
Although first discovered in hepatic microsomes and 
associated with catabolic processes, cytochromes P450 also 
exist elsewhere in the body and cytochromes P450 located in 
the adrenal gland are vital in the biosynthesis of steroids. 
These include two microsomal enzymes, steroid 
17a-hydroxylase and steroid 21-hydroxylase, and two 
mitochondrial cytochromes P450, the cholesterol side chain 
cleavage enzyme and steroid llp-hydroxylase. The biology, 
enzymology and regulation of adrenal enzymes has been 
extensively reviewed (Fevold, 1983; Hall, 1985).
51.2 Cytochrome P450 and hepatic monooxygenases.
1.2(a) Spectrophotometric studies.
Omura and Sato (1964b) detailed the study of the 
molecular extinction coefficient of the reduced carbon 
monoxide difference spectrum of cytochrome P450 and this is 
considered to be the most accurate index of the cytochrome 
P450 content in microsomes of a variety of partially 
purified preparations.
In this study it was revealed that there are several 
unusual optical properties of cytochrome P450;
(i) Carbon monoxide produces an atypical shift of the Soret 
peak of the reduced cytochrome P450 to higher wavelengths 
with almost no change in the visible region.
(ii) Reduction of cytochrome P450 elicits only a small 
spectral change.
(iii) Ethyl isocyanide causes an unusual splitting of the 
Soret peaks at 430nm and 455nm.
(iv) Type I and Type II spectra can be produced by a variety 
of substrates, such as hexobarbitone (Type I) and aniline 
(Type II).
The changes in Type I and Type II binding for 
cytochrome P450 are interpreted as changes in the ligand 
field of the haem iron which is present in cytochrome P450. 
The haem prosthetic group of cytochrome P450 is
generally accepted to be f-erriprotoporphyrin IX (Maines and 
Anders, 1973) and one distinct difference between cytochrome 
P450 and other haem containing proteins, such as haemoglobin 
and myoglobin, is that the haem of cytochrome P450 is not 
covalently bound to the protein (Hall, 1987). Four of the 
six ligands of the iron of cytochrome P450 are known to be 
coordinated with the pyrrole nitrogen (Gibson & Tamburini, 
1984), whilst the fifth ligand is thought to be a mercaptide 
link, probably involving thiolate (Mason, 1965; Waterman & 
Mason, 1972). The nature of the sixth ligand of the haem is 
unclear at the present time, although histyl imidazole (Dus, 
1976) and oxygen in the form of water, (Griffin & Peterson, 
1975) have both been implicated.
As well as combining with carbon monoxide and absorbing 
at 450nm, the haem of cytochrome P450 also has a natural 
absorption spectrum, which is produced in the absence of 
carbon monoxide. This absorption is dependent upon the 
arrangement of electrons in the d-orbital of the iron. At 
any one given instant, the electrons of iron within the d 
orbitals in a single molecule of cytochrome P450 exists 
entirely in a low spin (S = 1/2) or entirely in a high spin 
state (S = 5/2). In a low spin state, one electron is 
unpaired (S = 1/2) whilst in a high spin state 5 electrons 
are unpaired (S = 5/2). The time spent in each spin state 
is determined by a dynamic equilibrium between the two 
states and is established by the conformation of the protein 
associated with the haem in the presence of a substrate. For 
example, with Type I substrates, the substrate perturbs the
7protein by binding to a sibe on the hydrophobic portion of 
the protein, near to the iron. This causes a shift in the 
dynamic equilibrium into the high spin state. Type II 
substrates combine with the iron molecule itself and cause a 
shift in the equilibrium towards the low spin state. 
Confusion arises in spectral studies with some substrates 
which are hydroxylated by cytochrome P450, such as benzene 
and barbitone, but do not produce a binding spectra (Imai & 
Sato, 1967); as there is no absorption spectra, these 
substrates cannot be classified under the Type I and Type II 
headings. In the absence of any substrate, the equilibrium 
between the two spin states is in favour of a low spin 
configuration of electrons and this produces a major 
absorption peak at 420nm which is referred to as the Soret 
peak (Hall, 1987).
1.2(b) NADPH-Cytochrome P450 reductase.
The equation summarising cytochrome P450-dependent 
biotransformation reactions is shown below;
cyt P450
RH + 02 + H+ + N A D P H -----------> NADP+ + H20 + ROH
The molecular oxygen binds to the haem component of 
cytochrome P450, which is present in its oxidised ferric 
form, and upon oxidation of the substrate the haem iron is 
reduced to its ferrous form. Reoxidisation completes the 
cycle.
The electrons in the above equation are transferred 
from NADPH to cytochrome P450, in order to reduce the
8cytochrome. The electron transfer is not a direct pathway 
and the electrons pass through a flavoprotein electron 
carrier and from there to cytochrome P450. The electron 
carrier is NADPH-cytochrome P450 reductase and its ability 
to function as an electron carrier is due to the composition 
of this enzyme. The reductase contains two separate flavin 
moeities, which are flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN) (Iyanagi & Mason, 1973), making 
NADPH-cytochrome P450 reductase rather unusual because most 
other flavoproteins contain only FMN or FAD. The pathway by 
which NADPH-cytochrome P450 reductase acts to transfer 
electrons is summarised below;
NADPH + H+ — > ( F A D ----- > FMN) — > Cytochrome P450
NADPH Cyt.P450 Red.
The need for an intermediary electron transfer flavo­
protein is apparent when it is considered that (NADPH and 
H+ ) is a 2 electron donor system, and cytochrome P450 can 
only accept one electron at a time. NADPH-cytochrome P450 
reductase is thought to act as a "transducer" of reducing 
equivalents by accepting the electrons from NADPH and 
transferring them sequentially to cytochrome P450.
It has been discovered that within the microsomal 
membrane, there is an excess of cytochrome P450 molecules 
compared to the number of molecules of NADPH-cytochrome P450 
reductase. For each molecule of reductase there are between 
20 and 30 molecules of cytochrome P450, implying that 
NADPH-cytochrome P450 reductase can act as the electron 
carrier for numerous molecules of cytochrome P450.
9There have been two theories proposed for the spatial 
arrangement of cytochrome P450 and the reductase within the 
cell membrane. One theory proposes that there is a "rigid 
arrangement" of the two compounds with the reductase 
surrounded by a cluster of cytochrome P450 molecules in a 
structurally organised manner, whereas the "fluid " theory 
proposes that the reductase and the P450 molecules are 
surrounded by a sheath of phospholipids and this permits 
free movement through the membrane of each component. 
Evidence for each theory has been reported (Peterson et al, 
1971; Yang et al, 1977) .
1.2(c) The sequence of events in cytochrome P45O-dependent 
metabolism.
The central feature of the cytochrome P450 catalytic 
cycle is the ability of the haem iron to undergo cyclic 
oxidation and reduction reactions by the pathway summarised 
in figure 1. These changes in the state of the haem occur 
in close association to substrate binding and oxygen 
activation. The molecular details of the cytochrome 
P45O-dependent hydroxylation reactions are briefly 
summarised below into the seven major stages.
Stage 1 - Substrate binding.
This stage is well documented and it involves drug 
binding to the oxidised (ferric) form of cytochrome P450.
The way in which substrates bind to cytochrome P450 was 
characterised in the late 1960s by Schenkman into three main 
categories, Type I, Type II and modified Type II (Schenkman
Fe3+ (ROH)
[Fe-0]3+
Figure 1:
The catalytic cycle of cytochrome P450.
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et al, 1967) and the mode of binding of each substrate 
determines which category of substrate a drug belongs to. 
Each substrate causes a characteristic spectral perturbation 
of the haemoprotein of the cytochrome P450 molecule and each 
type of substrate has its own characteristic binding site.
Type I substrates bind to the polypeptide chain of the 
apoprotein and change the conformation of the protein and 
hence the ligation of the haem prosthetic group (White & 
Coon, 1980). This conformational change of the protein 
shifts the spin state of the cytochrome to high spin and 
results in a characteristic spectral change (Type I spectral 
change). The Type I spectra is characterized by a maximum 
absorption at 390nm and a minimum absorption at 420nm in the 
difference spectrum. The increase in absorbance at 390nm 
reflects the conversion to a high spin state upon binding of 
the substrate.
Type II substrates are generally nitrogenous bases and 
it is thought that they ligate to the haem iron of 
cytochrome P450 which produces a conformational change to 
the low-spin, 6 co-ordinated state (Schenkman et al, 1967). 
The spectral pattern produced by Type II substrates has an 
absorbance minimum at 395nm and a maximum at 430nm.
The final type of substrate are modified Type II 
substrates (reverse Type I) and it is thought that these 
substrates act by displacement of an endogenous component 
which is usually bound to cytochrome P450 at the Type I 
binding site, or by binding to the sixth coordinate position 
on the haem molecule (Peterson et al, 1971). Modified Type 
II substrates produce a spectral change which is maximum at
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420nm and minimum at 390nm, that is the exact reverse of the 
spectra produced by Type I substrates.
It is generally assumed that Type I substrates (e.g. 
hexobarbitone and natural steroids) act in a more 
physiological manner than the Type II substrates (e.g. 
aniline) and Type I substrates are, therefore, more widely 
used to investigate the regulatory control of cytochrome 
P450.
Stage 2 - Electron transfer.
Stage 2 involves the transfer of the first electron 
from NADPH-cytochrome P450 reductase to cytochrome P450, a 
process which results in a conversion of cytochrome P450 
from an oxidised ferric form to a reduced ferrous form.
The high spin / low spin equilibrium of cytochrome P450 
may well be an important factor in mediating the first 
electron transfer step and it appears that the fully reduced 
state of the low potential flavin protein acts as the 
electron donating species.
Stage 3 - Binding of oxygen.
Once the iron of cytochrome P450 has been reduced to 
its ferrous form, molecular oxygen then binds to the binary 
ferrous cytochrome P450-substrate complex at the sixth 
coordinate position of the haem. The binding of a substrate 
molecule in stage 1 displaces the sixth coordinate ligand 
and thus facilitates the binding of molecular oxygen (Wolf 
et al, 1988).
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Stage 4 - Electron insertion and oxygen "activation".
Insertion of the second electron causes the oxygen to 
become a reactive species and an internal rearrangement of 
the electrons then reoxidises the iron to its ferric form. 
Although extensive work has been performed, the exact nature 
of this reactive oxygen species and the precise mechanism of 
activation of the species remains poorly understood. White 
and Coon (1980) have reviewed this area of cytochrome 
P450-dependent reactions and they have tried to resolve some 
of the debate as to the nature of the reactive oxygen 
species.
Stages 5-7 in the catalytic cycle of cytochrome P450 
are still a subject of debate and although the events below 
are known to occur, the precise mechanisms remain to be 
elucidated. White and Coon have again proposed theories for 
each stage (1980).
Stage 5 - Cleavage of oxygen.
The activated oxygen species is cleaved to produce two 
separate atoms of oxygen. One combines with two hydrogen 
ions to yield water, whilst the other oxygen remains 
attached to the iron molecule.
Stage 6.
A hydrogen atom is removed from the carbon atom on the 
substrate. The hydrogen atom is combined with the oxygen to 
form a hydroxyl radical and as a consequence of removing 
hydrogen, a carbon radical is left on the substrate. These
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two radicals recombine and- the oxygen is thus transferred 
from the haem to the substrate to produce a hydroxylated 
product.
Stage 7 - Dissociation of product.
The hydroxylated product of stage 6 dissociates from 
the active site and this leaves haem in its ferric form, 
ready to repeat the cycle with the next molecule of 
substrate.
1.2(d) Other Phase I biotransformation pathways.
In section 1.2(c) hydroxylation of a substrate was used 
as an example to illustrate a Phase I reaction mediated by 
cytochrome P450. Cytochrome P450 is also involved in a 
variety of other oxidative metabolic reactions such as 
dealkylation, deamination, sulfoxidation and oxidation.
Most of these reactions proceed via a step which involves 
intermediate hydroxylation, and the hydroxylated 
intermediate then degrades to yield the final product. 
Although the final product is different for each type of 
reaction, all the reactions proceed through the the same 
initial pathway as illustrated in figure 1 (Brodie et al, 
1958) .
1.2(e) The involvement of lipid in drug metabolism.
In 1968, Lu and Coon discovered that in order for 
maximal fatty acid hydroxylation to occur, a heat stable, 
organic solvent-extractable factor was necessary. The same 
group later showed that lipid was required for the
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hydroxylation of carcinogens, steroids and other oxidative 
metabolic processes (Lu et al, 1969). The identity of this 
phospholipid was reported to be phosphatidylcholine (Strobel 
et al, 1970) and the involvement of phospholipid in 
microsomal hydroxylation reactions was further implied by 
other groups (Chaplin & Mannering, 1970; Eling & Di 
Augustine, 1971). These studies found that upon removal of 
approximately 70% of the total phospholipid content of 
microsomes, the metabolism of type I compounds was markedly 
reduced, whilst the binding of the type I substrate to the 
cytochrome P450 complex was completely prevented. Type II 
compounds, however, were found to have their binding and 
metabolism virtually unaffected by the removal of lipid.
In a repeat of the above experiments, Cater and his 
group (1972) suggested that the phospholipid dependence of 
hydroxylation reactions was due to the phospholipids 
relieving the inhibition caused by detergents, which were 
used to solubilise the protein.
In an attempt to resolve some of the controversy 
associated with the role of lipids in drug metabolism, Vore 
et al (1974) employed the use of lyophilised microsomes, 
which were more stable to organic extraction techniques and 
although the lipid is removed from them, the enzymes which 
remain within the microsomes are catalytically active.
Their study showed that removal of phospholipid (both 
phosphatidylcholine and phosphatidylethanolamine) caused a 
10-25% loss of cytochrome P450 and NADPH-cytochrome P450 
reductase. The enzymatic activity of these two enzymes, 
however, was reduced to 3 0-50% of control activities but
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upon addition of a total l-ipid extract, or synthetic 
phosphatidylcholine, the extracted microsomes expressed 
complete activity.
These studies imply that phosphatidylcholine is an 
essential component in the mediation of drug metabolism. 
Although the precise mechanism of action of the' phospholipid 
remains to be elucidated, it appears that the lipid factor 
may be essential for the transfer of electrons between NADPH 
and cytochrome P450 (Strobel et al, 1970).
1.2(f) Cytochrome b5 .
Although NADPH is the preferred source of reducing 
equivalents for cytochrome P450-linked mixed function 
oxidations, addition of NADH to an NADPH-containing medium 
has long been known to enhance the effect of NADPH (Conney 
et al, 1957). It was not until 1971, however, that 
Hildebrandt and Estabrook deduced that cytochrome b5 was a 
component of the hepatic cytochrome P450 monooxygenase 
system and that cytochrome b5 was responsible for the 
ability of NADH to stimulate cytochrome P450 monooxygenase 
activity. Cytochrome b5 is thought to be the carrier 
through which the second electron is transferred from NADH 
to cytochrome P45 0. Although NADPH via NADPH-cytochrome 
P450 reductase can also supply the second electron to 
cytochrome P450, the pathway through cytochrome b5 is 
thought to act in preference to the cytochrome P450 
reductase pathway, with NADH being the principal donor of 
the second electron in some systems (Imai & Sato, 1977). It 
has been shown that NADH alone is unable to support
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oxidative metabolism (Correia & Mannering, 1973).
1.3 Multiplicity of cytochrome P450.
1.3(a) Discovery of multiple forms of cytochrome P450.
In 1959, Conney and workers observed that 
benzo-a-pyrene administration resulted in an increase in the 
metabolism of benzo-a-pyrene and zoxazolamine, a decrease in 
the metabolism of pethidine and benadryl and little effect 
upon the metabolism of chlorpromazine. Later work with the 
classical inducers phenobarbital and 3-methylcholantherene 
(3-MC) led to the discovery that enzymes could be induced 
which had differing substrate specificities and also 
different carbon monoxide absorption spectra (Kuntzman,
1969; Sladek & Mannering, 1969). Multiplicity of cytochrome 
P450 has also been proposed on the basis of different rates 
of turnover for a variety of cytochrome P45O-dependent 
enzymes (Levin et al, 1974; Bradshaw et al, 1978)
1.3(b) Nomenclature of cytochrome P450.
One of the characteristics of cytochrome P450 research 
has been the confusing nature of the nomenclature of 
different forms of cytochrome P450. Every laboratory 
involved in cytochrome P450 purification has its own system 
of nomenclature and consequently, one cytochrome P450 can 
have a vast array of different names, all of which represent 
the same enzyme. The isolation and sequencing of many 
cytochrome P450 proteins, cDNAs and genes has facilitated 
the development of a cytochrome P450 classification system,
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which is based on primary amino acid sequence alignment data 
(Nebert et al, 1987). In this system, the cytochromes P450 
are grouped into a gene superfamily that is further 
subdivided into gene families and finally into gene 
subfamilies. To date, 13 gene families have been 
identified. There are problems associated with a cytochrome 
P450 nomenclature system based solely on sequence 
similarities, as expected due to the complexity of the 
cytochromes P450, their polymorphic nature and the fact that 
they are rapidly diverging.
The basics of the nomenclature system are as follows. 
The gene families are designated by Roman numerals, 
beginning with I . Gaps are left in the family numbers to 
allow for the addition of newly discovered gene families.
The primary hepatic drug metabolising enzymes currently 
comprise four gene families, designated I to IV. The 
extrahepatic cytochromes P450 involved in steroid 
biosynthesis, fall into families XVII (steroid 
17a-hydroxylase), XIX (P450 aromatase) and XXI (steroid 
21-hydroxylase) (Nebert et al, 1987). The mitochondrial, 
yeast and bacterial P450 gene families are referred to as 
XI, LI/LII and CI/CII respectively. Subfamilies are denoted 
with sequential capital letters and genes within a subfamily 
are indicated with sequential Arabic numbers.
For instance, there are eight subfamilies in the P450II 
gene family, designated A through H, and the next subfamily 
discovered would be called I . The individual genes are 
usually numbered depending on the order in which the 
sequence data was published. Once a cytochrome P450
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sequence has been determined, if a clear orthologous 
counterpart cannot be identified from another species which 
has been sequenced previously, then the cytochrome P450 is 
assigned the next consecutive number.
Table 1 lists some of the major rat cytochromes P450 
cloned and sequenced to date, along with their trivial 
names. Table 1 is only an example and is by no means 
exhaustive or complete.
A brief summary of each cytochrome P450 family is given 
below.
(i) The P450I gene family.
Two cytochrome P450 genes have so far been examined in 
mice (Gonzalez et al, 1985), rats (Hines et al, 1985), 
rabbits (Okino et al, 1985) and humans (Jaiswal et al,
1985) .
IA1 and IA2 genes appear to be ubiquitous in mammals 
and, for the most part, these enzymes have similar catalytic 
activities in several mammalian species. On the basis of 
the evolutionary conservation of IA1 and IA2 genes in 
mammals, and the ubiquitous nature of IA1, it has been 
tentatively proposed that these enzymes may be crucial for 
survival and may play a key role in the metabolism of 
critical endogenous substances. The role of IA1 in 
carcinogenesis has been reviewed (Gelboin, 1980).
(ii) The P450IIA gene subfamily.
The IIA1 and IIA2 genes are highly homologous, IIA2 
shares 93% of the nucleotide sequence and 88% of the deduced
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amino acid sequence of IIA-1 cDNA. These genes are regulated 
differently, however, during development and after 
administration of the carcinogen 3-MC.
IIA1 hydroxylates testosterone and other steroids at 
the 7a position (Matsunaga et al, 1988), with a minor 
metabolite resulting from hydroxylation at the 6a position. 
IIA2, in contrast, exhibits a high level of testosterone 15a 
hydroxylase activity and only about 5% of the total 
hydroxylated metabolites are due to hydroxylation at the 7a 
position®
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FAMILY/SUBFAMILY TRIVIAL NAME COMMENTS
P450IA1
P450IA2
P450IIA1
P450IIB2
P450IIC6
P450IIC7
P450IIC11
P450IIC12
P450IIC13
P450IID1
P450IID2
P450IIE1
P450IIIA1
P450IIIA2
P450IVA1
P450IVA2
Man P 1, rat c, Major 3-MC-inducible 
rabbit form 6. isozyme
Man P3 , rat d # Major isosafrole-induc- 
rabbit form 4. ible isozyme.Also 3-MC. 
Rat a Steroid 7a-hydroxylase.
Rat e Phenobarbitone-indicible.
RatPB-1, PB-C, Phenobarbitone-inducible,
k
Rat f
Rat h, M-l, 
2c, 16a 
Rat i, 2d, 
15p 
Rat g
Rat dbl 
Rat db2 
Rat j 
Rat PCN1
Rat PCN2 
Rat LAw
Rat IVA2
Hormone-independent. 
Cross-reactive with rat b, 
constitutive isozyme. 
Steroid 16a-hydroxylase.
Steroid 15p-hydroxylase.
Constitutive isozyme.Male- 
specific, strain-dependent 
Debrisoquine-4-hydroxylase.
Ethanol-inducible. 
Pregnenolone 16a-carbo- 
nitrile inducible.
Clofibrate-inducible, 
lauric acid w-hydroxylase.
Table 1; Nomenclature of some of the common rat 
cytochromes P450. From Gonzalez, 1989.
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(iii) The P450IIB gene sub-family.
The cDNAs for the P450b (P450IIB1) and P450e (P450IIB2) 
in rats were among the first to be isolated completely and 
sequenced, because they are strongly induced by 
phenobarbital and also specific polyclonal antibodies were 
available for these two isozymes. Both genes contain nine 
exons and only 40 nucleotide differences exist between the 
two mRNAs (Mizukami et al, 1983).
It has been known for several years that the rat IIB2
subfamily contains multiple genes and sequence data and 
published restriction maps suggest the presence of greater 
than six genes with considerable nucleotide similarities 
(Mizukami et al, 1983). It is unclear, however, whether all 
of these genes are expressed in the rat.
A third rat IIB gene was isolated from liver, 
designated IIB3 and has an amino acid sequence 77% similar
to IIB1 and IIB2 (Labbe et al, 1988). IIB3 is
constitutively expressed as a minor form in male and female 
rat liver and is not induced by phenobarbital.
(iv) The P450IIC gene subfamily.
The members of this subfamily of cytochromes P450 are, 
in most cases constitutively expressed. The IIC cytochromes 
P450 are also under developmental and sex-specific 
regulation and a few can be induced by phenobarbital.
Two members of the rat IIC family, designated P450 PB-1 
(Waxman & Walsh, 1984) and P450f (Ryan et al, 1984) have 
been isolated and protein sequences determined. PB-1 (also 
known as PB-C) is developmentally regulated in males and
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females (Waxman et al, 1985). P450f is also developmentally
controlled in a manner similar to PB-1 (Bandiera et al,
1986) and has a broad specificity and low catalytic activity 
toward a number of substrates.
The cytochrome P450 IIC11 designated P450h (Ryan et al, 
1984) metabolises testosterone at the 16a, 2a and 17 
positions. The cytochrome P450IIC11 is a male-specific gene 
and appears to be localised solely in the liver, as no mRNA 
of P450IIC11 was found in adult male lung, kidney or testes 
(Yoshioka et al, 1987).
(v) The P450IID gene subfamily.
The debrisoquine-4-hydroxylase P450, named dbl (IID1) 
has been purified from rat (Larry et al, 1984) and humans 
(Distlerath et al, 1985). This enzyme is noted for its 
polymorphic expression in humans and rats, and antibodies 
and cDNA probes have been used to study the molecular basis 
of the human and rat drug oxidation defect.
A second cDNA, db2 (IID2) has also been isolated and 
found to share a 78% cDNA-deduced amino acid homology with 
IID1. The IID subfamily has a unique lineage within the 
P450II family, caused as a consequence of the different 
evolution between humans and rodents, and the different 
dietary requirements of the two species.
(vi) The P450IIE gene subfamily.
A distinct ethanol-inducible form of P450, named IIE1, 
was first identified in rabbits (Koop & Coon, 1984) and 
later in rats (Patten et al, 1986) and humans (Wrighton et
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al# 1987). This enzyme can metabolise substrates such as 
ethanol, acetone, acetoacetate, diethyl ether, halothane, 
benzene and pyridine. The activity of IIE1 towards acetone 
oxidation suggests that IIE1 is involved in the pathway of 
gluconeogenesis during the fasting state.
The rat, rabbit and human IIE1 cDNAs have been isolated 
and sequenced and they are about 80% homologous in their 
deduced amino acid sequences.
(vii) The P450 IIH gene subfamily.
This is a chicken cytochrome P450 isozyme and was 
originally designated to the rat IIC6 subfamily. The 
precise sequence of this isozyme is still under 
investigation.
(viii) The P450III gene family.
The major cytochromes P450 in this family can be 
induced by the synthetic steroid pregnenolone 
16a-carbonitrile (Lu et al, 1972) and they have been shown 
to be unique from other cytochromes P450. The enzymes in 
the P450III family have catalytic activities for 
ethylmorphine N-demethylation, erythromycin demethylation 
and triacetyloleandomycin metabolism (Wrighton et al, 1985) 
and testosterone 60-hydroxylation (Waxman et al, 1985).
Most of the enzyme activity data associated with rat 
and human cytochromes P450 in the P450III family have been 
inferred from activity immunoinhibition data and data 
correlating an activity with levels of immunodetectable 
protein on Western blots. The reason for this is that
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reconstitution of enzyme activity from purified preparations 
of P450III enzymes has not been successful and as a 
consequence, the structure of the P450III genes from rats 
and humans have not been published as yet.
(ix) The P450IV gene family.
A clofibrate-inducible lauric acid w-hydroxylase, named 
P450IVA1, was first purified from rats (Tamburini et al, 
1984). This enzyme is very specific for fatty acid 
hydroxylations and has no detectable activity toward other 
substrates such as benzphetamine, ethoxyresorufin and 
testosterone. Cytochrome P450IVA1 can also be induced by 
other hypolipidaemic agents and is active in the oxidation 
of arachidonic acid.
1.4 Conserved domains in cytochrome P450 proteins.
1.4(a) Signal sequence and halt-transfer sequence for 
membrane insertion.
The membrane environment is highly suitable for 
cytochromes P450 because many cytochromes P450 substrates 
are hydrophobic and dissolve in the membrane lipid bilayers. 
The membrane also allows interactions with other cytochromes 
P450 and the electron donor enzyme NADPH-cytochrome P450 
reductase, for the microsomal enzyme. Highly specific 
cellular mechanisms allow the insertion of the cytochromes 
P450 and other intrinsic membrane proteins into the lipid 
bilayer. The microsomal cytochromes P450 are inserted by 
the signal sequence recognition particle and docking 
protein, reviewed by Sabatini et al (1982). Early studies
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with secretory and plasma -membrane proteins established the 
participation of amino-terminal hydrophobic segments called 
"signal sequences", which direct the insertion of the 
proteins into the membrane or the lumen of the endoplasmic 
reticulum. The signal sequence is cleaved in nearly all 
secretory products and most membrane proteins during their 
translation and membrane insertion.
The cytochromes P450 and other components of the 
microsomal mixed function oxidase system were found to be 
synthesised primarily on membrane-bound polyribosomes 
(Gonzalez & Kasper, 1981). This binding and insertion into 
the membrane are mediated by the hydrophobic amino-terminal 
sequence of these proteins.
The amino terminus of all eukaryote cytochromes P450 
contains an abundance of hydrophobic residues. An acidic 
residue that is near the initiation methionine is followed 
by about 14 to 20 residues of hydrophobic amino acids and 
then by several basic residues. It was suggested that the 
combined hydrophobic and basic segment probably serves as 
the "halt- transfer" signal (Sabatini et al, 1982). It 
appears that the cytochromes P450 are anchored to the 
membranes via their amino terminal and that the bulk of the 
enzyme is exposed to the cytoplasmic side of the endoplasmic 
reticulum (Finidori et al, 1987). This orientation is also 
supported by immunological studies in which membrane 
topology was investigated using antibodies to defined 
polypeptides located throughout the IIB1 primary sequences.
The mitochondrial cytochromes P450 are synthesized and 
transferred into membranes by a mechanism that is quite
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distinct from the insertion process for the microsomal 
enzymes. They are synthesized on membrane-free polysomes 
and released into the cytoplasm with an amino terminal 
peptide that is subsequently cleaved upon insertion into the 
mitochondria (Schatz, 1979). The length of the cleavable 
extrapeptides ranges from 37 to 56 amino acids and it was 
suggested that a conserved portion of this peptide, notably 
a periodic arginine and lysine distribution, serves to 
transport the cytochromes P450 across the outer membrane and 
into the mitochondrial compartment where they are then bound 
to the inner mitochondrial membrane. Microsomal and 
mitochondrial cytochromes P450 have, therefore, evolved 
distinct sequences common to some other cellular proteins 
that are required for their insertion into specific 
intracellular compartments.
1.4(b) Haem-binding, cysteine-containing peptide.
An excellent summary of the experiments leading to the 
conclusive identification of the fifth ligand to the haem at 
the active site of all the cytochromes P450 has been 
published (Gotoh & Fujii-Kuriyama, 1989). Briefly, early 
studies established that the thiolate of cysteine was 
involved in binding and two conserved cysteine-containing 
regions, designated HR1 and HR2, near the amino terminal 
half and the C-terminal half of the cytochrome P450, 
respectively, were identified as being highly conserved when 
mammalian and bacterial sequences were compared. Further 
evidence suggesting the C-terminal cysteine as the fifth 
ligand bound to the haem iron was provided by comparisons of
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other cytochrome P450 sequences. The crystal structure of 
the bacterial P450cam unequivocally established this 
cysteine as the haem-binding thiolate ligand (Poulos et al,
1986). This conserved sequence effectively serves as a 
fingerprint for a cytochrome P450 protein.
1.4(c) Cytochrome P450 membrane association models and 
predictions.
The topological association of a cytochrome P450 
molecule with the membrane has been predicted by comparative 
sequence analysis, including hydropathy plots of multiple 
mammalian cytochrome P45 0 proteins and extrapolations from 
the crystal structure of the soluble bacterial 
cytochrome P450cam. Several structural or biochemical 
features are probably common to the mammalian microsomal 
cytochromes P450 and are taken into consideration in the 
design of models: (a) cytochromes P450 are anchored to the
lipid bilayer by a hydrophobic amino terminus; (b) they 
interact with NADPH-cytochrome P450 reductase, an enzyme 
clearly exposed to the cytoplasmic side of the face of the 
membrane; (c) they react with many hydrophobic substrates 
and many of the products of cytochrome P450-mediated 
reactions are then substrates for other microsomal enzymes, 
such as UDP-glucuronyl transferase; and (d) the haem is 
either parallel or at a slight angle to the membrane 
surface.
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1.5 Regulation of cytochrome P450 gene expression.
1.5(a) Inducible genes.
1.5(a)(i) Phenobarbital-inducible cytochrome P450 genes.
The phenobarbital induction response was discovered 
more that 20 years ago. Administration of this drug 
resulted in a dramatic proliferation of liver endoplasmic 
reticulum membrane (Remmer & Merker, 1963) and an increase 
in the enzymes of the mixed function oxidase system 
(Orrenius et al, 1965). In 1975, Hutterer and his group 
reported that, as well as inducing cytochrome P450, 
phenobarbital also increased the size of the liver, the 
total microsomal protein content and the phospholipid 
content of the liver, implying that the effects of 
phenobarbital are not confined to an effect on cytochrome 
P450 monooxygenases but that there is a general 
proliferative effect upon the liver with phenobarbital.
The phenobarbital induction response provokes an 
increase in several mRNAs, including those coding for 
epoxide hydratase, NADPH-cytochrome P450 reductase (Hardwick 
et al,1983), UDP-glucuronyl transferase (Mackenzie, 1986) 
and cytochrome IIB1 and IIB2 (Atchison & Adesnik, 1983; 
Hardwick et al, 1983). Phenobarbital-induced mRNA 
accumulation is thought to be due to an increase in gene 
transcription rate (Atchison & Adesnik, 1983).
The IIB1 and IIB2 genes are coordinately regulated in 
the liver by phenobarbital, but as these two mRNAs exhibit 
97% nucleotide sequence similarity, oligonucleotide probes 
specific for the IIB1 and IIB2 genes have been used for 
quantitation (Omiecinski et al, 1985). The IIB2 gene is
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constitutively expressed, while IIB1 is transcriptionally 
inactive in untreated rats. Phenobarbital administration 
results in the induction of both mRNAs, IIB1 mRNA being more 
significantly induced than IIB2.
The expression of certain genes in the IIC family of 
rabbit and rat, and the rat IIA1 and IIA2 genes can also be 
induced by phenobarbital. Therefore, regulatory elements 
for phenobarbital inducibility appear to be conserved in 
many cytochrome P450 genes.
The cytochrome P450IIC7 (P450f) gene is subject to 
developmental inducibility with this gene becoming 
transcriptionally activated when rats reach puberty, and it 
is not significantly induced by phenobarbital when fully 
expressed in adult rats (Gonzalez et al, 1986a). A rat cDNA 
designated 1GC1, that shares 98% of the deduced amino acid 
sequence of cytochrome P450IIC7 (P450f), and a high level of 
the amino acid homology between 1GC1 and cytochrome P450IIC7 
(P450f) suggests that these cytochromes P450 may be allelic 
variants. The cytochrome P450IIC7 (P450f) and 1GC1 genes 
appear to be regulated differently, however. An 
oligonucleotide for 1GC1 revealed that this gene is 
activated by phenobarbital in immature rats (Barroso et al, 
1988). In contrast, only a slight increase in cytochrome 
P450IIC7 (P450f) protein was seen in 4 week old 
phenobarbital-treated rats (Bandiera et al, 1986).
Phenobarbital also induces two genes in the rat P450III 
family (Gonzalez et al, 1986b). Both the constitutively 
expressed male specific cytochrome P450IIIA2 (PCN-2) gene 
and the cytochrome P450IIIA1 (PCN-1) gene, a gene that is
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not expressed in either male or female untreated rats, are 
inducible by phenobarbital. Only cytochrome P450IIIA1 
(PCN-1) is induced by steroids, suggesting that these genes 
have overlapping regulatory controls for steroid 
inducibility and constitutive expression.
Data regarding the role of specific phenobarbital 
receptors or cis-acting DNA sequence elements in this 
induction process are lacking, possibly due to the low 
affinity of phenobarbital or its extensive metabolism by 
liver enzymes.
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1.5(a)(ii) Steroid-inducible cytochrome P450 genes.
The rat cytochrome P450IIIA1 (PCN-1) gene is induced by 
glucocorticoids such as dexamethasone and pregnenolone 
16a-carbonitrile. This induction is primarily the result of 
an activation of cytochrome P450IIIA1 (PCN-1) transcription 
(Simmons et al, 1987) and an increase in mRNA (Gonzalez et 
al# 1986b).
Of interest is the possible involvement of the 
glucocorticoid receptor (Govinda et al, 1985) which controls 
a variety of genes in the liver. Regulation of 
cytochrome P450IIIA1, however, seems to be distinct from the 
control of classical glucocorticoid-regulated genes, such as 
tyrosine aminotransferase. Cytochrome P450IIIA1 (PCN-1) 
induction requires about a 10-fold higher level of steroid 
than is needed to induce tyrosine aminotransferase and 
certain steroids that readily induce cytochrome 
P450IIIA1 (PCN-1) fail to induce tyrosine aminotransferase 
(Schuetz et al, 1984; Schuetz & Guzelian, 1984). These 
studies suggest that either cytochrome P450IIIA1 (PCN-1) 
gene activation may depend on other factors or that 
differences exist between these genes in their affinity for 
receptor-ligand binding to a cis-acting DNA control element.
1.5(a)(iii) Hypolipidaemic drug-inducible cytochrome P450 
genes.
The hypolipidaemic drug, clofibrate, induces a battery 
of enzymes, including the peroxisomal enzymes enoyl CoA: 
hydratase-3-hydroxyacyl-CoA dehydrogenase, fatty acyl CoA 
oxidase, 3-ketoacyl-CoA thiolase (Hashimoto, 1982) and the
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microsomal cytochrome P450IVA1 (Tamburini et al, 1984).
Many other hypolipidaemic agents, including aprofibrate and 
nafenopin also induce these enzymes. The net result of 
their induction is an increase in fatty acid w-oxidation.
The cytochrome P450IVA1, enoyl-CoA: hydratase-3-hydroxy acyl 
CoA dehydrogenase and fatty acyl CoA oxidase genes are 
transcriptionally activated by clofibrate administration. 
This activation is rapid and occurs within one hour of 
administration (Hardwick et al, 1987).
A second cytochrome P450 cDNA, designated 
cytochrome P450IVA2, has recently been isolated from a 
clofibrate-induced liver library and the cytochrome P450IVA2 
mRNA is markedly induced by clofibrate. A clofibrate 
receptor has recently been purified and it has a molecular 
weight of 70,000, and exists as a dimer of 140,000 (Lalwani 
et al, 1987).
1.5(a)(iv) Effect of haem on cytochrome P450 induction.
A relatively neglected area of study in recent years 
has been the effect of haem on cytochrome P450 induction.
In order that cytochrome P450 holoenzyme can accumulate, an 
adequate haem pool must be available to accomodate the newly 
synthesized apoprotein. The rate-limiting enzyme in 
haem biosynthesis, 5-aminolevulinate synthetase (ALV-5), is 
readily inducible by compounds such as phenobarbital 
(Granick, 1966) and 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) (Poland & Glover, 1973). This induction is due to 
transcriptional activation of the ALV-5 gene and a popular 
hypothesis is that the effect of these inducers is to
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indirectly decrease the haem pool by increasing the amount 
of apo-P450 (May et al, 1986). The induced apo-P450 
incorporates haem from the cellular haem pool and the 
resultant decrease in haem levels then derepresses the ALV-5 
gene. This metabolic end product control could be due to 
haem-modulated gene repression. Other evidence suggests 
that the level of haem mediates transcription of 
cytochrome P450 genes (Bhat & Padmanaban, 1988). It has 
been reported that inhibition of haem synthesis or 
stimulation of haem degradation blocks the induction of IIB2 
mRNA by phenobarbital.
1.5(B) Regulation of constitutively expressed cytochrome 
P450 genes.
1.5(b)(i) Transcriptional regulation during development.
One of the most interesting regulatory phenomena is the 
activation of cytochrome P450 gene transcription during 
development. At least four modes of constitutively 
expressed cytochrome P450 gene regulation have been 
described: (a) activation of expression immediately after 
birth; (b) activation of expression at the onset of puberty; 
(c) activation of expression in males or females referred to 
as "sex-imprinted" expression; and (d) specific suppression 
of gene activity in males or females at the onset of 
puberty.
Elevated levels of both the ethanol-inducible IIE1 and 
the IID1 and IID2 mRNAs have been detected immediately after 
birth in rats (Gonzalez et al, 1987; Song et al, 1986). 
Elevation of IIE1 mRNA was coincident with transcriptional
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activation of the IIE1 gene and begins within a few hours 
after birth. mRNA levels peak at the age of 6 days.
The mechanism governing this regulation is unknown; 
however, changes in the methylation state of the IIE1 gene 
correlated with transcription (Umeno et al, 1988). Using 
DNA restriction endonucleases that are sensitive to cytosine 
methylation, certain cytosine residues upstream of the IIE1 
transcription start site were found to be demethylated 
within 24 hours of birth. Further demethylation of 
cytosines, downstream of the start site, was detected at 1 
week and 10 weeks of age. It is not known whether this 
demethylation is a result of transcriptional activation of 
the IIE1 gene or if demethylation causes gene expression.
Two genes in the rat P450IIC family, cytochrome 
P450IIC6 (PB-1) and cytochrome P450IIC7 (P450f), are 
transcriptionally activated at the onset of puberty 
(Gonzalez et al, 1986). The cytochrome P450IIC7 (P450f) 
mRNA reaches a steady-state level in adult females that is 
about 2-fold higher than in adult males. The mechanism by 
which the cytochrome P450IIC6 (PB-1) and cytochrome P450IIC7 
(P450f) genes are activated is not fully elucidated.
1.5(b)(ii) Sex imprinting and gene expression.
Sex specific cytochromes P450 have been purified from 
rats (Cheng & Schenkman, 1982; Matsumoto et al, 1986; Morgan 
et al, 1986). Best studied are the male-specific and 
female-specific cytochrome P450 forms which are commonly 
designated cytochrome P450IIC11 (P450h) and cytochrome 
P450IIC12 (P450i), respectively (Ryan et al, 1982).
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Cytochrome P450IIC11 (P450h) is expressed only in adult male 
rats and this expression is dependent on androgen exposure 
both during the neonatal period and adulthood. Castration 
of neonates abolishes cytochrome P450IIC11 expression in 
adults, while castration of adults only partially decreases 
expression of the enzyme. This partial effect is eliminated 
if rats are supplemented with testosterone during adulthood, 
directly demonstrating a role for adult testosterone (Waxman 
et al, 1985). Similarly, testosterone injection to 
castrated rats during the first three days of life also 
results in significant cytochrome P450IIC11 (P450h) 
expression at adulthood, consistent with the proposal that 
this enzyme is one of the hepatic proteins that is subjected 
to neonatal "imprinting" or programming by androgen exposure 
(Einarsson et al, 1973; Gustafsson et al, 1983a).
The cDNA and gene sequences of cytochrome 
P450IIC11 (P450h) have been determined and a specific 
oligonucleotide probe has been used to quantitate 
cytochrome P450IIC11 (P450h) mRNA during development 
(Morishima et al, 1987). These studies established that the 
cytochrome P450IIC11 (P450h) mRNA is exclusively expressed 
in liver of adult male rats and absent in female liver and 
in several extrahepatic tissues in males and females. The 
increase in cytochrome P450IIC11 (P450h) probably results 
from the activation of gene transcription.
The rat cytochrome P450IIA2 gene is also male specific 
(Matsunaga et al, 1988). Expression of cytochrome P450IIA2 
mRNA is undetectable in females and is activated in males at 
the onset of puberty. The cytochrome P450IIA1 gene, on the
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other hand, is expressed in adolescent males and females and 
is specifically suppressed only in males at puberty (Nagata 
et al, 1987). Studies on the cytochrome P450IIA2 protein 
revealed that its expression in males is programmed by 
neonatal androgen exposure (Waxman et al, 1988).
The role of the pituitary hormones in the regulation of 
sex-specific cytochromes P450 has been extensively 
investigated (Kato et al, 1986; Morgan et al, 1986; Waxman 
et al, 1988a). Adult male rats have pulsatile secretion of 
pituitary growth hormone, while adult females have more 
constant levels, and these patterns are determined by both 
neonatal androgen exposure and adult testosterone levels 
(Jansson et al, 1985a). Hypophysectomy reduces expression 
of cytochrome P450IIC11 (P450h) and this can be reversed by 
periodic injections of growth hormone (Kato et al, 1986; 
Morgan et al, 1986). Cytochrome P450IIA2 expression in 
males, on the other hand, is not dependent upon pulsatile 
growth hormone secretion, unlike cytochrome P450IIC11 
(P450h) (Waxman et al, 1988a). Growth hormone secretion is 
also involved in the regulation of the female specific 
cytochrome P450IIC12 (P450i). Continuous infusion of growth 
hormone reestablishes levels of the female-specific 
cytochrome P450IIC12 (P450i) in hypophysectomised females 
(Kato et al, 1986) and this results from a specific increase 
in cytochrome P450IIC12 (P450i) mRNA levels (Mode et al,
1987). In some cases, growth hormone can suppress 
cytochrome P450 expression, as will be discussed below.
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1.5(b)(iii) Sex-specific gene suppression.
The sex-specific expression of certain male and female 
cytochrome P450s results from the suppression of gene 
expression. For instance, the expression of cytochrome 
P450IIIA2 (PCN-2) mRNA is specifically decreased in female 
rats when they reach puberty (Gonzalez et al, 1986b). This 
results in a loss of constitutively expressed testosterone 
60-hydroxylase in the female rat. Expression of 
cytochrome P450IIA1 mRNA is also decreased in males at 
puberty (Matsunaga et al, 1988; Nagata et al, 1987), 
resulting in a decline in IIA1 protein and its associated 
testosterone 7a-hydroxylase activity.
Growth hormone also appears to play a role in the 
suppression of cytochrome P450 gene expression. 
Hypophysectomy resulted in an increase in cytochrome 
P45GIIIA2 (PCN-2) and testosterone 60-hydroxylase activity, 
while high levels of growth hormone, administered either by 
intermittent injection or infusion, decreased levels of this 
enzyme in adult male rats (Kato et al, 1986; Waxman et al, 
1985; Waxman et al, 1988a). These data suggest that the 
developmental increase in cytochrome P450IIIA2 (PCN-2) 
expression is the result of continuously high levels of 
growth hormone as are found in adult females. Expression of 
the enzyme in immature males and females could be the result 
of low levels of growth hormone secretion. It was also 
suggested that suppression of cytochrome P450IIIA2 (PCN-2) 
expression in females could be the result of decreased 
circulating corticosteroid (Waxman, 1988).
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1.5(b)(iv) Developmental regulation of cytochrome P450 
induction.
The induction of proteins of the P450I and P450IIB gene 
families is also regulated during development. TCDD induces 
expression of the IA1 gene as early as 10 days of 
gestational age in the mouse (Tuteja et al, 1985).
Growth hormone has also been shown to have a role in 
regulation of rat IIE1 (Williams & Simonet, 1988). 
Hypophysectomy of male and female rats resulted in a 5-fold
and 10-fold, respectively, increase in IIE1 content. This
increase was partially repressed when these rats were 
treated with growth hormone. This is another example of 
suppression of cytochrome P450 expression by growth hormone 
that needs to be further examined at the gene level.
Hepatic induction of the rat IIB1 and IIB2 mRNAs by
phenobarbital is first apparent 2 days prior to birth (day
22 of gestation) and the ratio of inducible levels of these 
mRNAs varied as a function of age (Giachelli & Omiecinski,
1987). Induction of other cytochrome P450 genes, such as 
the steroid and clofibrate-inducible genes, has not been 
investigated in the developing rat. In general, most 
cytochromes P450 are not expressed or induced prior to 
birth. The cellular mechanisms controlling inducible, 
prenatal cytochrome P450 expression are currently unknown.
1.5(c) Posttranscriptional regulation of cytochrome P450.
Cytochrome P450IA2 is regulated to a large extent 
posttranscriptionally (Pasco et al, 1988). After comparing 
transcription rates and mRNA levels, it was concluded that
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IA2 mRNA is markedly stabilised in liver and extrahepatic 
tissue by TCDD administration. IA1# however, is regulated 
primarily at the transcriptional level.
When rats are treated with dexamethasone, mRNAs for 
IIB1/IIB2 and the NADPH-cytochrome P450 reductase are 
specifically stabilised in the absence of transcription 
(Simmons et al, 1987). However, the cytochrome P450IIIA1 
(PCN-1) gene is transcriptionally activated and induction of 
cytochrome P450IIIA1 (PCN-1) protein is directly 
proportional to mRNA levels after steroid administration in 
rats or primary hepatocytes (Watkins et al, 1986). The 
antibiotic, triacetyloleandomycin (TAO), caused an increase 
in the levels of a cytochrome P450 that is indistinguishable 
from the dexamethasone-induced enzyme cytochrome P450IIIA1 
(PCN-1); however, this increase occurred in the absence of 
an increase in mRNA in rat hepatocytes cultured in vitro. In 
contrast, dexamethasone causes an increase in 
cytochrome P450IIIA1 and P450IIIA2 (PCN-1; PCN-2) mRNA in 
these cultures. Both agents increase the mRNA(s) in intact 
animals. It has been suggested that TAO and dexamethasone 
have different mechanisms of action, possibly with TAO 
stabilising mRNA and dexamethasone increase transcription.
Induction of a cytochrome P450III protein occurs in the 
rat as well as in primary cultures of hepatocytes (Watkins 
et al, 1986). Protein radiolabelling experiments confirmed 
that TAO induction of cytochrome P450p (cytochrome 
P450IIIA1/P450IIIA2) is due in part to a decrease in 
cytochrome P450 degradation, while the degradation rates of 
other cytochromes P450 was not affected by TAO. It has been
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postulated that this effect results from binding of TAO or 
its metabolite to the cytochrome P450III protein. It has 
been found that TAO binds to the enzyme in vivo and this 
binding disrupts catalytic activity and inactivates the 
enzyme, suggesting that the long-held generalization that 
inactive proteins are more rapidly degraded may not apply to 
cytochrome P450III (Watkins et al, 1986)
One of the most profound examples of posttranscripti- 
onal regulation is seen with the IIE1 enzyme. This 
cytochrome P450 is induced under a variety of conditions, 
including ethanol and acetone treatment, fasting and 
streptozotocin- or alloxan- induced diabetes. Administration 
of small compounds such as acetone and ethanol to rats 
causes a rapid induction of IIE1 protein without affecting 
levels of IIE1 mRNA (Song et al, 1986). This suggests a 
posttranscriptional regulation of IIE1 at either the 
translational level or by stabilization of the protein 
against degradation. It has been implied that the binding 
of inducers to IIE1 results in a protection of the enzyme 
against degradation (Eliasson et al, 1988).
1.6 Steroid metabolism.
Endogenous and exogenous steroids are metabolised by 
complex enzyme systems which are both cytochrome P450- 
dependent and -independent. In this study, we employed the 
well characterised steroid substrate, 4-androstene-3,17- 
dione, and the metabolic routes of this steroid are 
illustrated in figure 2. Cytochrome P450- dependent 
monooxygenases hydroxylate 4-androstene-3,17-dione
05oc-reductase
70r-hydroxylase
160c-hydroxylase
17a 00)
hydroxy steroid 3oc(/3)-hydroxy 
dehydrogenase steroid dehydrogenase
6^3-hydroxylase
''OH0
(2)
(7)
(5)
Figure 2:
Metabolic pathway of 4-Androstene-3,17-dione (1).
Shown are; 4-Androstene-7a-OL-3,17-dione (2);
4-Androstene-6(l-OL-3,17-dIone (3); 4-Androstene-16a-OL-3,17-dione (4); 
Testosterone (5); 5a-Androstene-3,17-dione (6); and 
5a-Androstene-3a(P)-OL-17one (7).
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predominantly at the 7a-, 6p- and 16a-positions.
The male specific cytochrome P450IIC11 (see table 1) 
has been shown to catalyse 90% of the metabolism of 
4-androstene-3,17-dione at the 16a-position (Waxman, 1984) 
and the same isozyme also hydroxylates testosterone at the 
16a-position (Morgan et al, 1985).
Up to 80% of 4-androstene-3,17-dione hydroxylation at 
the 6p-position is thought to be catalysed by cytochrome 
P4502a (Waxman et al, 1985), although direct assessment of 
the activity of the purified enzyme has not yet been 
determined.
Cytochrome P450IIA1 is responsible for 7a-hydroxylation 
of 4-androstene-3,17-dione (table 1) (Waxman et al, 1987) 
and it therefore appears that in the uninduced liver, 
4-androstene-3,17-dione metabolism is catalysed by three 
separate and selective cytochrome P450-dependent isozymes.
5a-Reductase is another 4-androstene-3,17-dione 
metabolising enzyme and, although it is a membrane-bound 
microsomal enzyme, it does not contain cytochrome P450 as an 
integral component. It has been shown, however, that 
5a-reductase exists as part of a multicomponent system which 
possesses many similarities to the cytochrome P450 
monooxygenase system. The electron transport chain is 
composed of three enzymes; steroid 5a-reductase, coenzyme 
Q 10 and NADPH-cytochrome oxidoreductase. In this system, 
coenzyme Q10 is a cytochrome and electrons are passed from 
NADPH to coenzyme Qx 0 by NADPH-cytochrome oxidoreductase and 
thence from coenzyme Q10 to the steroid substrate by 5a- 
reductase, where they participate in the reduction of the
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double bond (figure 2) (Golf & Graef, 1978).
The final enzymes involved in the metabolism of 
4-androstene-3,17-dione are 17a/p and 3a/p hydroxysteroid 
dehydrogenase, both of which are microsomal, although 
details of their mode of action remain to be fully 
elucidated.
1.7 Hormonal regulation of hepatic metabolism.
Hepatic metabolism of both drugs and steroids can be 
performed by the same types of enzymes (Kuntzman et al,
1964) and it has been found that the activities of various 
hepatic enzymes are not constant, but they can be regulated 
by the endocrine system and also by hormones known to have 
in vivo effects. Three main types of hormones are known to 
exert effects upon hepatic metabolising enzymes and each 
type will be briefly discussed below. Most reports 
regarding hormonal control of hepatic metabolism concentrate 
on sexually differentiated enzymes and metabolic control, 
and this section will also consider the control of hepatic 
metabolism in this context.
1.7(a) Androgens.
In 1958, Yates and his coworkers showed that castration 
of male rats caused an increase in the activity of the 
steroid metabolising enzyme 5 a-reductase to levels of 
activity normally associated with a female profile of 
metabolising activity. Upon treatment of the castrates with 
testosterone, the effect upon 5 a-reductase was reversed.
This implied that the activity of 5 a-reductase in male rats
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was subject to androgenic control. The controlling 
influence of androgens upon drug metabolism has been 
reported for a variety of substrates, including aniline 
(Quinn et al, 1958), hexobarbitone (Quinn et al, 1958) and 
ethylmorphine (Castro & Gillette, 1967; Davies et al, 1968). 
Androgenic control of phase II metabolism reactions has also 
been reported, as reviewed by Skett (1987).
More extensive study, predominantly by Gustafsson and 
his group, determined that androgens appear to work through 
a complex pathway divided into two levels. A comprehensive 
review of this work has been published by Skett & Gustafsson 
(1979) and Gustafsson et al (1980). The main findings of 
this work, were that androgens can imprint the brain of a 
rat in the neonatal period (such that neonatally castrated 
male rats show a completely female pattern of metabolism) 
and secondly, androgens can maintain the activity of some 
enzymes in the adult period by an action via the pituitary 
gland. Imprinting appears to affect both enzyme activities 
and the ability of enzymes to respond to androgens in the 
adult period. The concept of imprinting with regards to 
regulating the expression of cytochrome P450 has been 
previously considered (section 1.5(B)2). Most of the 
effects of androgens upon enzyme activity are a consequence 
of imprinting and it appears that androgens have no direct 
effect on the liver to control drug and steroid metabolism.
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1.7(b) Pituitary hormones.-
It is widely accepted that the hypothalamo-pituitary 
axis is the site of control for hepatic drug and steroid 
metabolism and much work has been done to identify the 
factors from the pituitary which are involved in this 
control. Many pituitary hormones have been purified and 
tested on the liver for their effect on drug and steroid 
metabolism, including FSH (Gustafsson & Stenberg, 1975), LH 
(Gustafsson & Stenberg, 1975), prolactin (Colby et al,
1974), growth hormone (Colby et al, 1974; Mode et al, 1981) 
and ACTH (Colby et al, 1974). All of these hormones were 
found to have some effect upon the liver, but none of them 
was obviously the so-called "feminising factor", which had 
been proposed by Gustafsson and his workers (Gustafsson et 
al, 1975; Skett, 1978). A review of the attempts to define, 
isolate and characterise the "feminising factor" has been 
published (Gustafsson et al, 1980).
It was subsequently found that the "feminising factor" 
appears to be growth hormone (GH) (Mode et al, 1981 ; Skett 
& Young, 1982). It was shown that GH, upon infusion into 
male rats, causes a feminisation in the metabolism of both 
drugs and steroids (Mode et al, 1981; Skett & Young, 1982). 
The lack of effect with GH in early experiments was found to 
be due to the fact that in both male and female rats, mean 
serum concentrations of GH are very similar. However, it 
became apparent that GH is secreted differently in males and 
female and this difference in the pattern of secretion of GH 
appeared to be important for the maintenance of sex 
differences in the liver (Mode et al, 1981; Skett & Young,
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1982). In male rats, GH is secreted in a pulsatile manner, 
with large peaks of secretion at 3-4 hour intervals, and in 
the intervening time period, levels of GH are virtually 
undetectable. The female rat, in comparison, exhibits a 
more sustained and constant serum level of GH (Terry et al, 
1977; Eden, 1979).
Mode and coworkers (1982) investigated further the role 
of the secretory pattern of GH and they discovered that 
treatments which caused a feminisation of hepatic steroid 
metabolism also altered the secretory pattern of GH to a 
female type, that is from pulsatile to constant levels.
Upon injection of estradiol valerate into male rats, there 
was a decrease in the 16a-hydroxylation and an increase in 
the 5a-reduction of the steroid substrate 4-androstene- 
3,17-dione, an effect characteristic of a feminisation of 
steroid metabolism. Administration of estradiol valerate 
was also found to elevate the baseline secretion of GH, and 
depress the peak height of GH secretion, resulting in a more 
constant level of GH secretion. Castration of male rats 
produced the same effect as administration of estradiol 
valerate.
Somatostatin, the hypothalamic factor which inhibits 
the release of GH, was also investigated in the control of 
hepatic steroid metabolism. Norstedt et al (1983) showed 
that lesioning the periventricular area of the hypothalamus 
caused a decrease in the levels of somatostatin in the brain 
and a decrease in 60- and 16a-hydroxylation in hepatic 
microsomes (a feminisation). Addition of anti-somatostatin 
antibodies was found to mimic the effect of lesioning,
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implying that the effects on somatostatin and hepatic 
steroid metabolism are linked. The current idea as to how 
such an interaction occurs, is that the male pattern of 
hepatic drug and steroid metabolism is maintained by 
somatostatin from the hypothalamus, depressing the basal 
secretion of GH, and that the removal of this factor leads 
to a more female-type (constant) GH secretory pattern and a 
subsequent feminisation of hepatic metabolism. Recently, 
the role of GH in androgenic imprinting of steroid 
metabolism was investigated by Jansson and workers (1985b). 
They showed that upon neonatal castration of male rats, 
there was an appearance of female type GH secretion pattern, 
together with a feminisation of steroid metabolism, as 
described above. Neonatal androgen treatment reversed this 
effect, suggesting that neonatal androgen programs the brain 
for male type, pulsatile secretion of GH and, thus produces 
the male pattern of steroid metabolism in the adult period.
The control of sex differences in hepatic drug and 
steroid metabolism is thought to be as follows: androgens 
control the liver by their action on the secretory pattern 
of GH, both by a direct control in the adult period and as a 
consequence of androgenic imprinting in neonatal life. It 
is the sex difference in the secretory pattern of GH which 
appears to influence the rate at which, and the route by 
which, drugs and steroids are metabolised in the liver.
This "somatogenic" control of hepatic function appears 
to have some conflicting evidence. Monosodium glutamate 
(MSG) has been found to affect GH secretion, and drug and 
steroid metabolism. Administration of MSG to neonates
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destroys the arcuate nucleus in the brain and causes an 
impairment of GH pulsatile secretion (Terry et al, 1981).
MSG administered in this way was found, however, to have no 
effect upon the metabolism of aniline, hexobarbitone or 
4-nitrophenol (glucuronidation) (Shapiro et al, 1986), 
although a marked depression of GH secretion was observed. 
Such evidence questions the role of GH as the sole hormonal 
controller of hepatic drug and steroid metabolism.
1.7(c) Pancreatic hormones.
The discrepancies in the "somatogenic" theory of 
control mentioned above, can possibly be explained by the 
role of the pancreatic hormones in controlling hepatic 
function. It is well known that chemically induced or 
spontaneous diabetes mellitus can markedly affect drug 
metabolism in the rat liver (Kato & Gillette, 1965; Kato et 
al, 1970). The effects of diabetes are sex dependent in the 
rat with male specific enzyme activities being inhibited and 
some female enzyme activities being enhanced (Kato & 
Gillette, 1965; Kato et al, 1970; Reinke et al, 1978).
It was proposed (Kato & Gillette, 1965; Reinke et al, 
1978) that the effects of diabetes are related to decreases 
in serum testosterone levels and, indeed, testosterone 
synthesis and release has been found to be inhibited in rats 
(Murray et al, 1981). Insulin was thought to stimulate the 
synthesis and release of testosterone and thus indirectly 
maintain the male profile of hepatic steroid metabolism. 
Another report noticed that the effects of diabetes and 
castration were similar, streptozotocin treatment had little
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effect in castrated male rats and androgen administ/a;tion 
could partially reverse the effects of diabetes (Skett et 
al, 1984). However, the same study also reported that at 
the time of maximum diabetes (3 days) the levels of
testosterone in serum were normal, whilst at 2 1 days
diabetes, serum testosterone levels were markedly reduced, 
but hepatic drug metabolism was normal. The clear 
distinction between the two effects indicates that they are 
not linked directly, but there is some correlation between 
their effects upon hepatic function. It was thought that 
insulin and testosterone may act through a common mediator 
to exert their effects upon the liver and this mediator was
thought to be GH. GH was proposed as the mediator based on
the evidence that diabetes caused a marked change in the GH 
secretory pattern (Tannenbaum, 1981), and testosterone 
produced a similar effect (Gustafsson et al, 1983a).
Although GH has been proposed as the mediator for insulin 
and testosterone action upon the liver, the evidence is by 
no means conclusive.
The current level of knowledge as to the precise 
control of sex differences in drug and steroid metabolism is 
confusing, although it does now appear that GH acts as a 
"feminising" and insulin as a "masculinising" hormone.
In vivo experiments are difficult to interpret, as there are 
many complex interactions between hormones, but reports have 
suggested that glucagon and IGF-1 (and IGF-2) may also be 
involved in the control of heptatic drug and steroid 
metabolism (Hussin & Skett, 1987).
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1.8 Hormonal transduction through second messengers.
Two major second messenger systems exist within the 
cell and they are (a) adenylate cyclase activation and 
production of cyclic adenosine 3 1, 5'-monophosphate (cyclic 
AMP) and (b) turnover of inositol phospholipids and the 
production of the intracellular second messengers inositol 
1,4,5-trisphosphate (IP3 ) and diacylglycerol (DAG). As a 
consequence of producing these second messengers, protein 
kinases are activated, a process which initiates 
intracellular protein phosphorylation. Protein 
phosphorylation is thought to be responsible for the 
ultimate intracellular effect, mediated by these second 
messenger systems.
1.8(a) Cyclic AMP and cyclic AMP-dependent protein kinase.
Cyclic AMP was first identified in 1960 by Sutherland 
and Rail, and it was found to be produced intracellulary 
from adenosine 5 1-triphosphate (ATP) by a process which 
required magnesium ions and activation of the enzyme 
adenylate cyclase. Adenylate cyclase is a membrane-bound 
enzyme and originally it was thought to be composed of two 
components; one was thought to be a receptor for hormones, 
located on the extracellular membrane surface and the other 
a catalytic unit, which was situated on the cytosolic side 
of the membrane. Rodbell and his group (1971) determined 
that guanosine triphosphate (GTP) was essential for 
activation of the catalytic subunit of the receptor and the
same group showed later (Rodbell et al, 1975) that binding
of hormone to its receptor enhanced this interaction.
In 1977, a GTP-binding protein was identified as a
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component of adenylate cyclase (Pfeuffer, 1977). Activation 
of adenylate cyclase requires the interaction of three 
separate components: the hormone receptor on the outer
surface of the cell membrane, the catalytic subunit at the 
inner surface of the membrane and a GTP-binding protein (N) 
which mediates the effect of the hormone upon the catalytic 
subunit of adenylate cyclase (Rodbell, 1980). The 
GTP-binding components exist within the cell in the resting 
state as a heterotrimeric complex composed of three 
subunits, a, £ and X . At least two types of GTP-binding 
protein are known to exist, one is stimulatory and is 
referred to as Ns and the other is inhibitory and is known 
as Ni
The association of stimulatory hormones with their 
receptors initiates GTP binding to Ns , on its a subunit, and 
this binding of GTP dissociates the a subunit from the rest 
of the binding protein complex (p and tf). The a subunit of 
Ns , still coupled to GTP, then interacts with and activates 
the catalytic subunit of adenylate cyclase (Gilman, 1984). 
Activation of adenylate cyclase is terminated by the 
hydrolysis of GTP to the inactive form guanosine 
diphosphate (GDP) by the action of an intrinsic GTPase 
(Jakobs et al, 1984). The mechanism by which N 1 mediates 
inhibitory effects upon adenylate cyclase is less clearly 
understood, with conflicting reports as to the mechanism of 
action of Ni which need to be further elucidated before the 
precise mechanism of this binding protein can be explained 
in biochemical terms.
The intracellular actions of cyclic AMP are mediated
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through the activation of cyclic AMP-dependent protein 
kinase (PKA), and, as well as activating PKA, an elevation 
of intracellular cyclic AMP also causes a concomitant 
activation of cyclic AMP phosphodiesterase (Corbin et al,
1985). Activation of the phosphodiesterase is a regulatory 
mechanism, which causes the degradation of cyclic AMP to the 
inactive compound, adenosine 5'-monophosphate (5'-AMP) and 
the cessation of the intracellular effect. Figure 3 
illustrates the sequence of events in the hormonally 
stimulated generation of cyclic AMP and its subsequent 
degradation.
PKA is composed of two different subunits; a regulatory 
(R) subunit and a catalytic (C) subunit. PKA is activated 
by the dissociation of these two subunits and the subsequent 
release of a free C subunit (Kumon et al, 1970). PKA is not 
a single species but exists as a family of closely related 
enzymes with identical C groups but slightly differing R 
groups, with regards to amino acid sequences 
(Robinson-Steiner et al, 1984).
1.8(b) Inositol phospholipid hydrolysis.
Receptor-mediated hydrolysis of inositol phospholipids 
is an accepted mechanism for transducing various signals 
such as those from certain hormones, neurotransmitters and 
growth factors into the interior of the cell. In 1953, the 
response of the phospholipids to the stimulation of cell 
surface receptors was recognized by Hokin and Hokin, who 
first showed that, in some excretory tissues, such as the 
pancreas, acetylcholine induced a rapid incorporation of 32P
cyclic AMP/ 
phosphodiesterase /
5 -AMP Protein kinase A
tTarget protein phosphorylation
Figure 3:
Sequence of events in hormonal stimulation of cyclic AMP generation and 
subsequent degradation. Abbreviations: Ns. stimulatory receptor; Nj, 
inhibitory receptor; AC, adenylate cyclase; ATP, adenosine 5’-triphosphate; 
cAMP, cyclic adenosine 3', 5'-monophosphate; 5'-AMP, adenosine 
5'-monophosphate.
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into phosphatidylinositol and phosphatidic acid. It became 
evident later that this incorporation results from the 
enhanced breakdown and resynthesis of phospholipids occuring 
in many stimulated cells. Durell and workers (1969) 
suggested a potential role of this phospholipid response in 
receptor function and Michell (1975) subsequently postulated 
that the phospholipid breakdown may be related to calcium 
gating.
It was Michell (1975) who reported that hormones were 
capable of. stimulating the breakdown and resynthesis of 
inositol phospholipids and this led to the concept that 
turnover of inositol phospholipids could serve as a pathway 
for signal transduction.
A modification to the theory was proposed in 1981, when 
Michell and his group reported that the specific hydrolysis 
of phosphatidylinositol-4,5-bisphosphate (PIP2 ) by hormonal 
stimulation was the main mediator of intracellular hormonal 
communication. PIP2 can be hydrolysed by two different 
enzymes (Irvine, 1982): one is a phosphomonoesterase which 
cleaves off a phosphate from PIP2 to yield phosphatidyl- 
inositol-4-monophosphate (PIP) and the other is a phospho­
diesterase known as phospholipase C, which is activated by 
hormonal receptor occupation. Hydrolysis of PIP2 by 
phospholipase C yields two products, inositol-1,4,5- 
trisphosphate (IP3) and diacylglycerol (DAG).
IP3 is released into the cytoplasm where it functions 
to mobilise calcium from its intracellular stores, 
principally from the endoplasmic reticulum. IP3 is 
sequentially degraded into inositol-l-phosphate and then
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inositol, by a series of phosphatases, and the inositol is 
then reincorporated into the phosphatidylinositol turnover 
cycle.
DAG remains within the cell membrane and it functions 
by activating its specific kinase, protein kinase C (PKC). 
PKC will be dealt with in greater detail in a separate 
section (1.9). DAG is metabolised very rapidly into 
phosphatidic acid by DAG kinase and once again this product 
re-enters the phosphatidyl inositol biosynthesis pathway. 
PIP2 is resynthesized from inositol and phosphatidic acid by 
consecutive phosphorylation by phosphatidylinositol kinase 
and phosphatidylinositol-4-phosphate (PIP) kinase (reviewed 
by Berridge, 1985). The sequence of events in hormonal 
stimulation of inositol phospholipid hydrolysis and 
resynthesis are shown in figure 4.
1.9 Protein kinase C and signal transduction.
Protein kinase C (PKC) is an enzyme that is activated 
by the receptor-mediated hydrolysis of inositol 
phospholipids, and relays information in the form of a 
variety of extracellular signals across the cell membrane to 
regulate many calcium-dependent processes. This enzyme also 
serves as the receptor for tumor-promoting phorbol esters, 
and because of this, PKC has attracted the attention of 
biologists interested in the process of signal transduction 
and carcinogenesis. PKC is now known to be a large family 
of proteins with multiple subspecies that have subtle 
individual characteristics. Biochemical and 
immunohistochemical studies suggest that PKC subspecies may
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Inositol phospholipid cycle showing inositol phospholipid hydrolysis and 
subsequent resynthesis. Abbreviations: DAG, diacylglycerol, PIP2 , phosphatidyl 
inositol-4,5-bisphosphate; IP3 , inositol-1,4,5-trisphosphate; IP2 , 
inositol-1,4-bisphosphate; IP, inositol-l-phosphate.
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be differently located in particular cell types and with 
limited intracellular localisations.
1.9(a) Protein kinase C in signal transduction.
When PKC was first detected in 1977, as a 
proteolytically activated kinase present in many tissues, 
the enzyme had no obvious role in signal transduction (Inoue 
et al, 1977). Later, it was shown that PKC was a 
calcium-activated, phospholipid-dependent enzyme and it was 
firmly linked to signal transduction by the demonstration 
that diacylglycerol (DAG), one of the earliest products of 
inositol phospholipid hydrolysis, is essential for the full 
activation of PKC (Nishizuka, 1984a). The activation of 
cellular responses by this route is separate from, and 
synergistic to, those activated via an increase in 
intracellular calcium, as shown schematically in figure 5.
The pivotal role of PKC in signal transduction was 
first demonstrated in the release of serotonin from 
platelets (Kaibuchi et al, 1983). PKC has also been 
implicated in the release, secretion and exocytosis of 
cellular constituents from a variety of endocrine, exocrine 
and neuronal tissues, as well as in the modulation of 
membrane conductance and activation of other cellular 
function as reviewed by Nishizuka (1986). Under appropriate 
conditions the two routes for signal passage, PKC activation 
and calcium mobilization, can be opened selectively and 
independently by the application of a permeable DAG, 
l-oleoyl-2 -acetylglycerol, for the former, and a 
calcium ionophore, A23187, for the latter. DAG is normally
Out
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membrane
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Permeable DAG or 
phorbol ester.Ca -ionophore
PIP. DAG
GTP
PKC
GDP
Cellular 
response
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Figure 5:
Schematic representation of the bifurcating pathway of signal transduction 
involving protein kinase C (PKC) and calcium. Abbreviations; PIP2 ,
phosphatidyl inositol-4,5-bisphosphate; DAG/DG, diacylglycerol; PS, 
phosphatidylserine; P-Lipase C, phospholipase C; IP3 , 
inositol-1,4,5-trisphosphate.
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insoluble and cannot be intercalated into the cell membrane. 
However, if the fatty acyl moiety is replaced by a short 
chain such as an acetyl group, then the resulting DAG 
possesses detergent-like properties and is easily dispersed 
to activate PKC without disruption of the intact cell 
membrane. It was also noticed that a powerful 
tumor-promoter, 12-0-tetradecanoylphorbol-13-acetate (TPA), 
also known as 4p-phorbol-12-myristate-13-acetate (PMA), 
mimics the action of DAG and activates PKC directly 
(Castagna et al, 1982).
1.9(b) Protein kinase C as a target of tumor promoter 
action.
In 1941, Berenblum stated that "croton oil causes a 
marked augmentation of carcinogenesis when applied at weekly 
intervals to mice skin in conjunction with a dilute solution 
of benzpyrene in acetone". The principal constituent of 
croton oil was later identified as a phorbol ester by Hecker 
(1967) and Van Duvren (1969). Figure 6 shows the most 
powerful tumor-promoter, TpA (also called PMA), along with a 
cell-permeable DAG, l-oleoyl-2-acetylglycerol (OAG) and it 
can be seen that tumor-promoters possess a DAG-like 
structure in their molecule.
In 1982, it was found that TPA could substitufe for DAG 
and activate PKC directly both in vivo and in vitro, and it 
is now assumed that PKC is the intracellular receptor for 
tumor-promoting phorbol esters (Castagna et al, 1982; Niedel 
et al, 1983).
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Figure 6:
The chemical structure of a cell permeable diacylglycerol and a widely used 
tumor-promoting phorbol ester.
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1.9(c) Structural heterogeneity.
Although once considered to be a single entity 
(Nishizuka, 1984a), recent molecular cloning and 
enzymological analysis has revealed the existence of 
multiple subspecies of PKC ill a variety of mammalian tissues 
(Nishizuka, 1988). Initially four cDNA clones which encode 
for a-, pi-, pil- and ^-subspecies were found in bovine, rat 
and human brain, and later in human spleen cDNA libraries. 
The integrated nomenclature used here is the recognised 
nomenclature for PKC subspecies (Nishizuka, 1988).
Partial genomic analysis has indicated that pi- and 
pll-subspecies are derived from a single mRNA transcript by 
alternative splicing. Recently another group of cDNA 
clones, encoding at least a further three subspecies having 
0 , 6., and £  sequences have been isolated from the rat brain 
library by using a mixturs of a-, pil- and J'-cDNA as probes 
under low stringency conditions (Ono et al, 1987; Ono et al, 
1988a). These subspecies have a common structure closely 
related to, but clearly distinct from, the above four 
subspecies.
Figure 7 shows schematically the structures of the PKC 
subspecies identified to date. They are all composed of a 
single polypeptide chain, with the group of a-, pi-, pil- 
and V-subspecies each having four conserved regions (Cx to 
C4 ) and five variable regions (Vx to V5 ). The pi- and 
pil-subspecies differ from each other only in a short range 
of about 50 amino acid residues at their carboxy-terminal 
end region V5 and even in this area, they possess a high 
degree of sequence homology. Although the second group of
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Common structure of Protein Kinase C subspecies - C,G,K,X and M  represent 
cysteine, glycine, lysine, any amino acid and metal ion respectively.
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a, £ and ^ "-subspecies lack-the C2 region, the molecular mass 
of the enzyme molecules is, nevertheless, similar. The 
characteristics of these members of the PKC family are 
summarized in table 2 .
Amino acid Mol.Wt. Sub-fraction Activators Site
Residues
a 672 76,799 type III PS+DG+Ca2+ All body
AA+Ca2+ tissues
PI 671 76,790 type II PS+DG+Ca2+ Some
tissues & cells
pil 673 76,933 type II PS+DG+Ca2+ Many
tissues & cells
697 78,366 type I PS+DG+Ca2+ Brain &
AA spine
a 673 77,517 ? PS+DG+(Ca2+) Many
tissues
£  737 83,474 ? PS+DG+(Ca2+) Brain
only ?
592 67,740 ? PS+(DG+Ca2+) Many
tissues.
Table 2; Subspecies of protein kinase C from mammalian 
tissues.
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The conserved region G contains a tandem repeat of a 
cysteine rich sequence,
Cys-X2 -Cys-Xi 3(x 4 )-Cys-X2 -Cys-X7 -Cys-X7-Cys 
where X represents an amino acid. Jj'-PKC contains only one 
set of this cysteine-rich sequence, thus having a relatively 
smaller mass than the other PKC species. The cysteine-rich 
sequence resembles the so-called "zinc-finger" that is found 
in many metalloproteins which are related to transcriptional 
regulation. There is no evidence available, however, that 
PKC binds to DNA directly. The conserved regions of Ci and 
C2 include the regulatory domain of PKC (Lee & Bell, 1986), 
but as yet the sites involved in Ca2+, DAG and phospholipid 
binding have not been identified with any certainty. The 
mechanism of PKC activation is thought to be a complex 
interaction between all these different components, but it 
is known that fully activated PKC is a quaternary complex of 
PKC, DAG, calcium and phospholipid, located at the inner 
surface of the cell membrane.
The carboxy-terminal half of PKC, containing the 
regions C3 and C4 represents the actual kinase of the 
enzyme. The conserved region C3 has an ATP-binding 
sequence, Gly-X-Gly-X-X-Gly-...-Lys2 1 . The regulatory and 
protein kinase domains are cleaved by limited proteolysis, 
catalysed by the calcium-dependent neutral protease calpain, 
at one or two specific sites in the variable region, V3 .
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1.9(d) Individual enzymological characterization.
Characterization of each PKC subspecies is a 
prerequisite for determining the potential roles of this 
enzyme family in signal transduction. The variable regions 
seen in each subspecies may play key roles in governing the 
individual enzymological characteristics and possibly their 
specific localisation and function. The diversity of the 
sequence in these regions allows the separation of PKC into 
several fractions upon chromatography on hydroxyapatite 
columns (Huang et al, 1987). To date, three subfractions, 
type I, II, and III have been identified and shown to 
correspond to Y - , (pi & pil) and a-subspecies respectively 
(table 2) (Kikkawa et al, 1987). PKCs with pi and pil 
sequence show nearly identical kinetic and catalytic 
properties and can be distinguished from each other only by 
immunocytochemical properties (Shearman et al, 1988). The 
subspecies having a-,£ -  and jj” sequence expressed in COS 7 
cells can be partially separated upon chromotography (Ono et 
al, 1988a) but their correspondence to the subfractions 
chromatographically obtained from tissues remains to be 
clarified.
The PKC subspecies which have been identified thus far 
exhibit subtle differences in enzymatic properties. PKC 
with ^(type I) and a (type III) sequences show much less 
activation by DAG than the mixture with the pi and pil (type 
II) sequence. The PKCs with the pi and pil sequence show 
substantial activity without added calcium in the presence 
of DAG and phospholipid (Sekiguchi et al, 1988). In 
addition to the characteristic activation of PKC by DAG, it
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has also been reported that cis- and trans-unsaturated fatty 
acids can activate purified rat brain PKC (Seifert et al, 
1988), phosphatidylethanolamine selectively activates type I 
subspecies in rat brain (Asaoka et al, 1988) and a variety 
of acyl CoAs and diol-lipids appear to be capable of 
potentiating activation of PKC in the presence of calcium 
and phosphatidylserine (Bronfmann et al, 1988; Severin et 
al, 1988). Different phospholipids and products of 
arachidonate metabolism appear to play important regulatory 
functions in controlling PKC activity within the intact 
cell. A model has recently been proposed for PKC regulation 
based on a dual control mechanism through which 
phospholipase C activation and DAG production initially 
activates PKC and causes a subsequent down-regulation of the 
kinase, whilst activation of phospholipase A 2 and the 
production of arachidonic acid and its metabolites causes a 
sustained activation of PKC (Portilla et al, 1988).
In addition to the well-defined PKC subspecies, 
structurally undefined enzymes have been obtained from some 
tissues such as heart and platelets, and these enzymes 
respond to phospholipid, calcium and DAG in different ways. 
For instance, one enzyme obtained from human platelets is 
not sensitive to calcium (Tsukuda et al, 1988) and the exact 
relation of this kinase to the different subspecies already 
identified remains unclear.
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1.9(e) Limited proteolysis-of protein kinase C.
PKC was originally detected as an undefined protein 
kinase which was present in many tissues and could be 
activated by limited proteolysis with calpain (Inoue et al, 
1977). This hydrolytic cleavage occurs at one or two 
specific sites in the region V3 , resulting in the release of 
a catalytically fully active fragment, which subsequently is 
rapidly removed from the cell (Kishimoto et al, 1989). 
Calpain I, which is active in the micromolar range of 
calcium, cleaves PKC preferentially in the presence of 
phosphatidylserine and DAG or TPA, suggesting that the 
activated form of PKC is a target for calpain action 
(Kishimoto et al, 1983). Quantitative analysis shows that 
calpain has differential activity on the various PKC 
subspecies; the /-subspecies (type I) is very susceptible, 
whereas the a-subspecies (type III) is relatively resistent 
to proteolysis (Kishimoto et al, 1989).
Although the limited proteolysis of PKC may generate a 
catalytically fully active fragment, previously called PKM 
(Kishimoto et al, 1983; Inoue et al, 1977), the 
physiological significance of this proteolysis has not been 
unequivocally established. Two alternative possibilities 
may be considered:
Firstly, this proteolysis may be a process to activate 
PKC and the resulting protein kinase fragment may play some 
role in the control of cellular function (Melloni et al, 
1986). It is also possible that the regulatory fragment has 
some role in the control of gene expression, as it contains 
a DNA-binding motif.
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Secondly, in contrast-* the limited proteolysis may be a 
process by which degradation of PKC is initiated, eventually 
depleting PKC from the cell. Recent reports from different 
workers (Ballester & Rosen 1985; Ase et al, 1988a) have 
shown that, in a variety of tissues and cell types, PMA, 
which induces persistent activation of PKC due to its stable 
properties, elicits translocation of the enzyme from the 
soluble fraction to the membrane and its subsequent 
degradation, termed down-regulation. In fact the 
catalytically active fragment, PKM, is not always recovered 
from the cell and is probably degraded further by the action 
of proteases. It has recently been shown that upon 
treatment with PMA, some PKC subspecies co-expressed in a 
single cell such as KM3 or in the HL-60 cell line, disappear 
at different rates, which may reflect the selectivity of 
calpain action described above (Ase et al, 1988a). It is 
more plausible that the limited proteolysis of the PKC 
molecule by calpain, particulary calpain I, is directly 
related to the degradation of PKC and that, when activated 
persistently, various subspecies of PKC are depleted from 
the cell at different rates due to the differential rate of 
proteolysis at their variable region, V3 .
1.10 Protein phosphorylation and intracellular activity.
Activation of protein kinases with their respective 
agonists causes the phosphorylation of intracellular 
proteins, by employing the terminal phosphate of ATP in the 
presence of magnesium. Phosphorylation by kinases typically 
involves seryl & threonyl residues and once phosphorylated,
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these proteins undergo a conformational change which 
subsequently alters the biological activity of the protein. 
The proteins phosphorylated by PKA have been reviewed by 
Cohen (1985).
PKC is known to phosphorylate an extensive range of 
proteins within the cell (Nishizuka, 1986) and several of 
these proteins are used as intracellular molecular markers 
to implicate PKC in a biological phenomenon. Two of these 
markers are an 80kD protein (Erasalimsky et al, 1988; 
Rodriguez-Pena et al, 1986; Malvoisin et al, 1987) and a 
40kD protein (Watson et al, 1988; Kazlauskas & Cooper, 1988; 
Vila & Weber, 1988).
PKA and PKC frequently phosphorylate the same protein 
(Kitamura et al, 1988; Jahn et al, 1988) and some of these 
phosphorylations may be relevant in order to modulate in 
vivo functioning of these proteins. In 1978, Garrison 
reported that cyclic AMP analogues increased the 
phosphorylation state of 1 2 cytosolic proteins and that 1 0  
of the same proteins were also susceptible to 
phosphorylation by hormones which could initiate inositol 
phospholipid hydrolysis. In a later study (Garrison et al, 
1984) it was reported that 7 of the 10 proteins which could 
be stimulated by inositol phospholipid hydrolysis could also 
be phosphorylated by the addition of the calcium ionophore 
A23187, whilst the remaining 3 proteins were a target for 
phosphorylation in the presence of PMA, suggesting an 
involvement of PKC.
It has been shown that the amino acid sequence in the 
immediate vicinity of a phosphorylation site is a primary
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factor in determining substrate recognition, as reviewed by 
Krebs and Beavo in their classic article on the regulation 
of enzyme activity (1979). It is thought that 
phosphorylation of different proteins or of differing 
residues on the same protein may be attributable to 
differential recognition by each kinase.
1.11 Dual action for cellular regulation through protein 
kinase C transduction.
Several physiological functions have been assigned to 
PKC, including an involvement in secretion, exocytosis, 
modulation of ion conductance, interaction and 
down-regulation of receptors, smooth muscle contraction, 
gene expression and cell proliferation, as reviewed by 
Nishizuka (1986). It is attractive to speculate that the 
different members of the PKC family may each have different 
roles in the control of cellular function, although little 
is known at present to allow a discussion of such an action 
of the PKC subspecies in biochemical terms.
It is now recognised that synergistic interaction 
between PKC and calcium pathways, as described by Nishizuka 
(1984a), underlies a variety of cellular responses to 
external stimuli. In the calcium pathway, inositol- 
1 , 4 , 5 -trisphosphate (IP3 ) is shown to mobilize calcium from 
its internal store (Berridge & Irvine, 1984). A large body 
of evidence has accumulated to indicate that PKC has a dual 
action, providing positive forward, as well as negative 
feedback control over various steps of cell signalling 
processes (Nishizuka, 1986). In short-term responses, a
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major role of PKC appears to lie in decreasing calcium 
concentrations in a manner shown in figure 8. Persistent and 
high elevations of calcium concentrations within the cell 
can have deleterious effects and ultimately lead to cell 
death. The appearance of physiological second messengers, 
such as DAG, is very rapid and transient in comparison with 
the more sustained elevation in calcium levels. In 
biological systems, a positive signal is normally followed 
by an immediate negative feedback signal. A number of 
reports have suggested that, in various cell types, PKC has 
a function to activate the calcium-transport ATPase and 
Na+/Ca2+ exchange protein, both of which remove calcium from 
the cell cytosol (Nishizuka, 1986). The recent observations 
that the phorbol ester, PMA, inhibits the frequency of 
repetitive calcium transients recorded from single cells 
could be explained by such an inhibitory action of PKC. 
Although it sounds paradoxical, such a negative feedback 
role of PKC is not confined to short-term responses, but may 
be extended to long-term responses such as cell growth and 
proliferation.
1.12 Interaction between inositol phospholipid hydrolysis 
and cyclic AMP generating pathways.
It has been reported that elevation of intracellular 
cyclic AMP can produce an increase in intracellular calcium 
levels by enhancing calcium influx (Staddon and Hansford,
1986) and this effect appears to be mediated by the 
phosphorylation of a protein which is situated on or near 
the calcium gating channels (Poggioli et al, 1986). It is
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Figure 8:
A model for the dual action of protein kinase C and of tumor-promoting phorbol 
ester. The scheme emphasizes the negative-feedback role of protein kinase C 
in cellular regulation.
IP3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; PKC, protein kinase C; 
TPA, 12-0-tetradecanoyl- 13-acetate. (Adapted from Nishizuka, 1988).
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now recognised that PKA and PKC can affect each others 
activity in a variety of cellular functions. For instance 
PKC appears to be able to directly activate adenylate 
cyclase in order to promote cyclic AMP accumulation in 
response to hormonal (glucagon) stimulation (Thams et al, 
1988; Ho et al, 1988a). The precise method by which PKC can 
activate adenylate cyclase is still unclear, but the effect 
may be due to PKC enhancing the heterotrimeric form of 
Ni resulting from a decreased inhibition of basal adenylate 
cyclase activity (Choi & Toscano, 1988). It has also been 
reported that phorbol ester activation of PKC can inhibit 
the activation of adenylate cyclase (Heyworth et al, 1985) 
and the hormonal (glucagon) stimulation of cyclic AMP 
accumulation (Garcia-Sainz et al, 1985).
Although interactions between PKA and PKC signal 
transduction systems are known to exist, the precise 
physiological relevance and the mechanism of these 
interactions remain to be fully elucidated.
1.13 Intracellular transduction of hormonal signals through 
protein kinase C.
A variety of hormones are known to exert some of their 
intracellular actions through inositol phospholipid 
hydrolysis and a production of IP3 and DAG, resulting in an 
elevated intracellular level of calcium and activation of 
PKC, respectively. Some hormones appear more selective for 
one limb of this pathway than the other, for instance some
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hormones act to selectively increase the level of calcium, 
with only a minor effect upon activation of PKC.
1.13(a) Vasopressin.
The hormone vasopresin is known to bind to its 
membrane-bound receptors in order to simulate inositol 
phospholipid hydrolysis (Blackmore et al, 1986a; Cabot et 
al, 1988a). Vasopressin promotes the production of both DAG 
and IP3 and can consequently have effects mediated through 
both activation of PKC and elevation of intracellular 
calcium (Blackmore et al, 1986a). There is a strong body of 
evidence implicating PKC as the major effector of 
vasopressin's intracellular action, particularly in isolated 
rat hepatocytes.
It has been reported that vasopressin can inhibit 
a 1-mediated effects in isolated rat hepatocytes 
(Garcia-Sainz et al, 1986) and in producing this effect, 
vasopressin phosphorylates intracellular proteins in a 
manner which was consistent with activation of PKC. 
Garcia-Sainz and Hernandez-Sotomayor later reported (1987) 
that vasopressin was able to inhibit the stimulation of 
ureogenesis in isolated rat hepatocytes, again through the 
activation of PKC.
Other hepatic effects of vasopressin involving 
activation of PKC include inactivation of glycogen 
synthetase (Blackmore et al, 1986a), anti-ketogenic effects 
(Nomura et al, 1987) and regulation of hepatic phospholipid 
biosynthesis, particularly phosphatidylethanolamine and 
phosphatidylcholine (Tijburg et al, 1987b).
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Extrahepatic effects of vasopressin have also been 
reported to involve PKC including the hydrolysis of 
glycerophospholipids in a REF 52 rat embryo cell line (Cabot 
et al, 1988a) and contraction of mesangial cells (Troyer et 
al, 1988).
It appears, therefore, that activation of PKC as a 
consequence of vasopressin-stimulated inositol phospholipid 
hydrolysis is responsible for mediating the majority of the 
hepatic effects of this hormone, with minor extrahepatic 
effects.
1.13(b) Angiotensin II.
Angiotensin II is a hormone known to cause profound 
elevations in intracellular levels of calcium and a 
consequence of these high calcium levels is that PKC can 
become activated (Kishimoto et al, 1983). Again, hepatic 
effects of angiotensin II have been reported; angiotensin II 
is able to cause protein phosphorylation in a pattern 
consistent with activation of PKC, in an identical manner to 
vasopressin (Garcia-Sainz et al, 1986). Angiotensin II 
also inhibits ureogenesis in isolated rat hepatocytes, 
although the involvement of PKC in this effect is 
controversial (Garcia-Sainz & Hernandez-Sotomayor, 1987).
An extrahepatic effect of angiotensin II has been 
reported by McAllister and Hornsby (1988) who observed that 
the hormone could inhibit forskolin-induced increases in the 
activity of steroid biosynthetic enzymes in adrenocortical 
cells, apparently through activation of PKC.
Angiotensin II appears to be able to affect both PKA
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and PKC in a complex, and poorly understood, manner. The 
effect seems to be regulated by different G proteins 
(Bouscarel et al, 1988b) and a complex and highly 
integrated regulatory system appears to be at work. Hence, 
although angiotensin II has been reported to act via 
activation of PKC, studies investigating such an effect of 
this hormone require careful interpretation because of the 
interaction between PKA and PKC transduction pathways.
1.13(c) Insulin.
An unexpected hormonal activator of PKC was found to be 
insulin. Insulin is well known to exert intracellular 
effects through ribosomal S6 kinase, protease-activated 
kinase and a cytosolic serine kinase (Blackshear et al, 
1987b; Yu et al, 1987), but insulin was also found to be 
capable of activating PKC (Gomez et al, 1988).
The involvement of PKC in insulin action is 
controversial, some reports implicating an action through 
this kinase and others refuting such an action. The 
controversy arose because insulin does not activate PKC 
directly, being unable to initiate inositol phospholipid 
hydrolysis. Activation of PKC by insulin appears to be an 
indirect effect, with insulin acting to enhance PIP2 
hydrolysis which has been stimulated by agonists, as a 
consequence of stimulating de novo synthesis of PI and PIP 
(Pennington & Martin, 1985).
A physiological role for insulin activating PKC is 
being intensively studied at present, and hopefully some of 
the controversy about insulin's actions through this kinase
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will soon be resolved.
1.14 A role for protein kinase C in hepatic monooxygenase 
regulation?
Although PKC has been implicated in a variety of 
metabolic effects, such as lipogenesis and glucose transport 
in adipocytes (Allard et al, 1987) and also in hepatocytes 
(Bijleveld et al, 1988; Chowdhury & Agius, 1987), there is a 
lack of conclusive evidence implicating PKC in the 
regulation of hepatic monooxygenases. There is no evidence 
involving PKC in either the induction or degradation of 
cytochrome P450.
One report from Pyerin and his colleagues (1987), 
implied that both PKA and PKC could phosphorylate specific 
cytochrome P450 isozymes in both rats and rabbits. Some of 
these isozymes appeared to be more susceptible than others 
to phosphorylation, and also the kinases seemed to have 
different selectivities towards the isozymes. This report 
implied that in vitro phosphorylation of cytochrome P450 
isozymes was not solely dependent upon one kinase.
Hormones have been reported to be capable of inhibiting 
hepatic monooxygenases by increasing intracellular levels of 
cyclic AMP (Berry & Skett, 1988a). Elevation of cyclic AMP 
levels either directly or indirectly produced the same 
inhibitory effect upon the metabolism of the steroid 
substrate, 4-androstene-3,17-dione, and the effect was both 
time- and concentration-dependent. A role for cyclic AMP in 
the regulation of monooxygenase activity has been provided 
by Weiner and his group (1972), where it was reported that
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in vivo administration of the cyclic AMP analogue, dibutyrl 
cyclic AMP, inhibited the metabolism of hexobarbitone. In 
vivo administration of dibutyrl cyclic AMP has also been 
reported to inhibit the phenobarbitone-mediated induction of 
cytochrome P450 (Hutterer et al, 1975). Induction of 
cytochrome P450 in vivo by 3-methylcholantherene and 
phenobarbitone (Byus et al, 1976) has also been reported to 
be accompanied by an increase in intracellular cyclic AMP 
and activation of PKA. An analagous effect for PKC has not 
been reported.
1.15 Aims of the present project.
(a) To assess the effects of directly activating protein 
kinase C upon the hepatic metabolism of the steroid 
substrate, 4-androstene-3,17-dione, using a variety of 
agents (tumor-promoting phorbol esters, vasopressin, 
synthetic diacylglycerol, angiotensin II).
(b) To observe protein kinase C translocation in the 
presence of tumor-promoting phorbol esters.
(c) To determine the role of the NADPH- cytochrome P450 
enzyme system in any protein kinase C-dependent effect which 
we observed.
(d) To elucidate the role of protein kinase C upon hepatic 
steroid metabolism by using protein kinase inhibitors.
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(e) To elucidate the role of protein synthesis in the 
actions of protein kinase C upon hepatic steroid metabolism.
(f) To determine if the effects of protein kinase C upon the 
metabolism of 4-androstene-3,17-dione were due to changes in 
the phosophorylation state of cytochrome P450 isozymes.
(g) To determine if the effects of protein kinase C upon the 
metabolism of 4-androstene-3,17-dione were due to changes in 
the phosphorylation state of specific protein kinase C 
protein substrates.
It was hoped, therefore, that this study would 
determine whether or not protein kinase C was involved in 
the hormonal control of hepatic steroid metabolising 
enzymes, some of which are monooxygenases, and to try to 
determine the underlying mechanism of any effect which we 
observed. It was hoped that this study would provide an 
insight into the physiological and pharmacological roles of 
activation of protein kinase C in the regulation of 
the hepatic biotransformation system.
MATERIALS AND METHODS
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MATERIALS AND METHODS.
Methods can be separated into three main sections:
(1) Assessment of protein kinase C activation, directly and 
indirectly, and subsequent effects on 
4-Androstene-3,17-dione metabolism.
(2) Assessment of the NADPH/cytochrome P450 enzyme system.
(3) Assessment of Phorbol-12-myristate-13-acetate effects 
upon protein phosphorylation.
The methods used in each of these three sections is 
summarised below.
2.1 ANIMALS.
Mature Wistar rats, bred in the department and weighing 
250-300g, were used throughout the study.Males were used in 
each case, apart from section 2.5 in which female rats were 
used. The animals were kept in light and temperature 
controlled conditions (lights on 0700-1900; 19 ± 1°C) and 
allowed free access to food (CRM Nuts, Labsure,Croydon) and 
tap water.
2.2 HEPATOCYTE ISOLATION.
Rats were anaesthetised prior to hepatocyte isolation, 
using halothane (3.5%) in oxygen/nitrous oxide (0.4L/0.8L 
per minute). The method used was the two-stage collagenase 
perfusion technique of Seglen (1973). Prior to hepatocyte
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isolation approximately 500ml of calcium-free Hanks B.S.S. 
(section 2.24(a)) was gassed for 30 minutes with 95.5%:5% 
02/C02 at 37°C. The temperature of the perfusate was kept 
at 37°C for the duration of the perfusion process, using an 
insulated reservoir, and the perfusate gassed continously 
with 02/C02 as above. After induction of anaesthesia,the 
animal was dissected open and the hepatic portal vein 
isolated, cleared of fat and the vein cannulated. After 
cannulation, the liver was perfused in situ with 
calcium-free Hanks B.S.S. at a perfusion rate of flow of 
80ml per minute for 1 minute to wash out blood from the 
liver. After puncturing the vena cava, the liver was 
perfused for a further 10 minutes at a flow rate of 60ml per 
minute to cause breakdown of the calcium-dependent bonds 
between the cells. After this time,the perfusate buffer was 
changed to a buffer containing 60mg of collagenase in 120ml 
Hank's B.S.S. resupplemented with 4mM of CaCl2 .The perfusion 
was continued for a further 15-20 minutes, during which time 
the collagenase containing buffer was recycled through the 
liver. When the liver had been sufficiently digested, as 
ascertained by visual examination of the liver which showed 
the actual cells visible below the liver capsule, the entire 
liver was removed from the animal and after careful removal 
of the liver capsule, the hepatocytes were dispersed into 
incubation medium. The hepatocyte suspension was filtered 
through gauze to separate connective tissue and undigested 
liver from the hepatocytes and the suspension then 
centrifuged twice at 500g for 3 minutes in a Damon-IEC DPR 
6000 centrifuge to sediment intact cells. The supernatant,
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containing excess cell debris, was removed and the isolated 
cells resuspended in Ham's F-10 culture medium, supplemented 
with 0.1% Bovine serum albumin and 1000 IU of 
penicillin/streptomycin per ml (Hussin & Skett, 1987) at a 
cell density of 3 x 107 cells per ml. This method yielded 
approximately 5 x 107 cells per gram wet weight of 
liver,with a cell viability of greater than 97%, assessed by 
trypan blue exclusion.
2.3 INCUBATION OF INTACT HEPATOCYTES WITH PROTEIN KINASE C 
ACTIVATING AGENTS.
Freshly isolated hepatocytes were plated onto sterile 
10cm diameter culture dishes (Nunclon, Denmark) at a cell 
density of 107 cells per ml in Ham's F-10 supplemented with 
0.1% bovine serum albumin. The dishes were then placed in 
an incubator set at 5% C02 , 98% humidity and 37°C for 30 
minutes to allow the cells to recover from the isolation 
process before the experiment commenced. Studies involving 
incubations of 24 hours, to allow receptor levels to recover 
prior to study, were maintained in the incubator as stated 
above. After recovery in the incubator, the cells were 
transferred to 25 ml conical flasks in a shaking water bath 
at 37°C, where they were subjected to treatment with the 
various protein kinase C activating agents. The agents were 
added to the cells in the conical flasks and left in contact 
with the cells for periods of time ranging between 5 and 200 
minutes. The agents investigated are known to exert either 
all of their effect via protein kinase C or partially via 
protein kinase C (Castagna et al, 1982; Niedel et al, 1986;
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Nishizuka, 1986). The agents studied were: (a) 
4p-Phorbol-12-myristate-13-acetate (PMA; InM and 50nM); (b) 
4a-Phorbol (4aP; lOOnM); (c) 4a-Phorbol-12,13-didecanoate 
(4aPDD; lOOnM); (d) 1,2-Dioctanoylglycerol (DOG; 5pM); (e) 
Vasopressin (lOOnM and lOOpM); (f) Calcium ionpohore A23187 
(lOOnM); (g) PMA and A23187 (50nM/100nM respectively); and
(h) Angiotensin II (lOOnM). The phorbol esters were 
dissolved in the solvent dimethyl sulfoxide (DMSO) and DOG 
was dissolved in acetone. All other compounds were dissolved 
in glass distilled water. Control cells received drug 
vehicle alone. Following incubation with the various agents, 
the cells were removed from the conical flasks and 
centrifuged at 500g for 3 minutes in a Damon-IEC DPR 6000 
centrifuge. After removal of the supernatant and washing 
the cells in incubation medium (section 2.24(b) ) viability 
was assessed by trypan blue exclusion and was found to be in 
excess of 90% following each incubation period. The cell 
suspensions were centrifuged once more under the same 
conditions as above and finally resuspended in incubation 
medium for the determination of 4-androstene-3,17-dione 
metabolising activity.
2.4 DETERMINATION OF 4-ANDROSTENE-3,17-DIONE METABOLISM.
Metabolism of the steroid substrate 4-androste- 
ne-3,17-dione is known to occur due to the action of the 
various enzymes in the liver as shown if figure 2.
Gustafsson and Stenberg (1974) were responsible for 
elucidating the activities of the various enzymes involved 
in the metabolism of 4-androstene-3,17-dione and a
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modification of their methods of assessing its metabolism 
were employed here. Approximately 107 hepatocytes were 
suspended in incubation medium (section 2.24(b) ) and to the 
cell suspension was added 500pg (O.lpCi) of 
(4_i4 C)-androstene-3,17-dione and the suspension incubated 
for 30 minutes at 37°C in a shaking water bath.The reaction
was stopped by adding 10 ml of Folch (chloroform : methanol
2:1) to each sample, followed by lml; 0.9% of NaCl solution 
to aid extraction of the substrate and its metabolites into 
the organic layer. The samples were then shaken overnight.
The organic layer, once removed, was evaporated to dryness
under nitrogen at 45°C and the residue redissolved in 5 
drops of chloroform.Samples were then applied to TLC plates 
(Merck F254) and developed in chloroform/ethyl acetate (4:1) 
to separate the metabolites and unchanged substrate. 
Autoradiography of the TLC plates identified the location of 
each of the bands shown in figure 9 and the amount of 
14C-label present in each band (metabolites and substrate) 
was evaluated by liquid scintillation counting in 5ml 
Ecoscint (National Diagnostics, New Jersey) in a Packard 
Tricarb 2000CA counter. The amount of each metabolite, 
expressed as pmole metabolite formed per minute per 106 
cells was determined using the formula shown on the 
following page:
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pmol metabolite/min/106 cells = S x C m x l x l x l
Ct t n MW
S = amount of substrate added (pg)
Cm = d.p.m. metabolite
Ct = d.p.m. total
t = incubation time (minutes)
n = number of cells (divided by 106)
MW = molecular weight of substrate (280)
It is apparent from figure 9 that there are six main 
metabolites of androstenedione which can be separated by 
this method. However, in figure Q. we have shown that 3a/p 
oxosteroid oxidoreductase does not metabolise the parent 
compound, but metabolism by this enzyme occurs subsequent to 
metabolism by 5a-reductase. Hence, for the purpose of this 
study, only the activities of the enzyme metabolising the
parent molecule was evaluated and hence the amount of
metabolite produced by subsequent metabolism of 
5a-androstane-3,17-dione ( as produced by 5a reduction of 
androstenedione) by 3a/p oxosteroid oxidoreductase was not 
determined separately but the amount of metabolite produced 
by this enzyme was added to the amount of unchanged 
5a-androstane-3,17-dione to detemine the total amount of 
metabolite produced by the activity of 5a reductase per 
minute per 106 cells.
5 a - r e d u c t a s e
</ / 7  /'/'/>
S u b s t r a t e
3  Oc(/3) -hyd roxys te ro i d 
1 d e h y d r o g e n a s e
17cx(/3)-hydroxysteroid 
1 d e h y d r o g e n a s e
1 6 a - h y d r o x y l a s e
6/5- h y d r o x y l a s e
7o c- hyd ro xy las e
S u b s t r a t e
Figure 9:
Diagrammatic representation of the separation of the metabolites of 
4-androstene-3,17-dione by one dimensional thin layer chromatography.
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2.5 DETERMINATION OF SEX DIFFERENCES IN PHORBOL ESTER-
MEDIATED ALTERATION OF 4-ANDROSTENE-3,17-DIONE METABOLISM.
To investigate if the effect of the phorbol esters upon 
steroid metabolism were dependent on the sex of the animal, 
the effects of the active phorbol ester PMA and its inactive 
analogues 4aP and 4aPDD upon the metabolism of 4-androstene- 
-3,17-dione were examined in hepatocytes isolated from 
female Wistar rats kept under the same conditions as 
described in section 2.1. Hepatocytes were isolated as 
described in section 2.2, incubated with PMA (50nM), 4aP 
(lOOnM) or 4aPDD (lOOnM) for 10-120 minutes, carried out as 
described in section 2.3 and androstenedione metabolising 
activity was determined as described in section 2.4.
2.6 ELECTROPERMEABILISATION OF HEPATOCYTES.
2.6(a) THEORETICAL ASSESSMENT OF ELECTROPERMEABILISATION 
PARAMETERS.
Electropermeabilisation of freshly isolated hepatocytes 
was carried out essentially by the method of Knight and 
Baker (1982). By this method, a potential difference 
applied across the plasma membrane of the hepatocyte punc­
tures two pores in the membrane which allows the access of 
small molecules to the interior of the cell. A diagrammatic 
representation of the hepatocyte subjected to an electrical 
field is shown in figure 10 and the potential difference 
across the membrane at any point (P) around the 
circumference of the cell (Vp) is given by the equation
Vp = CbEcosG.
In the equation, b is the cell radius, the angle 0 is
Figure 10:
Diagrammatic representation of a  cell of radius b subjected to an electrical field 
of force E. (Adapted from Knight & Baker, 1982).
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as shown in the diagram, E~is the strength of the applied 
electric field and C is a constant dependent on the relative 
conductivities of the extracellular field, the cytosol and 
the membrane with relation to cell size and membrane 
thickness. For ease, the value of C is taken to be 1.5 
(Knight & Baker, 1982). By the equation, it can be seen 
that between points A and B, the potential difference across 
the membrane of the hepatocyte will be at its greatest and 
at this point the value of cosG will be 1. Hence,the equa­
tion can be simplified to;
Vp = 1. 5bE
It has been shown that plasma membranes can rupture at 
voltages in excess of IV (Zimmerman et al, 1974) and it has 
been shown that hepatocytes have a radius of approximately 
10pm (Knight & Baker, 1982) and so an applied field strength 
of lOOOV/cm would yield a transmembrane potential of 1.5V 
across the plasma membrane. Cell mitochondria have a radius 
of approximately 0.5pm (Knight & Baker, 1982) and so an 
applied field strength of lOOOV/cm would yield a transmem­
brane potential of 75mV. An applied field strength of 
lOOOV/cm is theoretically sufficient to cause rupture of the 
cell membrane of the hepatocyte without causing damage to 
other cell organelles.
2.6(b) EXPERIMENTAL ASSESSMENT OF ELECTROPERMEABILISATION 
PARAMETERS.
The apparatus used to induce cell electropermeabilisa­
tion of the hepatocyte is shown in figure 11.
The efficiency of the apparatus to electro-
High Voltage 
Supply
Capacitor
Electrodes (metal
Cells
1 cm
Figure 11:
Representation of the apparatus used to induce electropermeabilisation to 
hepatocyte suspensions. (Adapted from Knight & Baker, 1982).
81
permeabilise hepatocytes and to allow access of the small 
compound, cyclic AMP, was investigated extensively in our 
laboratory by Dr. Lesley Berry (Ph.D. thesis, 1989). By 
subjecting the cells to a range of parameters to cause 
electropermeabilisation (2-10 pulses at 1000-3000V/cm) and 
then assessing the cells for the degree of access of cyclic 
AMP, determined by radioimmunoassay it became apparent that 
5 pulses at lOOOV/cm resulted in an almost 100% 
permeabilisation of the cell membrane, without excessive 
cell damage, a value which correlated well with the 
theoretical assessment of permeabilisation.
As a further confirmation that permeabilisation had 
occurred, cells were stained with the dye ethydium bromide. 
Permeabilisation of the cells allows the dye into the cell 
where it can be seen as a red intracellular marker. Cell 
viability, as assessed by trypan blue exclusion, was found 
to be reduced to 75-80% by electropermeabilisation (lOOOV/cm 
x 5) but there was no apparent further reduction in cell 
viability over a three hour incubation period following 
permeabilisation. The optimum parameters to use for further 
experiments were chosen to be 5 pulses at lOOOV/cm.
2.7 ASSESSMENT OF THE ROLE OF PROTEIN SYNTHESIS IN THE 
ACTIONS OF PHORBOL ESTERS.
To assess the role of protein synthesis in the effects 
of PMA (50nM) in electropermeabilised hepatocytes, the 
translation blocker cycloheximide (lOpM) (Peshka, 1971) was 
added to permeabilised hepatocytes after a 30 minute prein­
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cubation period as described in section 2.3. After the 
initial preincubation with cycloheximide, the cells were 
resupplemented with cycloheximide to give a final concen­
tration in the incubations of lOpM and then challenged with 
PMA (50nM). The cells were then incubated for times ranging 
between 10 and 80 minutes under conditions described previ­
ously (section 2.3). 4-Androstene-3,17-dione metabolism was 
assessed as described in section 2.4.
2.8 ASSESSMENT OF THE ROLE OF PROTEIN KINASES IN THE EFFECTS 
OF PHORBOL ESTERS.
The role of the different intracellular protein kinases 
in the effects of PMA in permeabilised hepatocytes were 
assessed by the use of the following non-selective and 
selective protein kinase inhibitors: (a) K252a, 20nM
( (8R*,9S,11S*)-(-)-9-Hydroxy-9-methoxycarbonyl-8-methyl-
2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a- 
triazadibenzo(a ,g )cycloocta(c,d ,e )trienden-l-one; inhibits 
all protein kinases) ; (b) K252b, 20nM (the 9-carboxylic 
acid derivative of K252a; a selective inhibitor of protein 
kinase C) ; and (c) KT5720, 60nM (the 9-hexoxy-carbonyl 
derivative of K252a; a selective inhibitor of protein kinase 
A) (Kase et al, 1986; Nakanishi et al, 1986; Kase et al,
1987). The inhibitors were added to the hepatocytes prior 
to permeabilisation to give the concentrations listed above. 
The cells were preincubated with the inhibitors for 30 
minutes and then repermeabilised and resupplemented with the 
inhibitors to maintain the correct active concentrations.
The inhibitors were added in DMSO and control cells received
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DMSO only. Incubation with-PMA (50nM) (section 2.3) and 
assessment on 4-androstene-3,17-dione metabolism (section 
2.4) was as described previously. Preliminary experiments 
indicated that the inhibitors were unable to penetrate the 
cell membrane in the intact cell and so the roles of the 
protein kinase inhibitors on the actions of PMA were 
assessed in electropermeabilised hepatocytes only.
2.9 ASSESSMENT OF PROTEIN KINASE C ACTIVATION BY PHORBOL 
ESTERS.
Measurement of protein kinase C translocation from the 
cytosol to the plasma membrane is a well-accepted method for 
determining levels of activation of this kinase by various 
agonists (Gopalakrishna et al, 1986; Niedel & Blackshear, 
1986). As the kinase is the proposed intracellular receptor 
for the phorbol esters (Niedel et al, 1983; Nishizuka,
1984a) techniques now exist which determine protein kinase C 
levels in both the soluble and particulate fractions and 
this can provide information as to the degree of protein 
kinase C activation in the presence of known activators of 
this enzyme. The experimental details of the assay used in 
this study are described in detail by Pelech et al (1986) 
and the advantage of this procedure over other assays is 
that it avoids homogenization and fractionation of the cells 
and thus minimizes the influence of factors that could 
potentially interfere with a quantitative analysis of the 
subcellular distribution of protein kinase C. Isolated 
intact hepatocytes (as described in section 2.2) were 
incubated with either PMA (lOOnM, lOnM, 5nM or O.lnM) or
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DMSO as described in section 2.3.
(a) Preparation of extracts: After centrifugation, the cells 
were washed twice with 1ml of ice-cold phosphate buffered 
saline (lOOmM, pH 7.4) . The soluble extract was produced 
by incubating the cells at 0°C for 5 minutes with 0.2ml of 
buffer A (0.5mg of digitonin/ml, 20mM MOPS, pH 7.2, lOmM 
EGTA and 5mM EDTA). The cell remnants, after removal of the 
soluble extract, were solubilized in 0.2ml of buffer A plus 
0.5% Triton X to obtain the particulate extract. The 
extracts were used immediately after they were prepared.
(b) Enzyme assay: The cellular extracts were incubated for 
10 minutes at 30°C in the absence or presence of 7.5pg of 
trypsin/ml and 0.15mg of lima bean trypsin inihibitor added 
subsequently to terminate trypsinolysis. All kinase assays 
contained 20nM KT5720 (see section 2.9), 50pM (tf”32P )ATP,
75mM magnesium chloride, lmg histone Hl/ml and lOpl of the 
soluble or particulate extract in a final volume of 25pl.
The kinase assays commenced upon the addition of (^32P)ATP 
and were of 15 minutes duration at 30°C. At the conclusion 
of the reaction period, 20pl aliquots were spotted onto 
1.5cm2 pieces of Whatman P81 phosphocellulose paper and 
washed five times for at least 2 minutes per wash in a 
solution of 10ml of phosphoric acid/L of H20. The wet 
filter papers were transferred into scintillation vials 
containing 5ml Ecoscint and analyzed for radioactivity in a 
Packard Tricarb 2000CA counter. The results are expressed 
as fmole ATP/minute/106 cells.
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2.10 ASSESSMENT OF THE ROLE OF COFACTORS IN PHORBOL
ESTER-MEDIATED ALTERATIONS IN 4-ANDROSTENE-3,17-DIONE 
METABOLISM.
To investigate if the effects of PMA are mediated by 
changes in the levels of cofactors associated with the 
cytochrome P450-linked enzymes, the metabolism of 
4-androstene-3,17-dione was examined in hepatocytes which 
had been homogenized and then supplemented with excess 
cofactors following incubation with PMA (incubation with PMA 
as described in section 2.3). Before resuspending in 
incubation medium and before assaying with 
4-androstene-3,17-dione, the washed hepatocytes were 
resuspended in a small volume of incubation medium and 
homogenized using a Potter-Elvejhem homogeniser with a 
teflon pestle (2500 r.p.m. for 5 strokes). The homogenates 
were then made up to 3ml volume with incubation medium, to 
give a cell density of approximately 107 homogenized cells 
in each 3ml aliquot. To each homogenate aliquot was added 
0.8mg NADP and 4mg isocitric acid in lOOpl manganese 
chloride (6mg/100ml) followed by lOpl of isocitrate 
dehydrodgenase to start the reaction. The samples were then 
preincubated at 37°C for 2 minutes to allow the generation 
of NADPH in the homogenates. 500pg (O.lpCi) of 
4-androstene-3,17-dione was then added to each sample and 
the metabolism of 4-androstene-3,17-dione was assayed as 
described in section 2.4
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2.11 FURTHER ASSESSMENT OF THE ROLE OF COFACTORS IN PHORBOL
ESTER-MEDIATED EFFECTS IN HEPATOCYTES.
As well as assessing cofactor availability (section 
2.10) cofactor degradation was also studied. Intact 
hepatocytes were treated with PMA (50nM) or DMSO as in 
section 2.3. The centrifuged cells were resuspended in a 
small volume of incubation medium and homogenised using the 
Potter-Elvejhem homogeniser (2500 r.p.m. for 5 strokes) and 
the homogenate resuspended in incubation medium to give a 
cell density of 3 X 107 homogenBlB cells per ml. 3ml 
aliquots of homogenate suspension were added to cuvettes and 
to the test cuvette was added 2mg of NADPH. The contents 
were mixed rapidly and read against a reference cuvette, 
which contained homogenate only, in a Shimadzu UV/VIS 
spectrophotometer at 340nm. The rate of disappearance of 
NADPH from the homogenate aliquot was determined using a 
rate assay programme and the rate of disappearance of NADPH 
was expressed as pmole NADPH per minute per 106 cells.
2.12 ASSESSMENT OF NADPH CYTOCHROME C(P450) REDUCTASE 
ACTIVITY IN THE PRESENCE OF PMA.
NADPH cytochrome c (P450) reductase activity was 
routinely measured by the method of Philips and Langdon 
(1962). This assay makes use of the increase in absorbance 
at 550nm of the artificial electron acceptor, cytochrome 
c, when reduced. For this assay, three solutions were 
prepared; Solution A which contained 9.75mg potassium 
cyanide, 366mg nicotinamide dissolved in 100ml Tris buffer 
(0.05M at pH7.4) containing ImM EDTA; Solution B which
87
contained cytochrome c, 3.68mg/ml in distilled water and 
solution C which contained NADPH, 5mg/ml in distilled 
water. Hepatocytes were incubated as described in section 
2.3 with PMA (50nM)/DMSO and centrifuged cells homogenised 
with the Potter-Elvejhem homogeniser (2500 r.p.m. for 5 
strokes) then made up to 3ml aliquots in incubation medium 
at a cell density of 3 X 107 cells. The procedure for the 
assay was; 2ml of solution A and 0.1ml of solution C were 
incubated in a test-tube for 8 minutes at room temperature. 
After this time, 0.5ml of solution B was added and 
incubated for a further 2 minutes at room temperature.
0.5ml of cell homogenate was added to the solution mix, the 
contents mixed rapidly and then added to a cuvette. The 
change in absorbance at 550nm was recorded against a blank 
which had the same contents as above, except the addition of 
solution C was replaced by the addition of 0.1ml of 
distilled water. The concentration of NADPH cytochrome c was 
determined using the molar extinction coefficient (19.1 X 
103). The activity of the reductase is expressed as pmole 
cytochrome c (P450) reduced per minute per 106 cells.
2.13 ISOLATION OF HEPATOCYTES IN PHOSPHATE-FREE MEDIUM.
Hepatocytes were isolated by the two stage collagenase 
perfusion technique as described in section 2.2. The 
protocol was modified slightly in that phosphate-free, 
calcium-free Hanks B.S.S. (section 2.24(c) ) was used for 
the isolation procedure instead of calcium-free Hanks B.S.S. 
as used in section 2.2. Again viability was assessed by 
trypan blue exclusion and found to be greater than 98%.
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Following isolation, the hepatocytes were suspended in 
phosphate-free incubation medium (section 2.24(d) ) 
supplemented with 0.1% bovine serum albumin at a cell 
density of 2 X 107 cells per ml. The medium was found to 
maintain cells in a satisfactory condition for up to 4 
hours, a time period well in excess of the incubation times 
of our studies.
2.14 PREINCUBATION OF HEPATOCYTES WITH (32P )ORTHOPHOSPHATE.
Intact hepatocytes were labelled up with 
(32p )orthophosphate for 90 minutes at 37°C, at a 
concentration of lOpCi per 106 cells. The incubations were 
performed in 25ml conical flasks in a water bath maintained 
at 37°C. The cell suspension was aspirated with 95% 02 / 
5%C02 to maintain the atmosphere and to prevent cell 
clumping.
2.15 INCUBATION OF (32P) LABELLED HEPATOCYTES WITH PMA.
After preincubation with (32P)orthophosphate, cells 
were centrifuged at 500g for 3 minutes in a Damon-IEC DPR 
6000 centrifuge, the supernatant was removed and cells 
washed with phosphate-free incubation medium (+ 0.1% bovine 
serum albumin). This process was repeated three times to 
remove excess and unbound (32P) orthophosphate from the 
cells. The final suspension of the cells was in
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phosphate-free incubation medium (+ 0.1% bovine serum 
albumin) at a cell density of 5 X 106 cells per ml. 
Incubations were performed in lOOpl aliquots of this cell 
suspension ( 5 X 105 cells per incubation).
PMA was added in a 5pl volume to the lOOpl aliquot to
give a final concentration of 50nM and control cells
received 5pl of drug vehicle alone. Incubations were 
conducted at 37°C for times ranging between 10 and 60 
minutes.
2.16 PREPARATION OF SOLUBILISED CELL SAMPLES. Following 
incubation with PMA (50nM), 400pl of sample solvent 
(bromophenol blue,0.01% w/v, sodium dodecyl sulphate, 4.6% 
w/v, "Tris" base, 20% w/v, mercaptoethanol, 10% w/v and 
glycerol, 15%w/v, in distilled water , pH 6.8) was added to 
each lOOpl aliquot sample and the samples were then boiled 
in a 100°C water bath for 5 minutes to ensure solubilisation 
of cell proteins. The solubilised samples were allowed to
cool to room temperature and the samples either used
directly or stored at -20°C.
2.17 ISOLATION OF SPECIFIC CYTOCHROME P450 ISOZYMES 
FOLLOWING INCUBATION WITH 32P-LABELLED ORTHOPHOSPHATE.
After preincubation with (32P)orthophosphate as in section 
2.14, the cells were spun at 500g for 3 minute in a 
Damon-IEC DPR 6000 centrifuge and the supernatant removed. 
The cells were resuspended in phosphate-free incubation 
medium and then treated with PMA(50nM)/DMSO for 60 minutes 
as described in section 2.15. After centrifugation, the
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cells were resuspended in 2ml of 1.8% sodium cholate 
solution and the cells dispersed by passage through a 
syringe and needle (26g). The dispersed sample was then 
made up to 10ml with sodium cholate (1.8% w/v) in 
nitrocellulose ultracentrifuge tubes, the tubes capped and 
centrifuged at 105,000g for 1 hour at 4°C in a Beckman L8-M 
ultracentrifuge. 500pl aliquots of a 1:1000 dilution of 
specific cytochrome P450 antibodies were then added to 1ml
aliquots of ultracentrifuged supernatant (106 cells). The
following specific P450 antibodies were investigated:
Trivial Name P450 Family
* aPB2c P450II Cll
* aPB3a P450II B1
* MC-lb P450I Al
* UT 1 P450II Al
From nomenclature by Pyerin et al (1987) and Gonzalez 
(1989)
The antibodies were raised in rabbits against purified 
rat cytochrome P450 isozymes. The antibodies were made up 
in phosphate-free incubation medium supplemented with 0.1% 
bovine serum albumin. After addition of the antibodies, the 
samples were incubated on ice for 30 minutes and then 
centrifuged at 25,000g for 30 minutes at 4°C in a Beckman 
L8-M ultracentrifuge. The supernatant was removed from each 
sample and the immunoprecipitate was washed and dissolved in 
50pl of sample solvent, boiled and cooled as in section 
2.16.
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2.18 FURTHER ASSESSMENT OF-SPECIFIC CYTOCHROME P450
ISOZYMES.
To further assess phosphorylation of specific 
cytochrome P450 isozymes, the experiments described in 
section 2.13 - 2.17 were repeated, with modifications.
After collagenase perfusion, the hepatocytes were isolated 
into phosphate-free incubation medium, as in section 2.13, 
but the incubation medium was supplemented with 20mM 
p-glycerophosphate, a phosphatase inhibitor. After 
isolation, hepatocytes were treated as described in sections
2.14 and 2.17 to yield the specific isozyme precipitates.
The specific isozyme precipitates were then added to 5ml 
Ecoscint scintillation fluid and the degree of phosphate 
incorporated into the precipitates was determined by 
counting the precipitates in a Packard Tricarb 2000 CA 
liquid scintillation counter.
2.19 ASSESSMENT OF HAEM CONTENT.
Antibody-antigen precipitates to the specific isozymes 
aPB2c, aMC-lb, UT-1 and aPB3a were obtained as described in 
section 2.15 and 2.17. The resulting precipitates were 
dissolved in 5.3ml of 0.1M NaOH and 0.7ml of pyridine and 
the resulting mixture left to stand at room temperature for 
30 minutes. After this time, 3ml samples were taken and 
placed in cuvettes and baseline readings obtained. The 
samples were then reduced by the addition of 5mg of sodium 
dithionite and the test sample bubbled for 30 seconds with 
carbon monoxide. The reduced CO spectrum was then measured 
in a Shimadzu UV/VIS spectrophotometer between the
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wavelengths of 500 and 600nm, based on the method of Omura 
ans Sato (1964b). The change in absorbance (A Abs) between 
557 and 575nm was measured and nmoles haem produced 
determined.
2.20 PREINCUBATION OF HEPATOCYTES WITH (^-32P)ADENOSINE-5- 
TRIPHOSPHATE (ATP).
Intact hepatocytes were isolated as in section 2.13, 
into phosphate-free incubation medium supplemented with 20mM 
p-glycerophosphate and 0.1% bovine serum albumin, at a cell 
density of 2 X 107 cells per ml. The intact cells were 
electropermeabilised (1000V for 5 pulses) and the 
permeabilised cells were then incubated at 0°C for 15 
minutes in the presence of lOOpCi of (^32P)ATP.
2.21 INCUBATION OF Cff32P )ATP-LABELLED HEPATOCYTES WITH PMA. 
After preincubation with (^32P)ATP as in section 2.20,
the hepatocytes were divided into lOOpl aliquots 
(approximately 5 X 105 cells per incubation). To each lOOpl 
aliquot was added 5pl of DMSO or 5pl of PMA (final 
concentration 50nM per incubation), and all incubations were 
then performed at 37°C for time periods ranging between 10 
and 60 minutes. After the respective incubation time, cell 
samples were solubilised as described in section 2.16.
93
2.22 ASSESSMENT OF THE ACTION OF PROTEIN KINASE INHIBITORS 
IN (^3 2P )ATP-LABELLED HEPATOCYTES.
Hepatocytes were isolated as in section 2.20. After 
labelling with (^32P)ATP/ lOOpl aliquots of labelled cells 
were incubated at 37°C for 30 minutes with the specific 
protein kinase C inhibitor, K252b (section 2.8), which was 
added in a 5 pi volume to give a concentration of 20nM. 
Control cells received drug vehicle alone (DMSO) and were 
also incubated at 37°C for 30 minutes. Following treatment 
with K252b, 5pl of PMA (50nM final concentration) or 5pl 
DMSO were added to the aliquots and the samples further 
incubated for between 10 and 60 minutes at 37°C.
Solubilised samples were prepared as in section 2.16.
2.23 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS PAGE) OF SOLUBILISED CELL SAMPLES AND 
DETECTION OF PHOSPHOPROTEINS.
The solubilised cell samples were resolved into their 
constituent proteins on 7.5% polyacrylamide slab gels, as 
described by Smith (1984). Samples generated from whole cell 
proteins were applied to the gels in 20pl aliquots 
(equivalent to 2 X 104 cells, 12-15pg protein) to each 
sample well. Samples generated from immunoprecipitated 
cytochrome P450 isozymes were applied in the full 50pl 
volume (extract from 106 cells) to the sample well. The 
samples were subjected to electrophoresis towards the anode 
at a constant voltage of 150V for 3.5 hours until the 
bromophenol blue marker in the sample solvent had reached 
the bottom of the gel. The gels were then fixed and stained
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for 1.5 hours at room temperature in 0.1% w/v coomasie 
brilliant blue R-250 in methanol/glacial acetic acid/water 
(5:1:1). Gels were destained for 24 hours at room 
temperature in methanol/glacial acetic acid/water (8:1:1) 
with several changes of destaining solution. Destained gels 
were placed on absorbent paper, covered in non porous 
plastic film (Cling Wrap) and then dried under vacuum at a 
temperature of 60°C on a Bio-Rad Model 224 Gel slab dryer 
for 3 hours. Dried gels were then autoradiographed at -70°C 
for 4 weeks ((32P)orthophosphate-labelled samples) or for 10 
days ((^32P)ATP-labelled samples). The degree of 
incorporation of 32P into whole cell proteins or 
immunoprecipitated samples was assessed by visual analysis 
of X-ray film after developing.
2.24 BUFFERS AND PHYSIOLOGICAL SOLUTIONS.
(A) CALCIUM-FREE HANKS BALANCED SALT SOLUTION.
KCL 200mg
KH2P04 (anhydrous) 30mg
4000mg (4g)NaCl
Na2HP04 (anhydrous) 24mg
NaHC03 (anhydrous) 1050mg (1.05g)
In glass distilled water to 1 litre, pH 7.4.
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(b) INCUBATION MEDIUM.
Glucose lOOOmg (lg)
MgS04 .7H2 0 lOOmg
MgCl2 .6H20 lOOmg
CaCl2 185mg
In 100ml of Hanks B.S.S. and made up to 1 litre.
(c) CALCIUM-FREE, PHOSPHATE-FREE HANKS BALANCED SALT 
SOLUTION.
KCl 200mg
K2S04 (anhydrous) 30mg
NaCl 4000mg (4g)
Na2S04 (anhydrous) 24mg
NaHC03 (anhydrous) 1050mg (1.05g)
In glass distilled water to 1 litre.
(d) PHOSPHATE-FREE INCUBATION MEDIUM.
As in 2.24(b) but made up in 100ml of calcium-free, 
phosphate-free Hanks B.S.S. and made up to 1 litre with 
distilled water.
2.25 CHEMICALS.
Chemicals and reagents are listed according to the
manufacturer.
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Sigma Chemicals Ltd.,- Poole, Dorset, U.K.
4p-Phorbol-12-myristate-13-acetate
4a-Phorbol
4a-Phorbol-12,13-didecanoate 
1 ,2-Dioctanoylglycerol 
4-Androstene-3,17-dione (Unlabelled)
Ionophore A23187 
Angiotensin II 
Vasopressin 
Cycloheximide 
"Tris" Base 
Bromophenol Blue 
Bis-acrylamide 
Acrylamide
Sodium dodecyl sulphate
Coomasie Brilliant Blue R-250
p-Glycerophosphate
Nicotinamide
Cytochrome c
Digitonin
MOPS (3-(N-Morpholino)propanesulfonic acid)
EDTA (Ethylenediaminetetraacetic acid)
EGTA (Ethylene Glycol-bis(p-aminoethyl
Ether)N/N,Nl,N’-Tetraacectic acid )
Trypsin
Trypsin inhibitor (Lima bean)
Histone HI
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BCL Ltd., Lewes, East-Sussex, U.K.
Collagenase
Bovine serum albumin (Fraktion V)
NADP
NADPH
Isocitrate dehydrodgenase 
Isocitric acid
Amersham International pic., Aylesbury, Bucks., UK. 
(4-14C)Androstene-3,17-dione
(X32P)Adenosine triphosphate (Triethylene ammonium 
salt)
Gibco BRL Ltd., Paisley, Scotland, UK.
Hams F10
Penicillin/Streptomycin solution
Kodak, France 
X Ray film (X-Omat S)
Developer (D-19)
Fixer (FX-40)
Miscellaneous
(3 2p)Qrthophosphate was supplied by the Radionuclide 
Dispensary, Western Infirmary, Glasgow, U.K.
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K-252a,K-252b & KT572Q:These were kindly donated by Dr 
H. Kase, Kyowa Hakko Kogyo Co. Ltd., Tokyo, Japan.
Cytochrome P450 antibodies specific for cytochrome P450 
isozymes were a kind gift from Dr C.R. Wolf, ICRF, 
Edinburgh, Scotland, U.K.
All other chemicals and reagents were of the highest 
analytical grade commercially available.
2.26 STATISTICS
Results were expressed as percentage of relevant con­
trol ± standard deviation. Statistical analysis was per­
formed using Student's t-test. Statistical significance was 
set at p<0.01 in all cases.
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RESULTS.
3.1 Metabolism of 4-androstene-3,17-dione in hepatocytes
from freshly isolated male and female rat hepatocytes.
The first part of our study was to investigate the 
actual method of 4-androstene-3,17-dione metabolism and to 
determine what could be seen from the results of the assay 
and how these are interpreted. The methods section 2.4 
(figure 9) shows the characteristic band pattern of 
4-androstene-3,17-dione metabolism and each band is 
interpreted as follows;
Band 1 Start point for chromotography run
and not analyzed further.
Band 2 Represents 7a-hydroxylase .
Band 3 Represents 6f3-hydroxylase .
Band 4 Represents 16a-hydroxylase.
Band 5 Represents 17a(£)-hydroxysteroid
dehydrogenase.
Band 6 Represents 3a(p)-hydroxysteroid
dehydrogenase
Band 7 Represents unmetabolised androstene-
dione substrate.
Band 8 Represents 5a-reductase.
The values for activity for the enzymes 
3a(p)-hydroxysteroid dehydrogenase and 5a-reductase are 
amalgamated to give one overall value for the activity of 
5a-reductase (see section 2.4 for explanation). The start 
band and the band for unmetabolised androstenedione 
substrate are not analyzed further and hence, the assay for 
androstenedione is concerned with determining the activities
1 0 1
of 5 different enzymes. Tabular data expresses the enzyme 
activities as pmole product per minute per 106 cells, 
whereas graphical data is transferred to mean percentage of 
relevant control to give a better illustration of changes in 
activity which may be occuring.
Table 3 shows the activities of each of the five 
enzymes metabolising 4-androstene-3,17-dione in freshly 
isolated hepatocytes from male and female rats. It can be 
seen that the well documented sexually differentiated 
pattern of enzyme profiles are expressed in the isolated rat 
hepatocyte. Thus;
7a-hydroxylase Female > Male
6p-hydroxylase Female < Male
16a-hydroxylase Female << Male
17-hydroxysteroid dehydrodgenase Female < Male 
5a-reductase Female >> Male
In the results in table 3, female 6p-hydroxylase 
activity is 54.7% of male 6p-hydroxylase activity and female 
5a-reductase activity is 156.9% of male 5a-reductase 
activity. In our experiments in general,in contradiction to 
the above enzyme profile of activity, 7a-hydroxylase 
activity was greater in males than females and 
17-hydroxysteroid dehydrogenase activity was also greater in 
males than females. Table 3 shows that these enzymes in 
females have activities of 85.6% and 81.4% respectively of 
corresponding male activities.
7aOH 6fiOH 16aOH 170HSD 5aRed.
Male 89.3±10.5 64.3±7.9 102.3±7.2 85.5±6.4 413±24
Female 76.419.8 35.214.3 49.615.3 69.417.9 639163
Table 3: The activities of 7a-hydroxylase (7aOH),
60-hydroxylase (60OH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) in freshly isolated rat hepatocytes from males and 
females. Results expressed as pmole metabolite formed per 
minute per 106 cells 1 S.D. for 5 cell samples.
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3.2 Effects of phorbol est-ers upon the metabolism of 
4-androstene-3,17-dione in isolated male rat hepatocytes.
3.2(a) Effects of 40-Phorbol-12-myristate-13-acetate in 
male rat hepatocytes.
To account for biological variation and cellular 
differences from preparation to preparation, the effects of 
the different compounds investigated upon the activities of 
the enzymes metabolising 4-androstene-3,17-dione are 
expressed as percentage of the relevant control activity. By 
expressing results in this way, we compensate for the fact 
that control activities can vary during the time course of 
the experiment.
The effects of the biologically active protein kinase C 
-activating phorbol ester 40-phorbol-12-myristate-13-acetate 
(PMA), at two different concentrations are shown in Figures 
12 and 13.
Figure 12A & 12B shows the effect of PMA at a 
concentration of 50nM. It can be seen that all enzymes, 
apart from 5a-reductase, were showing reductions in activity 
after 10 minutes incubation with PMA. The reductions were to 
70 - 90% of control and the reduction in activity for 
17-hydroxysteroid dehydrodgenase was statistically 
significant (71% of control, p<0.01). By 30 minutes, enzyme 
activity was further reduced, apart from 16a-hydroxylase 
which had drifted back towards control activity. The 
reductions in enzyme activity seen at 60 minutes were 
maximal for the following enzymes: 7a-hydroxylase reduced to 
54% of control, 60-hydroxylase reduced to 56% of control and
10 3
5a-reductase reduced to 60-% of control. These maximum 
reductions in enzyme activity were all statistically 
significant (p<0.01). The activities of all enzymes, except 
16a-hydroxylase, had returned to control levels by 120 
minutes. The maximum reduction in activity for 
16a-hydroxylase was seen at 120 minutes (54% of control,
p<0.01).
The effect of InM PMA is shown in figure 13A & 13B.
The effects of InM PMA upon enzyme activity parallels quite 
closely that seen with 50nM PMA (figure 12A & 12B), 
indicating that the effects of PMA had reached their maximum 
at InM. All enzyme activities, apart from the 
16a-hydroxylase noted above, showed maximum reductions after 
60 minutes incubation with PMA. The reductions were: 
7a-hydroxylase and 5a-reductase reduced to 55% of control, 
60-hydroxylase reduced to 56% of control and 
17-hydroxysteroid dehydrogenase reduced to 69% of control 
(p<0.01 in all cases). The maximum reduction in activity 
for 16a-hydroxylase was at 20 minutes, with a reduction to 
79% of control, but this was not statistically significant. 
All enzyme activities, except 60-hydroxylase, had returned 
to control levels by 80 minutes. As both concentrations of 
PMA produced similar effects upon the enzymes metabolising 
4-androstene-3,17-dione, 50nM PMA was chosen as the 
concentration of phorbol ester for subsequent experiments.
Table 4 shows the activities of all the enzymes in the 
presence of 50nM PMA with time. Table 5 shows the effect of 
InM PMA upon enzyme activity.
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TABLE 4A
7aOH 6{30H 16aOH 17QHSD 5aRed.
10 min 89.1±1.9 64.2±7.4 53.4±8.2 63.512.4 72.418.1
30 min 76.412.1 68.818.3 50.611.5 41.814.2 65.412.3
60 min 79.313.8 62.312.5 59.311.4 56.318.1 65.319.8
120 min 40.111.6 39.411.4 57.213.9 42.911.9 46.811.9
TABLE 4B
7aOH 6j30H 16aOH 170HSD 5aRed.
10 min 69.413.4 57.217.1 46.512.1 *45.214.1 78.418.1
30 min *58.112.4 54.412.9 48.317.2 *32.616.1 49.216.1
60 min *43.414.1 *34.514.1 70.413.9 *43.418.1 *39.316.5
120 min 42.614.2 36.216.1 *31.216.1 40.318.2 45.617.1
Table 4: Changes in the activities of 7a-hydroxylase
(7aOH)# 6p-hydroxylase (6pOH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated male rat hepatocytes from 
control (Table 4A) and PMA-treated (50nM)(Table 4B) samples. 
Results expressed as pmole metabolite formed per minute per 
106 cells 1 S.D. of 9 cell samples. (* p<0.01)
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TABLE !5A
7aOH 6f30H 16aOH 170HSD 5aRed
10 min 62.418.1 13316 66.316.1 10219 42314
20 min 75.315.1 11613 84.512.2 9718 37716
40 min 66.216.4 11716 70.218.9 9715 30013
60 min 84.315.3 11012 74.312.1 10719 35114
80 min 56.218.1 10615 63.818.1 9013 336110
TABLE !5B
7aOH 60OH 16aOH 170HSD 5aRed
10 min 70.318.1 *10316 73.216.1 92.414.1 40615
20 min *54.414.3 10612 66.414.1 74.512.0 29518
40 min 59.413.9 * 6915 64.315.1 *67.315.1 * 22518
60 min *47.218.4 6015 63.215.1 *59.418.1 *24312
80 min 55.415.2 * 6316 60.414.7 81.612.1 29717
Table 5: Changes in the activities of 7a-hydroxylase
(7aOH), 6p-hydroxylase (6£0H), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in hepatocytes isolated from male rats 
from control (Table 5A) and PMA-treated (InM)(Table 5B) 
samples. Results expressed as pmole metabolite formed per 
minute per 106 cells ± S.D. of 6 cell samples. (* p<0.01)
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3.2(b) Effects of 4a-Phorbol in male rat hepatocytes. The 
effect of the phorbol ester, 4a-phorbol (lOOnM), which does 
not activate protein kinase C, is shown in figure 14A & 14B.
In comparison to the protein kinase C activating 
phorbol ester, PMA (Figures 12 & 13), the inactive 
4a-phorbol shows some increases and decreases in enzyme 
activity as time proceeds. Although some of the reductions 
appear quite marked, such as 16a-hydroxylase (reduced to 80% 
of control at 60 minutes) none of the reductions in activity 
were statistically significant. There are also some marked 
increases in activity, notably for 16a-hydroxylase (126% of 
control at 10 minutes), 5a-reductase (136% of control at 10 
minutes), 17-hydroxysteroid dehydrogenase (134% of control 
at 30 minutes) and 7a-hydroxylase (138% of control at 120 
minutes). These increases were statistically significant 
(p<0.01), compared to control activities. Apart from these 
four significant increases in activity, 4a-phorbol caused 
only minor fluctuations in enzyme activity at all time 
points.
The effect of 4a-phorbol (lOOnM) upon each of the 
enzymes activities with time are shown in table 6.
3.2(c) Effects of 4a-Phorbol-12,13-didecanoate in male rat 
hepatocytes.
The effects of another phorbol ester,
4a-phorbol-12,13-didecanoate (4aPDD) (lOOnM), which is also 
inactive toward protein kinase C, are shown in figure 15A & 
15B.
As seen with 4a-phorbol, (Figures 14A & 14B), 4aPDD
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TABLE 6A
7qOH 6{30H 16qOH 170HSD 5aRed.
10 min 89.1±1.9 64.2±7.4 53.4±8.2 63.5±2.4 72.4±8.1
30 min 76.4±2.1 68.818.3 50.611.5 41.814.2 65.412.3
60 min 79.313.8 62.312.5 59.311.4 56.318.1 65.318.9
120 min 40.111.6 39.411.4 57.213.9 42.911.9 46.812.9
TABLE 6B
7aOH 6ftOH 16aOH 170HSD 5aRed.
10 min 101.014.0 66.216.1 *67.513.1 65.412.3 *98.214.1
30 min *81.316.1 77.314.1 59.215.1 *56.114.1 68.313.4
60 min 70.513.4 55.418.2 47.314.1 49.316.2 64.615.1
120 min*64.212.1 49.312.1 49.512.8 48.519.1 49.314.3
Table 6: Changes in the activities of 7a-hydroxylase
(7aOH), 6p-hydroxylase (6pOH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated male rat hepatocytes from 
control (Table 6A) or 4a-phorbol-treated (lOOnM)(Table 6B) 
samples. Results expressed as pmole metabolite formed per 
minute per 106 cells 1 S.D. of 9 cell samples. (*p<0.01)
105
causes minor increases and- decreases in enzyme activity for 
all the enzymes metabolising 4-androstene-3,17-dione. None 
of these fluctuations in activity were statistically 
significant when compared to their relevant control 
activities at each time point, suggesting little or no 
effect of 4aPDD on the activities of the enzymes 
metabolising 4-androstene-3,17-dione. Table 7 shows
the effect of 4a-phorbol-12,13-didecanoate (lOOnM) upon each 
of the enzyme activities with time.
3.3 Effects of phorbol esters upon the metabolism of 
4-androstene-3,17-dione in isolated female rat hepatocytes.
3.3(a) Effect of 4p-Phorbol-12-myristate-13-acetate (PMA) in 
female rat hepatocytes.
The effects of PMA (50nM) upon the activities of all 
enzymes metabolising 4-androstene-3,17-dione in isolated 
female rat hepatocytes are shown in figure 16A & 16B. The 
pattern of activity in the female correlates quite closely 
to that seen for the male rat (Figure 12). All enzymes 
showed a reduction in activity at 10 minutes ranging between 
80-90% of control. Apart from 7a-hydroxylase , all the 
enzymes continued to show a gradual decline in activity and 
the maximum degree of reduction was seen at 60 minutes. The 
reductions at this time were: 6p-hydroxylase (78% of
control), 16a-hydroxylase (51% of control),
17-hydroxysteroid dehydrogenase (74% of control) and 
5a-reductase (45% of control). These reductions were 
statistically significant (p<0.01). 7a-hydroxylase showed
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TABLE 7A
7aOH 6{30H 16qOH 170HSD 5aRed.
10 min 89.1±1.9 64.2±7.4 53.4±8.2 63.5±2.4 72.4±8.1
30 min 76.4±2.1 68.8±8.3 50.6±1.5 41.8±4.2 65.4±2.3
60 min 79.313.8 62.312.5 59.311.4 56.318.1 65.319.8
120 min 40.111.6 39.411.4 57.213.9 42.911.9 46.811.9
TABLE 7B
7aOH 6POH 16aOH 17QHSD 5aRed.
10 min 78.312.4 74.312.4 57.614.3 62.315.4 76.312.4
30 min 75.913.1 65.317.1 59.312.5 50.413.4 69.813.2
60 min 55.615.2 48.313.4 46.517.3 53.614.2 51.515.2
120 min 37.116.2 47.215.1 46.215.1 37.812.9 52.615.4
Table 7: Changes in the activities of 7a-hydroxylase
(7aOH), 6{5-hydroxylase (6pOH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated male rat hepatocytes from 
control (Table 7A) and 4a - p h o r b o l -12,13-didecanoate-treated 
(lOOnM)(Table 7B) samples. Results expressed as pmole 
metabolite formed per minute per 106 cells 1 S.D. of 9 cell 
samples.
1 0 6
its maximum reduction in activity at 120 minutes (56% of 
control; p<0.01). Apart from 7a-hydroxylase, all activities 
had returned to control levels by 120 minutes.
The effects of PMA (50nM) upon each of the enzyme 
activities with time are shown in table 8.
3.3(b) Effects of 4a-Phorbol in female rat hepatocytes.
The effects of 4a-phorbol (lOOnM) upon the activities 
of all the enzymes metabolising 4-androstene-3,17-dione are 
shown in Figure 17A & 17B.
Again, as in the male rat (Figure 14A & 14B),
4a-phorbol caused only minor fluctuations in enzyme activity 
for all enzymes concerned. The one discrepancy appears to 
be for 60-hydroxylase, where a non-significant increase in 
activity of 145% of control was seen at 120 minutes.
The effect of 4a-phorbol(lOOnM) upon the activities of 
all the enzymes with time is shown in Table 9.
3.3(c) Effects of 4a-Phorbol-12,13-didecanoate (4aPDD) in 
female rat hepatocytes.
The effects of 4aPDD (lOOnM) upon the activities of all 
the enzymes metabolising 4-androstene-3,17-dione are shown 
in Figure 18A & 18B.
As in the male rat (Figure 15A & 15B), 4aPDD exerted 
only slight alterations in enzyme activities. None of these 
alterations in activity were statistically significant 
compared to the respective control activity. The effects of 
4aPDD (lOOnM) with time upon the activities of all enzymes 
is shown in table 10.
_ oCD
_ o
N'l
b ^H
- o
CO
CD
+->
Z5
C
II u
I ^
sL TJ<u
.— > H-J
Q rt 
W  o  
K  w  
a  ""
i n  CO 
0)
a  >»LO o 
o* -t->
cd
a<D
A
Q JJ 
LO g
ffi 3 
o
w $ 
>30 -M
s s
A h CJ
O  Cd
■ ^  (/) u  cr ° <u ti 
>3 • -*^ 2
O  H10 LO •£ S
H + |  h
5  <u
g o o ft
^ is -b’a £ c « S11 o o E 
^ ° O E
ojtcO
cdH-J
c<D
ou
<u
O h
taO co 
C rt
3  T3 
O  <u 03 w
o  wCd <u
I-H
O h
. X  
cd v
’- ' o  
O  £> 
d  &O  +j
v  <u 
CD 6
<u
CO
COQJ 4-1
Id 3
6 CO aj
CO o
B n 6  
6 a  
OJ 2 •'•co cd
_ .  *a a
^  oo co 
°  t o o
<U -H <u u  
C Oh 1-.B * 2C <L> O h
q  00 05 oo
>-' oi cd o> 
+1 -H -H -H 
ID CO CO CO MNNCO M rH <SJ W
CO HIS* 00
cd oo ai cd 
+i + m  -h
CO CO 00
d  id a w  
co in co co
B B B B
B B B B
O  O  O  o
rH CO CO cs
7  ^
Ao
o
00
T
CO
CD
O
cn
,oi\
o
LO
.o
K5
■ O
• O
o■=r
co
joj iuoo  % iusnoqe}0UJ pjcua is
\a0 co w  73 
fl 2
' I  T3 Oh «   ^U C P* _o  W c  
co cd co 
<u co cd
S3 <u <J
fl) flj
<D CO
a  
S  cotiO 1—1
G
Cd T3 
rC C3 
O  a
vC
crl
_ o
Q  ^. ■4- >£  C T 3
o  ^  c °  2 
“ 5  o u  6
•H CJ >-l 
CO ^  < 2
+i fl Si • u 
cj XJ -m £  7?
O t d d 9 °
■y ,Q <U O  'h 
§h 0 cj V -2
S4 2 u & 2 
.5 puJ-h 6
05 O) CO
cd "d3 id co
-H -H -H -H 
lO O O O 
N  ID 00 CO
cd cd id 
CO N  10 CO
^  CO <N -H
cd cd cd n  
■H +1 -H +) 
C W  N  
cd o  00 id 
10 co 10 co
CO CO O) I
^  td cd 00
-H +1 -H -H
C O r H  ID
o  00 cd ^  
CO 10 ID ID
•2 B 5 B
g i i i
0 0 0 0
rH CO CO <N
TABLE 8A
7aOH 60OH 16aOH 170HSD
10 min 60.3±4.3 59.2±6.4 64.8±3.9 69.412.3
30 min 58.417.6 60.116.3 76.514.9 55.618.1
60 min 52.112.9 58.416.2 59.815.3 69.319.4
120 min 54.518.1 35.717.1 65.316.1 64.813.8
5aRed
22519
17319
27617
23619
TABLE 8B
7aOH
10 min *46.315.1 
30 min 47.413.1 
60 min 47.619.4 
120 min*30.514.2
60OH 16aOH
53.216.1 51.812.4
54.618.1 *48.216.3 
*42.416.1 *30.515.2
33.218.4 64.215.1
170HSD 5aRed
55.212.4 18918
48.312.1 15619
*51.618.4 *12416
49.316.1 *17615
Table 8: Changes in the activities of 7a-hydroxylase
(7aOH), 60-hydroxylase (60OH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated female rat hepatocytes from 
control (Table 8A) and PMA-treated (50nM)(Table 8B) samples. 
Results expressed as pmole metabolite formed per minute per 
106 cells 1 S.D. of 9 cell samples. (* p<0.01)
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TABLE 9A
7aOH 6pOH 16aOH 170HSD
10 min 60.314.3 59.216.4 64.813.9 69.412.3
30 min 58.417.6 60.116.3 76.514.9 55.618.1
60 min 52.112.9 58.416.2 59.815.3 69.319.4
120 min 54.518.1 35.717.1 65.316.1 64.813.8
5aRed
22519
17319
27617
23619
TABLE 9B
7aOH 6j30H 16aOH 170HSD 5aRed.
10 min 70.117.4 59.612.4 60.914.1 56.216.1 20718
30 min 56.312.1 59.815.4 66.615.3 56.312.4 18818
60 min 61.918.4 53.219.4 63.412.8 63.517.1 21319
120 min 58.318.4 51.612.4 71.913.6 73.212.9 24516
Table 9: Changes in the activities of 7a-hydroxylase
(7aOH), 6p-hydroxylase (6pOH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated female rat hepatocytes from 
control (Table 9A) and 4a-phorbol-treated (lOOnM)(Table 9B) 
samples. Results expressed as pmole metabolite formed per 
minute per 106 cells 1 S.D. of 9 cell samples.
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TABLE 10A
7aOH 6{30H 16aOH 170HSD 5aRed.
10 min 60.314.3 59.216.4 64.813.9 69.412.3 22519
30 min 58.417.6 60.116.3 76.514.9 55.618.1 17319
60 min 52.112.9 58.416.2 59.815.3 69.319.4 27617
120 min 54.518.1 35.717.1 65.316.1 64.813.8 23619
TABLE 10B
7aOH 6J30H 16aOH 170HSD 5aRed.
10 min 70.315.1 59.615.1 70.614.1 67.415.4 214111
30 min 64.312.9 54.318.4 63.512.9 67.812.3 17117
60 min 66.815.1 49.219.1 53.815.4 56.815.2 22214
120 min 56.314.2 52.613.2 62.712.1 55.414.8 24415
Table 10: Changes in the activities of 7a-hydroxylase
(7aOH), 6p-hydroxylase (6pOH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated female rat hepatocytes from 
control (Table 10A) and 4a-phorbol-12,13-didecanoate-treated 
(lOOnM)(Table 10B) samples. Results expressed as pmole 
metabolite formed per minute per 106 cells ± S.D. of 9 cell 
samples.
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3.4 Effect of 1,2-Dioctanoylglycerol upon the metabolism of 
4-androstene-3,17-dione in isolated male rat hepatocytes.
1,2-Dioctanoylglycerol is a synthetic, cell-permeable 
analogue of the endogenous protein kinase C activator, 
diacylglycerol. The effect of 1,2-dioctanoylglycerol (DOG) 
(5pM), upon the metabolism of 4-androstene-3,17-dione is 
shown in Figure 19A & 19B. DOG, in comparison to the active 
phorbol ester PMA (Figures 12 & 13), produced a similar 
pattern in the reduction in enzyme activity to PMA but there 
are some apparent differences to the phorbol ester effect. 
Firstly, DOG exerts a much more rapid onset of effect upon 
enzyme activity than PMA, the maximum effect upon activity 
is seen at 20 minutes for all enzymes except 7a-hydroxylase. 
The maximum effect of PMA in comparison was seen at 60 
minutes. The second main difference to PMA is that although 
a higher concentration of DOG was used than PMA, the 
magnitude of reduction in enzyme activity with DOG is not as 
marked as the reduction with phorbol ester. The reductions 
with DOG are to 78 - 85% of control, whereas maximum 
reductions with PMA were to 50 - 60% of control. These
maximum reductions in activity with DOG, although quite 
small, were still statistically significant (p<0.05). The 
action of DOG had ceased by 60 minutes, by which time 
activities were back to, or approaching, control levels. 
5a-reductase was the only enzyme still showing a reduction 
in activity at 60 minutes (85%) of control, but this was not 
statistically significant.
Table 11 shows the effect on reduction of enzyme
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TABLE 11A
7aOH 60OH 16aOH 170HSD 5aRed
10 min 55.3±7.4 76.815.2 52.417.4 94.716.1 304110
20 min 56.8±9.3 83.118.7 59.616.4 92.417.2 31718
40 min 56.4±7.1 74.619.3 53.217.6 90.319.7 27515
60 min 56.8±6.1 74.217.3 55.319.4 88.315.4 28019
80 min 50.2±7.1 84.119.2 52.119.5 88.516.2 27814
TABLE 11B
7aOH 60OH 16aOH 170HSD 5aRed
10 min 51.4±7.2 65.319.1 58.214.1 87.415.1 *24718
20 min 62.3±8.1 *71.415.1 *50.316.1 *71.612.1 *26118
40 min 56.2±6.4 74.216.3 53.917.1 91.316.4 24917
60 min 66.311.1 79.819.4 52.618.4 *100 1 7 *23912
80 min 47.417.1 81.615.1 56.319.1 88.216.1 24513
Table 11: Changes in the activities of 7a-hydroxylase 
(7aOH), 60-hydroxylase (60OH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5ared.) with time in isolated male rat hepatocytes from 
control (Table 11A) and 1 ,2 -dioctanoylglycerol-treated 
(5pM)(Table 11B) samples. Results expressed as pmole 
metabolite formed per minute per 106 cells ± S.D. of 6 cell 
samples. (* p<0.01)
1 0 8
activity by 1,2-dioctanoylglycerol (5pM) with time.
3.5 Effect of Vasopressin upon the metabolism of 
4-Androstene-3,17-dione in isolated male rat hepatocytes.
The effects of the hormone, vasopressin, upon the metabolism 
of 4-androstene-3,17-dione are shown in figures 20 and 21.
Figure 20A and 20B shows the effect of a physiological 
concentration of Vasopressin (lOOnM) (Garcia-Sainz et al, 
1987; Cabot et al, 1988). Figure 21A and 21B shows the 
effect of a supraphysiological concentration (lOOpM).
3.5(a) Effect of lOOnM vasopressin. The effect of lOOnM 
vasopressin is shown in Figure 20A & 20B, and it shows a 
high degree of similarity to the effects of PMA (Figure 12 & 
13). The magnitude of reduction in enzyme activity with 
vasopressin correlates well with that seen with PMA and the 
maximum reductions in enzyme activity were; 7a-hydroxylase 
reduced to 49% of control, 60-hydroxylase reduced to 57% of 
control, 16a-hydroxylase reduced to 60% of control, 
17-hydroxysteroid dehydrogenase reduced to 68% of control 
and 5a-reductase reduced to 69% of control. These maximum 
reductions in activity were all statistically significant 
(p<0.01). Apart from 16a-hydroxylase, these maximum 
reduction in activity were all seen after 40 minutes 
incubation with vasopressin, which again correlates well 
with the time when the maximum effect of PMA was seen (60 
minutes). Vasopressin differs from PMA in that there 
appears to be a biphasic mode of action upon enzyme 
activity. After 10 minutes incubation, for all enzymes,
1 0 9
there is a statistically significant reduction in the levels 
of enzyme activity (p<0.01) and the magnitude of this 
reduction is to between 55 - 72% of control activities. 
Between 10 and 20 minutes there appears to be a return of 
enzyme activities towards the control activities, and after 
20 minutes there is a gradual decline in enzyme activity 
until 40 minutes, when the maximum reductions in activity 
are seen. The enzyme 16a-hydroxylase is the only exception 
to this pattern. 16a-hydroxylase still shows a biphasic 
pattern of reduction in activity, but the maximum reduction 
in activity is seen at 20 minutes and not at 40 minutes. 
After. 60 minutes incubation, all enzyme activities had 
returned toward control activities. The reduction in 
activity with vasopressin at 10 minutes correlates more 
closely to the time of onset of action of
1,2-dioctanoylglycerol (Figure 19A & 19B), although the 
magnitude of reduction is more akin to that seen with PMA 
(Figures 12 & 13).
The effects of vasopressin (lOOnM) on all enzymes with 
time are shown in table 12.
3.5(b) Effect of lOOpM Vasopressin. The effects of 
vasopressin (lOOpM) upon the metabolism of 4-androstene- 
3,17-dione is shown in Figure 21A and 21B.
The pattern of reduction of enzyme activity with lOOpM 
vasopressin is similar to that seen with lOOnM vasopressin 
(Figure 20A & 20B) and once again a biphasic pattern of 
reduction in activity is seen. The magnitude of reduction 
is also quite similar (between 50 - 70% of control) and
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TABLE 12A
7aOH 60OH 16aOH 170HSD 5aRed.
5 min 52.1±8.6 60.8±6.1 46.316.4 66.318.4 414111
10 min 77.4±9.3 86.3±8 .1 69.8±6.3 86.417.4 35018
15 min 71.2±7.9 62.3±7.8 52.6±5.4 64.6110.2 29418
to o min 64.3±8.1 75.6±9.4 87.614.1 69.116.3 32516
40 min 86.7±7.8 72.3±7.9 63.916.1 75.519.1 34917
60 min 45.2±6.1 55.4±6.1 48.513.1 65.218.2 27515
TABLE 12B
7aOH 6J30H 16aOH 170HSD 5aRed.
5 min 42.313.1 48.315.1 56.317.1 59.215.1 32315
10 min *42.416.1 *54.619.1 *44.219.1 *62.316.1 25017
15 min *37.215.4 54.319.1 47.314.2 59.819.3 28916
20 min *35.419.2 *51.215.1 *51.615.2 69.416.1 *23014
40 min *42.312.1 *41.212.1 *51.417.2 *51.318.9 *25215
60 min 44.618.4 *39.416.2 49.317.1 60.417.9 28916
Table 12: Changes in the activities of 7a-hydroxylase
(7aOH), 6p-hydroxylase (60OH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated male rat hepatocytes from 
control (Table 12A) and vasopressin-treated (lOOnM)(Table 
12B) samples. Results expressed as pmole metabolite formed 
per minute per 106 cells ± S.D. of 6 cell samples. (* 
p<0.01)
1 1 0
maximum reductions were again statistically significant 
(p<0.01). The only major difference between the two 
concentrations of vasopressin is that 100pM vasopressin 
exerts its maximum reductions in activity at 10 minutes, 
instead of at 40 minutes as was seen with lOOnM vasopressin. 
Reductions at both 10 and 40 minutes were still observed for 
both concentrations of vasopressin. Again with lOOpM 
vasopressin, all enzyme activities had returned to control 
levels by 60 minutes.
The effect of lOOpM vasopressin with time upon enzyme 
activity is shown in table 13.
3.6 Effect of A23187 upon the metabolism of 
4-androstene-3,17-dione in isolated male rat hepatocytes.
The actions of the calcium ionophore A23187 (lOOnM) 
alone and in combination with PMA (50nM) upon the metabolism 
of 4-androstene-3,17-dione are shown in Figure 22.
Intact cells were incubated with A23187 and PMA for 60 
minutes before being assayed with 4-androstene-3,17-dione;
60 minutes incubation was the time period chosen as it is at 
this time that the maximum effects of PMA had been seen 
previously (Section 3.2(a), Figures 12 & 13). From Figure 22 
it can be seen that A23187 (lOOnM) alone had very little 
effect upon the activities of the enzymes. Small 
nonsignificant increases in activity were seen for all 
enzymes, apart from 5a-reductase which showed a slight 
nonsignificant decrease in activity (reduced to 78% of 
control). None of the increases were more than 120% of 
control.
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TABLE 13A
7aOH 60OH 16aOH 170HSD 5aRed.
5 min 52.1±8.9 60.816.1 46.316.4 66.318.4 414111
10 min 77.4±9.3 86.318.1 69.816.3 86.417.4 35018
15 min 71.2±7.7 62.317.8 52.615.4 64.6110.2 29418
20 min 64.318.1 75.619.4 87.614.1 69.116.3 32516
40 min 86.717.8 72.317.9 63.916.1 75.519.1 34917
60 min 45.216.1 55.416.1 48.513.1 65.218.2 27515
TABLE 13B
7aOH 60OH 16aOH 170HSD 5aRed.
5 min *33.615.1 *41.216.2 43.219.1 *52.416.1 *28614
10 min *37.212.1 *44.318.2 *51.418.2 *53.912.1 *22713
15 min *49.417.1 52.118.1 39.612.4 59.618.4 27615
20 min 49.316.9 *55.313.1 *44.117.4 68.416.1 24716
40 min *50.215.1 *42.618.1 62.314.1 *55.215.5 *30315
60 min 55.415.1 65.413.1 64.513.1 69.819.1 30814
Table 13: Changes in the activities of 7a-hydroxylase 
(7aOH), 60-hydroxylase (60OH), 16a-hydroxylase (16aOH),
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated male rat hepatocytes from 
control (Table 13A) and vasopressin-treated (lOOpM)(Table 
13B) samples. Results expressed as pmole metabolite formed 
per minute per 106 cells ± S.D. of 6 cell samples. (* 
p<0.01)
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Changes in activity of the enzymes metabolising Androstene dione after 60 mins. 
incubation with either A23187 alone (lOOnM) or PMA + A23187 in combination 
(50nM/lOOnM). Results expressed as percentage control ± S.D. for six cell 
samples. Control activities expressed as pmole metabolite formed per minute 
per 106 cells:-
7aOH 6pOH 16aOH 170H S.D. SaRED
60 min. 73.1 ± 5 .1  130 ± 6.2 179 ± 5.2 240 ± 8.3 590 ± 4.2
7aOH 6j30H 16aOH 170HSD 5aRed.
Control 73.115.1 13016 17915 24018' 59014
A23187 90.418.2 14117 21213 25915 45317
PMA+A23187 *35.117.1 *43.219.1 *50.414 *10917 *21313
Table 14: Changes in the activities of 7a-hydroxylase
(7aOH), 6p-hydroxylase (60OH), 16a-hydroxylase (16CIOH),
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) in isolated male rat hepatocytes after 60 minutes 
preincubation from control, A23187 alone (lOOnM) and PMA + 
A23187 (50nM + lOOnM respectively) samples. Results 
expressed as pmole metabolite per minute per 106 cells 1 
S.D. of 6 cell samples. (* p<0.01)
Ill
When A23187 (lOOnM) and PMA (50nM) were used in 
combination, the activities of all the enzymes was found to 
be markedly reduced. These reductions were of greater 
magnitude than for PMA acting alone (section 3.2(a), Figures 
12 & 13) and the reductions were; 7a-hydroxylase and 
17-hydroxysteroid dehydrogenase both reduced to 46% of 
control, 60-hydroxylase and 5a-reductase both reduced to 35% 
of control and 16a-hydroxylase reduced to 28% of control.
All of the reductions were statistically significant 
(p<0.01). In section 3.2(a), the greatest reduction seen 
for PMA (50nM) was to 54% of control. The effects of A23187 
(lOOnM) and A23187 + PMA (lOOnM & 50nM) upon enzyme 
activity are shown in Table 14.
3.7 Effect of Angiotensin II upon metabolism of 
4-androstene-3,17-dione in isolated male rat hepatocytes.
The effect of the calcium-dependent hormone, angiotensin II 
(lOOnM), upon the metabolism of 4-androstene-3,17-dione is 
shown in figure 23A & 23B. The activities of the enzymes 
metabolising 4-androstene-3,17-dione were found to all show 
an increase in activity when incubated with angiotensin II. 
The maximum increases in activity were shown at different 
times for different enzymes. 7a-hydroxylase showed its 
maximum increase in activity at 20 minutes (143% of 
control), 60-hydroxylase was maximal at 60 minutes (149% of 
control), 16a-hydroxylase was maximal at 10 minutes (161% of 
control), 17-hydroxysteroid dehydrogenase was maximal at 40 
minutes (159% of control) and 5a-reductase was maximal at 40 
minutes (126% of control). All of these maximum increases
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TABLE :15A
7aOH 60OH 16aOH 170HSD 5aRed.
10 min 128±7 132±4 111±9 142±6 460±9
20 min 112±6 131±8 101±9 132±2 418±8
40 min 110±4 132±10 112±6 105±7 411±9
60 min 108±9 129±8 110±2 130±2 408±9
80 min 111±8 99±4 98±8 115±9 392±7
TABLE 15B
7aOH 60OH 16aOH 170HSD 5aRed.
10 min 143±2 *174±6 *180±4 *185±3 51916
20 min *171±2 *178±4 *140±5 *199±2 *51615
40 min *147±3 *16716 *150±3 *167±7 51819
60 min *138±2 *167±3 *155±4 *183±2 50118
80 min 152±3 *14819 *143±4 *159±2 44215
Table 15: Changes in the activities of 7a-hydroxylase
(7aOH), 60-hydroxylase (60OH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated male rat hepatocytes from 
control (Table 15A) and angiotensin II-treated (lOOnM)(Table 
15B) samples. Results expressed as pmole metabolite formed 
per minute per 106 cells ± S.D. of 6 cell samples. (* 
p<0.01)
1 1 2
were statistically significant (p<0.01). The activity of all 
the enzymes in the presence of angiotensin II (lOOnM) with 
time are shown in Table 15.
3.8 Assessment of Protein Kinase C activation by 
40-Phorbol-12-myristate-13-acetate.
The activation of the enzyme, protein kinase C, by the 
active phorbol ester 40-phorbol-12-myristate-13-acetate 
(PMA) was assessed by the method of Pelech et al (1986). 
Figure 24 shows the result. It is clear that as the 
concentration of the phorbol ester increases from O.lnM to 
lOOnM, the activity of protein kinase C in each fraction is 
altered. Increasing the concentration of PMA causes the 
activity of protein kinase C in the soluble fraction to 
decrease, from 115 fmole ATP per minute per 106 cells at 
O.lnM PMA to 40 fmole ATP per minute per 106 cells at lOOnM 
PMA. The soluble fraction in this assay represents the cell 
cytosol of an intact cell, and so it appears that as the 
concentration of PMA is increased there is a gradual loss of 
protein kinase C from the cell cytosol. The particulate 
fraction, which is representative of the plasma membrane of 
an intact cell, showed the opposite effect to the soluble 
fraction, that is increasing the concentration of PMA caused 
an increase in protein kinase C activity from 81 fmole ATP 
per minute per 106 cells at 0.InM PMA to 122 fmole ATP per 
minute per 10^ cells at lOOnM PMA. The increase in activity 
of protein kinase C in the particulate fraction occurred 
concomitantly with the decrease in activity seen in the 
soluble fraction. This suggests that the loss of protein
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expressed as fmole ATP per minute per 106 cell ± 
S.D.
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Particulate 129.4 ± 1 . 2
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kinase C activity from the- soluble fraction is reflected by 
the increase in activity of protein kinase C in the 
particulate fraction. This effect is characteristic of the 
fact that protein kinase C has undergone translocation, from 
cytosol to plasma membrane, and activation of protein kinase 
C has subsequently occured at the plasma membrane. The 
maximum level of protein kinase C activity in the 
particulate fraction was seen at lOnM PMA, which correlates 
well with the concentration of PMA used in our earlier 
studies (50nM).
3.9 Effects of 4p-Phorbol-12-myristate-13-acetate upon the 
NADPH/Cytochrome P450 enzyme system.
3.9(a) Effects of homogenisation and addition of excess 
cofactors on the actions of
4p-Phorbol-12-myristate-13-acetate in male rat hepatocytes.
The time-course of the effect of the active phorbol 
ester PMA (50nM) in homogenised hepatocytes which have been 
supplemented with an excess of the cofactor NADPH, before 
determination of 4-androstene-3,17-dione metabolism is shown 
in Figure 25A & 25B.
As was apparent in the intact hepatocyte (Figure 12 & 
13), all Of the enzymes metabolising 4-androstene-3,17-dione 
underwent an inhibition of activity in the presence of PMA, 
with the maximum reduction in activity being observed at 60 
minutes (the same as the time of the maximum effect of PMA 
in section 3.2(a) ). The reductions in activity were to 60 
- 80% of control and were statistically significant
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TABLE !L6A
7aOH 60OH 16aOH 170HSD 5aRed
10 min 52±3 6018 5713 10614 30717
20 min 42±4 6919 5817 11213 25813
30 min 4316 5916 5416 9715 26013
60 min 3919 5419 4314 9013 26513
TABLE :16B
7aOH 60OH 16aOH 170HSD 5aRed
10 min *40.215.1 53.217.1 *44.316.1 94.212.9 27917
20 min 36.418.1 *49.419.4 *45.219.1 *93.414.5 23913
40 min *29.217.4 *36.417.1 *36.413.2 86.312.8 *19613
60 min *31.414.2 50.218.1 38.216.1 93.412.8 24413
Table 16: Changes in the activities of 7a-hydroxylase
(7aOH), 60-hydroxylase (60OH), 16a-hydroxylase (16aOH), 
17-hydroxysteroid dehydrogenase (170HSD) and 5a-reductase 
(5aRed.) with time in isolated male rat hepatocytes from 
control (Table 16A) and PMA-treated (50nM)(Table 16B) 
samples in the presence of excess cofactor, NADPH. Results 
expressed as pmole metabolite formed per minute per 106 
cells ± S.D. of 6 cell samples. (* p<0.01)
1 1 4
(p<0.01).
The effects of PMA acting in the presence of excess 
NADPH are shown in Table 16.
3.9(b) Effects on the rate of loss of NADPH caused by 
40-Phorbol-12-myristate-13-acetate in male rat hepatocytes.
The time-course of the rate of degradation of NADPH in 
homogenised hepatocytes from control (DMSO) or PMA-treated 
samples (50nM), is shown in Figure 26. As time proceeds, 
the rate of loss of NADPH in both control and PMA-treated 
samples remains at a fairly constant level (between 0.65 and 
0.85 pinole NADPH per minute per 106 cells). There is little 
difference between the rate of loss of NADPH for control and 
PMA-treated samples, except at 40 and 50 minutes where there 
is a difference between control and PMA-treated samples - 
control samples metabolised 0.67 pmole NADPH per minute per 
106 cells and PMA-treated samples 0.89 pmole NADPH per 
minute per 106 cells. The deviation between the two samples 
was not, however, statistically significant.
The effect of PMA (50nM) upon the rate of loss of NADPH 
is shown in Table 17.
3.9(c) Effect of 40-Phorbol-12-myristate-13-acetate upon 
NADPH/Cytochrome c (P450) Reductase in male rat hepatocytes.
The effect of PMA (50nM) upon NADPH/cytochrome c (P450) 
reductase activity with time is shown in Figure 27.
In both control (DMSO) and PMA-treated samples, there 
is a gradual decline in cytochrome c (P450) reductase 
activjt-y after 20 minutes, but there is no significant
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Rate of degradation of NADPH with time in hepatocytes isolated from male rats
after incubation with DMSO [Control] (-------) and PMA (50nM) Results
expressed as pinole NADPH/minute/106 cells. Control activities expressed as 
jimole NADPH/minutes/106 cell:-
5 min 10 min 15 min 20 min 30 min 40 min 50 min 60 min
Control 0.85 ±0.36 0.67 ± 0.39 0.62 ± 0.24 0.76 ± 0.43 0.85 ±0.26 0.67 ± 0.2 0.67 ± 0.46 0.86 ±0.38
Time (Min) Control PMA
5 850±4 76113
10 669±4 80815
15 62412 63115
20 76414 81414
30 85313 64014
40 66512 89812
50 66915 86514
60 85514 100013
Table 17: Rate of loss of the cofactor NADPH from isolated
male rat hepatocytes from control and PMA-treated (50nM) 
samples. Results expressed as nmole NADPH per minute per 
106 cells ± S.D. of 9 cell samples.
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Reduction of cytochrome C (P450) reductase in the presence of DMSO (Control) 
(■ —) and PMA (50nM) (———) with time in hepatocytes isolated from male rats. 
Control activities expressed as jimole cytochrome C reduced /m inute/106 cell:-
5 min 10 min 20 min 40  min 60 min
Control 0.083 ± 0.025 0.083 ± 0.015 0.084 ± 0.015 0.078 ±0.02 0.066 ±0.014
Time(Min) Control PMA
5 83±2 80±2
10 83±2 84±2
20 84±1 87±2
40 78±2 72±2
60 66±4 63±4
Table 18: Effect of PMA (50nM) in isolated male rat
hepatocytes upon NADPH cytochrome c (P450) reductase with 
time. Results expressed as nmole cytochrome c per minute 
per 106 cells ± S.D. of 9 cell samples.
11 5
difference between the two* samples.
The effect of PMA (50nM) upon NADPH cytochrome c (P450) 
reductase with time is shown in Table 18.
3.10 Effect of Cycloheximide upon the actions of 
4p-Phorbol-12-myristate-13-acetate in electropermeabilised 
cells.
The effects of PMA (50nM) upon the metabolism of 
4-androstene-3,17-dione in the absence and presence of 
cycloheximide (10pM) are shown in Figure 28 (A - E ) . 
Cycloheximide, an inhibitor of mRNA translation at the 
ribosomal level (Peshka, 1971), was used to determine 
whether or not there was a role of protein synthesis in the 
action of PMA.
Blocking protein synthesis with cycloheximide was found 
to cause an inhibition of PMAs effect upon all the enzymes 
metabolising 4-androstene-3,17-dione. This effect occured 
throughout the time course, apart from 17-hydroxysteroid 
dehydrogenase, which still showed a statistically 
significant reduction in activity at 10 minutes in the 
presence of cycloheximide (74% of control, p<0.01). PMA 
acting alone reduced activity in the same manner as before 
(section 3.2) and maximum reductions in activity were at 40 
minutes. Significant reductions in activity (p<0.01) were 
seen for all enzymes from 20 minutes onwards.
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Changes in the activity of 5a (5aRED) in hepatocytes 
isolated from male rats following incubation with PMA
(50nM) (------), (Control + Cycloheximide [lOpMD (———}■
and (PMA (50nM) + Cycloheximide [lOpM] ) (~— "0.
Results expressed as percentage control ± S.D. of six cell 
samples (*p<0.01). Control activities expressed as pmol 
metabolite formed per min. per 106 cell:-
10 min 20 min 30 min 40 min 60 min
Control 774 ±7.5 514 ±5.2 612 ±4.1 796 ±9.8 613 ±5.2
Control
(Cycloheximide)
809 ± 8.6 721 ±6.1 552 ±5.8 691 ± 10.6 624 ±4.2
(PMA +
Cycloheximide)
697 ± 6.7 563 ± 5.4 743 ±3.3 821 ±7.2 612 ±5.2
1 1 6
3.11 The effects of protein kinase inhibitors upon the 
actions of 4p-Phorbol-12-myristate-13-acetate in alteration 
of 4-androstene-3,17-dione metabolism in 
electropermeabilised hepatocytes.
3.11(a) Effect of K252a (general non-selective protein 
kinase inhibitor).
The effect of K252a (20nM) (inhibits all protein 
kinases) (Kase et al, 1986; Kase et al 1987), is shown in 
Figure 29 (A - E). This shows the effect of K252a upon the 
time course of PMA's (50nM) effect for each enzyme 
metabolising 4-androstene-3,17-dione.
For each enzyme, PMA acting alone reduces activity in 
its usual manner (as described in section 3.2(a), Figure 
12). Maximum reductions were at 60 minutes and 
statistically significant (p<0.01). Cells with both PMA and 
K252a added show that PMA was still able to reduce enzyme
activity in a similar way as to when PMA acted alone. Some
enzymes still showed a maximum decrease in activity at 60 
minutes, such as 6p-hydroxylase (84% control, p<0.01) and 
16a-hydroxylase (69% of control, p<0.01).
3.11(b) Effect of KT5720 (inhibitor of cyclic AMP-dependent 
protein kinase).
The effect of preincubating hepatocytes with KT5720 
(60nM) (specific protein kinase A inhibitor) upon the 
actions of PMA (50nM) on 4-androstene-3,17-dione metabolism 
is shown in Figure 30 (A - E).
PMA acting alone again produced its usual effect on
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C hanges in the activity of 5a  (5aRED) in hepatocytes  
isolated from made rats following incubation w ith PMA
(50nM) (------ ), (Control + K 252a [20nM]) (— — ) and (PMA
(50nM) + K 252a [20nM] ) (———)■ R esu lts expressed  as
percentage control ± S .D . of s ix  cell sam ples (*p<0.01). 
Control activ ities exp ressed  a s  pm ol m etabolite formed  
per m in. per 106 cell:-
10 min 20 min 40 min 60 min 80 min
Control 385 ±9.3 436 ±4.2 386 ±7.1 375 ± 5.2 374 ±3.4
Control 
+ K252a
357 ±8.6 409 ±4.1 375 ± 5.2 394 ±5.7 378 ± 2.6
(PMA + K252a) 437 ±7.0 385 ±4.1 408 ±4.3 345 ± 8.3 355 ±3.6
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enzyme activity - maximum reductions at 60 minutes, p<0.01. 
Cells with PMA and KT5720 added also showed a reduction in 
activity for all enzymes at all time points studied. PMA in 
the presence of KT5720 was still able to cause significant 
reductions in enzyme activity for all the enzymes. Hence, 
PMA appears to be capable of reducing enzyme activity 
equally efficiently either alone or in the presence of 
KT5720.
3.11(c) Effect of K252b (specific inhibitor of protein 
kinase C ) .
The effect of preincubating hepatocytes with K252b 
(20nM) upon the actions of PMA (50nM) on metabolism of 
4-androstene-3,17-dione are shown in Figure 31 (A - E) .
Inhibiting protein kinase C with K252b revealed a more 
efficient blockade of PMA action than inhibition with K252a 
(Figure 29). K252b was found to block the effect of PMA for
all enzymes studied and returned enzyme activities towards 
control levels at all time points investigated. PMA in the 
presence of K252b still showed several isolated reductions 
in activity, such as 7a-hydroxylase (86% of control at 60 
minutes, p<0.01) and 17-hydroxysteroid dehydrogenase (80% of 
control at 20 minutes, p<0.01) but the overall effect was a 
blockade of PMA actions with K252b. PMA alone reduced 
activity in its usual way (as described in section 3.2(a) ).
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Changes in the activity of 5a (5aRED) in hepatocytes 
isolated from male rats following incubation with PMA
(50nM) (------), (Control + K252b [20nM]) (------) and (PMA
(50nM) + K252b (20nM] ) (----- ). Results expressed as
percentage control ± S.D. of six cell samples (*p<0.01). 
Control activities expressed as pmol metabolite formed 
per min. per 106 cell:-
10 min 20 min 40mln 60min 80 min
Control 516 ±5.4 559 ± 5.2 512 ±6.3 459 ±3.0 465 ±4.2
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3.12 Effect of 50nM 4p-Phorbol-12-myristate-13-acetate (PMA)
upon the phosphorylation of protein in intact hepatocytes.
Figure 32 illustrates the SDS-PAGE of six different 
immunoprecipitated isozymes of cytochrome P450, precipitated 
by their specific antibodies . These isozymes were preci­
pitated out from freshly isolated hepatocytes from male 
rats, which had not received any form of treatment, to 
assure us that the precipitation technique was working effi­
ciently.
Figure 33 shows the effect of 50nM PMA upon the 32P 
labelling of whole cells and the immunoprecipitated isozymes 
of cytochrome P450 UT-1 (Figure 33, Lane F), cytochrome P450 
MC-lb (Lane G), cytochrome P450 PB2c (Lane H) and cytochrome 
P450 PB3a (Lane I). The immunoprecipitated samples were 
compared to whole cell samples from control (Lane B) and 
PMA-treated (Lane C) hepatocytes. The immunoprecipitated 
cytochrome P450 isozymes and PMA-treated whole cell samples 
were preincubated with PMA for 60 minutes before 
solubilisation (whole cells) or immunoprecipitation 
(isozymes).
It is apparent from Figure 33 that the whole cell 
samples show phosphate incorporation into proteins, which 
can be detected by autoradiography - Lane D is the autora­
diogram of control whole cells (Lane B) and Lane E is the 
autoradiogram of PMA-treated whole cells (Lane C). However, 
the immunoprecipitated cytochrome P450 isozymes, which 
produce a reasonable amount of protein, as detected by 
SDS-PAGE, at approximate molecular weight 42,000 - 50,000, 
failed to show any incorporation of 32P into any of the
a b e d  e f
FIGURE 32. SDS-PAGE of a variety of immunoprecipitated 
cytochrome P450 isozymes from untreated male rat 
hepatocytes.
Lane A; Cytochrome P450IIC11 (P450 PB2c).
Lane B; Cytochrome P450IIA1 (P450 UT-1).
Lane C; Cytochrome P450IA1 (P450 MC-lb).
Lane D; Cytochrome P450IIB1 (P450 PB3a)
Lane E; Cytochrome P450IA2 (P450 MC-la).
Lane F; Cytochrome P450IIC6 (P450 PB-lb).
a b e d  e f g h i
FIGURE 33. SDS PAGE and autoradiograms from intact male rat 
hepatocytes and immunoprecipitated cytochrome P450 isozymes 
from male rats, prelabelled with (32P) and incubated for 60 
minutes in the presence or absence (control) of 50nM 
4p-Phorbol-12-myristate-13-acetate (PMA).
Lane A shows SDS PAGE of molecular weight markers.
Lane B shows SDS PAGE of control whole cell hepatocytes.
Lane C shows SDS PAGE of PMA-treated whole cell hepatocytes. 
Lane D shows the autoradiogram from control (Lane B) 
hepatocytes. Lane E shows autoradiogram of PMA-treated 
(Lane C) hepatocytes.
Lane F shows SDS PAGE of cytochrome P450IIA1 (P450 
UT-1). Lane G shows SDS PAGE of cytochrome P450IA1 (P450 
MC-lb) . Lane H shows SDS PAGE of cytochrome P450IIC11 
(P450 PB2c). Lane I shows SDS PAGE of cytochrome P450 IIB1 
(P450 PB3a). All immunoprecipitates treated with 50nM PMA 
for 60 minutes. Lane J shows the autoradiogram for a 
representative immunoprecipitated cytochrome P450 isozyme.
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immunoprecipitates, by analysis of the autoradiogram (Lane 
J). Although only one autoradiogram is shown, the 
autoradiograms for all immunoprecipitated samples were 
identical, that is there is no incorporation of 32P.
3.13 Assessment of Haem precipitation from whole cell 
samples and immunoprecipitated cytochrome P450 isozymes.
Table 19 shows the amount of haem precipitated from 
both whole cell and immunoprecipitated cytochrome P450 iso­
zymes from control and PMA-treated (50nM) hepatocytes. 
Cytochrome P450 is a haem-containing flavoprotein and the 
detection of the presence of haem in the immunoprecipitated 
cytochrome P450 isozymes has been employed here to confirm 
that we are precipitating out haem, and hence cytochrome 
P450, in our samples.
It is apparent from table 19 that control whole cell 
samples contain the highest amount of haem (0.698 nmoles), 
whilst PMA-treated whole cell samples have significantly 
less (0.239 nmoles). The immunoprecipitated cytochrome P450 
isozymes, which were preincubated with PMA (50nM) for 60 
minutes before immunoprecipitation, showed very low levels 
of haem compared to control whole cell samples, although a 
reasonable amount of haem was detected for each 
immunoprecipitate (between 0.053 and 0.132 nmoles). The 
lower values in the immunoprecipitated samples reflect the 
fact that the immunoprecipitates contain only one form of 
cytochrome P450 each, whilst the whole cell sample contain 
the complete range of cytochrome P450 isozymes.
nmole Haem per sample
Control (whole cell) 
PMA (whole cell) 
aPB UT-1 (+PMA) 
aMC-lb (+PMA) 
aPB 2c (+PMA) 
aPB 3a (+PMA)
0.698±0.366 
0.239±0.239 
0.132±0.108 
0.097±0.076 
0.053±0.081 
0.111±0.097
Table 19: Assessment of haem precipitation in whole 
cell preparations from control and PMA-treated (50nM) 
hepatocytes and in immunoprecipitated cytochrome P450 
isozymes, treated with PMA (50nM) for 60 minutes. Results 
expressed as nmole haem produced per sample (mean) ± S.D. c 
6 cell samples.
1 2 0
3.14 Direct analysis of 32P incorporation into immunopreci­
pitated cytochrome P450 isozymes by liquid scintillation 
counting.
Table 20 shows the amount of 32P present in whole cell 
and immunoprecipitated cytochrome P450 isozymes from control 
and PMA-treated (50nM for 60 minutes) samples.
Both control and PMA-treated whole cell samples show 
high counts for 32P, although there is no significant dif­
ference in the amount of 32P present in either sample, 
suggesting that PMA has not enhanced 32P incorporation into 
the whole cell samples, compared to the control whole cell 
samples.
The immunoprecipitated cytochrome P450 isozymes show a 
markedly lower degree of 3 2 P present compared to the control 
whole cell samples, again reflecting the fact that only one 
isozyme of cytochrome P450 is present in each isozyme. The 
number of counts for each immunoprecipitate for control and 
PMA-treated samples shows no significant difference, again 
suggesting that PMA has not enhanced 32P incorporation into 
the immunoprecipitated isozymes.
3.15 Effect of 50nM 4p-Phorbol-12-myristate-13-acetate (PMA) 
upon protein phosphorylation in electropermeabilised hepa­
tocytes .
Figure 34 shows a typical gel from whole cell samples, 
prelabelled with (^-32P)ATP, and treated either with or 
without (control) PMA (50nM). Figure 34 shows an effect of 
PMA with time, 5 - 2 0  minutes.
counts per minute % of control
per sample
Control (whole cell) 360613±7760 100
PMA (whole cell) 371156110002 103
aPB UT-1 (control) 3321163 0.09
aMC-lb (control) 4181171 0.116
aPB 2c (control) 514167 0.143
aPB 3a (control) 2961149 0.082
aPB UT-1 (+PMA) 5711352 0.158
aMC-lb (+PMA) 4181174 0.116
aPB 2c (+PMA) 5131353 0.142
aPB 3a (+PMA) 4611239 0.128
Table 20: Assessment of 32P incorporation into whole
cell and immunoprecipitated cytochrome P450 isozymes from 
control or PMA-treated (50nM for 60 minutes) hepatocytes. 
Results expressed as counts per minute per sample (mean) ± 
S.D. of 6 cell samples.
a b c d e f g h
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FIGURE 34. Representative SDS PAGE gel from intact male rat 
hepatocytes, prelabelled with (^32P)ATP, and incubated in 
the presence and absence (control) of 50nM 4p-Phorbol-12- 
myristate-13-acetate (PMA).
Lane A shows SDS PAGE of control hepatocytes at 5 minutes,
Lane B shows SDS PAGE of PMA-treated hepatocytes at 5
minutes.
Lane C shows SDS PAGE of control hepatocytes at 10 minutes,
Lane D shows SDS PAGE of PMA-treated hepatocytes at 10
minutes.
Lane E shows SDS PAGE of control hepatocytes at 15 minutes,
Lane F shows SDS PAGE of PMA-treated hepatocytes at 15
minutes.
Lane G shows SDS PAGE of control hepatocytes at 20 minutes,
Lane H shows SDS PAGE of PMA-treated hepatocytes at 20
minutes.
Lane I shows SDS PAGE of molecular weight markers.
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3.15(a) Effect of PMA (50nM) with time upon protein phos­
phorylation.
Figure 35 shows SDS-PAGE and autoradiograms of the 
effect of PMA with time in electropeFmeabilised hepatocytes 
prelabelled with (^-32P)ATP.
Lane B shows SDS-PAGE of control hepatocytes at £ )  min­
utes and Lane C shows SDS-PAGE of PMA-treated hepatocytes at 
IS- minutes. The SDS-PAGE shows no apparent differences in 
the amount of protein present in each lane. The correspon­
ding autoradiograms, Lane D autoradiogram of control (Lane 
B) and Lane E autoradiogram of PMA-treated (Lane C) hepato­
cytes, show ho visible 32P incorporation into any particular 
protein for either sample.
Lane F shows SDS-PAGE of control hepatocytes at 60 
minutes and Lane G shows SDS-PAGE of PMA-treated hepatocytes 
at 60 minutes. Lane H is the autoradiogram of control (Lane 
F) and Lane I is the autoradiogram of PMA-treated 
hepatocytes (Lane G ) . Again the autoradiograms show no 
significant 32P incorporation into any particular proteins 
for either sample.
5 and 60 minutes were used in Figure 35 as example 
times to illustrate the result. The actual time course for 
the experiment was treatment with PMA for 60 minutes with 
samples taken at 5 minute intervals for analysis. All 
samples showed the same result, that is no visible incorpo­
ration of 32P.
FIGURE 35. SDS PAGE and autoradiograms of electropermeabil- 
ised male rat hepatocytes, prelabelled with (#32P)ATP, and 
incubated for various times in the presence and absence 
(control) of 50nM 4{3-Phorbol-12-myristate-13-acetate (PMA).
Lane A shows SDS PAGE of molecular weight markers.
Lane B shows SDS PAGE of control hepatocytes at 5 minutes. 
Lane C shows SDS PAGE of PMA-treated hepatocytes at 5 
minutes. Lane D shows autoradiogram of control hepatocytes 
at 5 minutes (Lane B). Lane E shows autoradiogram of 
PMA-treated hepatocytes at 5 minutes (Lane C).
Lane F shows SDS PAGE of control hepatocytes at 60 
minutes. Lane G shows SDS PAGE of PMA-treated hepatocytes 
at 60 minutes. Lane H shows the autoradiogram of control 
hepatocytes at 60 minutes (Lane F). Lane I shows the 
autoradiogram of PMA-treated hepatocytes at 60 minutes (Lane 
G) .
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3.15(b) Effect of PMA (50nM) upon protein phosphorylation in 
the presence and absence of K252b.
Figure 36 shows SDS-PAGE and autoradiograms for PMA 
acting alone or in the presence of the specific protein 
kinase C inhibitor K252b (section 3.9(c) ). Cells were 
preincubated for 30 minutes with K252b (20nM) before 
incubation with PMA (50nM) for 10 - 60 minutes.
Lane B shows SDS-PAGE of control hepatocytes at 60 
minutes, Lane D is the corresponding autoradiogram, and Lane 
C shows SDS-PAGE of PMA-treated hepatocytes at 60 minutes, 
Lane E being the corresponding autoradiogram. Again, as in 
Figure 35, despite the presence of many different proteins 
there is no indication that incorporation of 32P has 
occured.
Lane F is the SDS-PAGE of (control + K252b) hepatocytes 
at 60 minutes, Lane H being the relevant autoradiogram and 
Lane G is the SDS-PAGE of (PMA + K252b) at 60 minutes, Lane 
I being the relevant autoradiogram. The presence of K252b 
in the sample has had no effect on the amount of 
protein present in each sample, reflected by the SDS-PAGE, 
but once again there is no sign of any 32P incorporation 
into any proteins in the presence of K252b.
Hence, PMA in the presence and absence of the inhibitor 
K252b failed to show any 32P incorporation into any proteins 
with time. 60 minutes was chosen as the representative time 
to show the result, all other times showing the same effect.
a b c d e f g h i
FIGURE 36. SDS PAGE and autoradiograms of electropermeabil- 
ised male rat hepatocytes, prelabelled with (^32P)ATP, and 
incubated for various times in the presence and absence 
(control) of 50nM 4p-Phorbol-12-myristate-13-acetate (PMA) 
and in the presence and absence (control) of K252b (20nM).
Lane A shows SDS PAGE of molecular weight markers.
Lane B shows SDS PAGE of control hepatocytes at 60 minutes. 
Lane C shows SDS PAGE of PMA-treated hepatocytes at 60 
minutes. Lane D shows autoradiogram of control hepatocytes 
at 60 minutes (Lane B). Lane E shows autoradiogram of 
PMA-treated hepatocytes at 60 minutes (Lane C).
Lane F shows SDS PAGE of (control hepatocytes + K252b) 
at 60 minutes. Lane G shows SDS PAGE of (PMA-treated 
hepatocytes + K252b) at 60 minutes. Lane H shows autoradio­
gram of (control hepatocytes + K252b) at 60 minutes (Lane 
F). Lane I shows autoradiogram of (PMA-treated hepatocytes 
+ K252b) at 60 minutes (Lane G).
DISCUSSION
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4.1 The use of 4-Androstene-3,17-dione as a substrate.
The use of xenobiotic substances has been the principal 
mode of study for discerning mechanisms of action and 
regulation of the hepatic monooxygenase system. It became 
apparent, however, that there are marked differences in the 
kinetics of the metabolism of drugs and steroids by this 
enzyme system and also some apparent differences in the 
control of drug-and steroid-metabolising enzyme activities. 
Kinetic studies have shown that the hepatic monooxygenase 
system generally has a higher apparent Km for xenobiotics 
than for steroid substrates (Skett, 1978). To attempt to 
overcome some of these differences, we utilized the 
endogenous steroid substrate, 4-androstene-3,17-dione, in 
our study.
4-Androstene-3,17-dione is a convenient and easy 
substrate to use, being readily available in both an 
unlabelled and (14C)-labelled form. Metabolism of this 
steroid substrate has been well characterised by Gustafsson 
& Stenberg (1974) and the metabolites can be readily 
separated in the laboratory by one-dimensional thin layer 
chromatography. Radio-gas chromatography and gas 
chromatography-mass spectrometry provide more detailed 
separation and identification of the metabolites (Gustafsson 
& Stenberg, 1974), but these techniques were not used in 
this study.
The activities of the enzymes metabolising 
4-androstene-3,17-dione are regulated either by an integral 
cytochrome P450 component or independently of cytochrome
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P450, and so by using 4-androstene-3,17-dione as a 
substrate, we are able to compare cytochrome P450-dependent 
and -independent effects at the same time. The 
P450-containing enzymes are 7a-hydroxylase (Waxman et al,
1987), 6f3-hydroxylase (Waxman et al, 1985) and 
16a-hydroxylase (Waxman, 1984), whilst the P450-independent 
enzymes are 17a(p)-hydroxysteroid dehydrogenase and 
5a-reductase (Golf & Graef, 1978).
Another advantage of 4-androstene-3,17-dione as a 
substrate is that the activities of the enzymes mediating 
its metabolism are subject to sexual differentiation 
(Gustafsson & Stenberg, 1974a) and so the role of 
sex differences in metabolism can also be readily 
investigated.
4-Androstene-3,17-dione therefore lends itself as a 
convenient substrate to assess cytochrome P45O-dependent 
versus cytochrome P450-independent monooxygenases and also 
to assess changes in enzyme activity arising from 
feminisation or masculinisation of hepatic enzyme profiles.
4.2 The use of the isolated rat hepatocyte.
The early studies investigating hormonal regulation of 
the hepatic monooxygenase system relied upon the rather 
crude method of injecting hormones directly into the whole 
animal and then studying in vivo effects. An obvious 
problem with this method is that the animal will still be 
subject to extensive internal regulation from the endocrine 
system and so any effect which may be seen is probably not a 
true reflection of a single hormonal effect but is more
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likely to be a complex hormonal effect modified by the rest 
of the functional endocrine system.
As techniques became more refined, in vitro systems 
came into use. These systems were typically either 
microsome preparations or reconstituted enzymes systems. 
Neither of these systems is a true representation of the 
physiological situation; microsomes are only artefacts of 
the preparation technique, and so their use as models of the 
physiological situation is limited. Although these in vitro 
systems overcame some of the problems of endocrine 
interactions, they are of no use in the study of 
extracellular effects or to compare the effects of 
intracellular pathways.
The next system to emerge as a model to investigate 
hepatic function was the isolated rat hepatocyte. Isolated 
rat hepatocytes are now the most widely employed 
experimental model to investigate hepatic function 
(Cockcroft & Taylor, 1987; Gabbay & Lardy, 1987).
Although hepatocytes represent a more physiological 
situation than microsomes or reconstituted systems, they 
still present a problem in that they do not conserve the 
physiological structure of the liver and also they can lack 
cell-cell contacts when in a homogenous suspension or when 
cultured.
The maintenance of cell contact is important because, 
in the intact liver, cooperation between the different cell 
types in the liver is vital to maintain hepatic function.
The parenchymal cells of the liver, which represent the 
isolated hepatocyte, are the principal stores of cytochrome
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P450 isozymes. The content of cytochrome P450 isozymes can 
vary between different regions of the liver, eg there is a 
30 fold higher concentration of cytochrome P450IIE1 in the 
centrilobular than in the periportal region of rat liver 
(Ingleman-Sundberg et al, 1988). The content of other types 
of enzymes in the liver can also vary, eg phase 2 
conjugating enzymes are at a much higher concentration in 
the centrilobar region than the periportal region of the 
liver lobule (Ioannides & Park, 1987).
The loss of the structural arrangement of hepatic cells 
upon isolation must be borne in mind when extrapolating data 
from isolated hepatocytes to the physiological situation.
Another problem with using cultured hepatocytes is 
that the hepatic monooxygenase system suffers rapid loss of 
cytochrome P450 content during culture (Stewart et al,
1985). The constituency of the culture medium has been 
found to be vital in order to maintain cytochrome P450 
levels and cytochrome P450 activities. Many cell lines, 
including hepatocytes, require the presence of serum to 
sustain their growth in culture, although fetal calf serum 
was found to cause a loss of androstenedione-16a-hydroxylase 
and androstenedione-5a-reductase activities (Stenberg et al, 
1978).
Turner et al (1988) reported that amounts of 
cytochrome P450 isozymes, their inducibility by 
phenobarbitone and their activity toward the substrate DMBA 
(7,17-dimethyl benz(a )anthracene) depends upon the 
constituency of the medium. Studies into the 
supplementation of culture medium with different substances
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found that levels of cytochrome P450 could be fairly well 
maintained for short periods of time upon the inclusion of 
different supplements. Some of the supplements used were 
DMSO (dimethyl sulfoxide) (Muakkassah-Kelly, 1987), collagen 
(Dich et al, 1988), dexamethasone (Michalopoulos & Pitot, 
1975) and adrenocorticoids (Michalopoulos et al, 1976). 
Another study employed the co-culture of hepatocytes with 
epithelial cells (Agius, 1988). These supplemented culture 
media still cause problems in that some of the cytochrome 
P450 isozymes can become more susceptible to in vitro 
degradation than others (Turner et al, 1988) and this can 
result in a change in the overall profile of the hepatocyte 
monooxygenases. Dexamethasone and adrenocorticoids present 
additional problems in that they themselves can produce 
effects upon enzyme activities (van der Hoeven & Galivan, 
1987; Karasik & Kahn, 1988).
Some of these difficulties with culture medium and 
conditions have been overcome in our laboratory. Hussin & 
Skett (1986) characterised a system for the primary culture 
of adult rat hepatocytes maintained in Ham's F10 medium 
supplemented with 0.1% bovine serum albumin and 100IU 
penicillin/streptomycin. The absence of hormones and serum 
in the medium allows the examination of hormonal regulation 
of hepatic monooxygenases at both extracellular and 
intracellular levels.
Our cultures were typically at a cell density of 106 
cells per cm2 and it has been reported that proliferation of 
hepatocytes in culture occurs at low cell densities but is 
inhibited by these high cell densities (Nakamura et al,
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1983a). It has been postulated that a growth-inhibiting 
factor is produced by the plasma membrane of mature rat 
hepatocytes which inhibits growth and differentiation of the 
cells (Nakamura et al, 1983a). This postulated factor may 
prevent growth and promote differentiation of hepatocytes 
when cultured at the high cell densities used in this 
present study.
Over the time period used in this study, we consider 
the isolated rat hepatocyte, maintained in Ham's F10 and 
supplemented with 0.1% bovine serum albumin and 
penicillin/streptomycin, to be a valid, although not 
perfect model, for the study of hormonal and intracellular 
regulation of hepatic steroid metabolising enzymes.
4.3 The effects of activating protein kinase C directly or 
indirectly upon hepatic steroid metabolising enzymes.
The main problem in investigating physiological 
regulation of intracellular functions of protein kinase C 
(PKC) is that the endogenous activator of the kinase, 
diacylglycerol, is produced only transiently and is subject 
to rapid inactivation (Berridge,1985). We overcame this 
problem in two ways;
Firstly, the effects of the tumor-promoting phorbol 
ester, 4£-phorbol-12-myristate-13-acetate (PMA) upon 
hepatic steroid metabolism were assessed. PKC is the 
recognised intracellular receptor for PMA (Castagna et al, 
1982; Nishizuka, 1984a) and so by using PMA we can 
investigate whether or not direct activation of PKC plays a 
role in mediating changes in hepatic steroid metabolism.
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Secondly, the effects- upon hepatic steroid metabolism 
of activating PKC by using agents known to activate this 
kinase was investigated. The agents employed were 1,2- 
dioctanoylglycerol (a cell-permeable analogue of the 
endogenous activator of PKC), the hormone vasopressin (acts 
by causing receptor-mediated hydrolysis of inositol 
phospholipids to activate PKC), A23187 alone and in 
combination with PMA (A23187 is a calcium ionophore and high 
intracellular concentrations of calcium can activate PKC) 
and finally angiotensin II (a calcium-elevating hormone, 
which exerts some of its effects via PKC).
4.3(a) The effect of PMA upon hepatic steroid metabolism.
Incubation of isolated rat hepatocytes with PMA caused 
a marked inhibitory effect upon the activities of the 
enzymes metabolising 4-androstene-3,17-dione. Both 50nM PMA 
(figure 12) and InM PMA (figure 13) exerted similar effects 
upon inhibition of enzyme activity, implying that InM PMA 
is capable of activating PKC maximally, and this correlates 
well with previous studies (Standaert et al, 1987; Shoji et 
al, 1987; Kiss et al, 1988c).
The effect of PMA appears to be transient, with maximum 
inhibitions of enzyme activity being seen at between 40 
and 60 minutes, after which time the action of PMA wore off. 
The cessation of PMA's effect probably reflects the fact 
that long term activation of PKC by PMA causes 
down-regulation of the kinase (Terbush & Holz,1986; Darbon 
et al, 1987). The usual time period for PKC being 
down-regulated by PMA is between 3 and 6 hours (Cherqui et
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al, 1987; Hepler et al, 19B8),although down-regulation of 
PKC has been reported after 60 minutes (von Reucker et 
al,1988). Down-regulation of PKC by PMA is the most 
plausible reason for a return of enzyme activities to 
control levels, as most of PMAs effects are known to be 
mediated by this kinase. PMA caused quite marked inhibitions 
in enzyme activity, typically between 60 and 50 % of control 
activities. This implies that PKC plays quite an important 
role in controlling the activity of 4-androstene-3,17-dione 
metabolising enzymes.
The effect of PMA appears to be sexually-independent as 
it exerted similar effects in female rats (figure 16) to 
that seen in the male rats (figure 12). As all the enzyme 
activities were affected similarly, it suggests that the 
action of PMA upon the enzyme activities is not a feminising 
effect of PMA. Feminisation of the enzyme profile would 
have resulted in the suppression of 16a- and 6p-hydroxylase 
activities, little effect upon the activities of 
7a-hydroxylase and 17a(p)-hydroxysteroid dehydrodgenase and 
a stimulation of 5a-reductase activity. The inability of 
PMA to feminise the male profile of steroid metabolising 
enzyme activity may indicate that activation of PKC haj£ no 
role to play in controlling in vivo sex differences of 
hepatic monooxygenases.
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4.3(b) Effect of 1,2-Dioct-anoylglycerol upon hepatic steroid 
metabolism.
Incubation of intact rat hepatocytes with the synthetic 
diacylglycerol, 1,2-dioctanoylglycerol (DOG) was also found 
to produce an inhibition of the activities of the enzymes 
metabolising 4-androstene-3,17-dione (Figure 19). It 
appears, therefore, that DOG can produce a similar effect to 
that seen with PMA, presumably via activation of PKC.
Similarities between the effects of PMA and DOG have 
been previously reported, eg both compounds enhance 
catecholamine secretion and protein phosphorylation in 
intact and permeabilised adrenal chromaffin cells (Lee & 
Holz, 1986), both compounds block the anti-IgM-induced 
inositol phosphate production and the anti-IgM-stimulated 
increases in cytoplasmic calcium in WEH-231 cells (Gold & De 
Franco, 1987). The similarity in effect between phorbol 
esters and synthetic diacylglycerols reflects the fact that 
both compounds bind to a similar site on the PKC molecule, 
supposedly a 32kD protein fragment (the regulatory fragment 
of PKC) (Lee & Bell, 1986).
There are some subtle differences between the effects 
of PMA and DOG upon steroid metabolising enzymes in isolated 
rat hepatocytes.
Firstly, DOG appears to have a more rapid loss of 
activity than PMA; the maximum effect with DOG was seen at 
20 minutes whilst the maximum effect of PMA was typically 
between 40 and 60 minutes. The rapid loss of activity with 
DOG is a reflection of the fact that although it is a 
synthetic analogue of the endogenous PKC activator, it is
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nevertheless a target for degradation by diacylglycerol 
kinase and is converted to its corresponding phosphatidic 
acid. The loss of effect with DOG after 20 minutes suggests 
that DOG has been broken down by this time. Endogenous 
diacylglycerol is also rapidly degraded to phosphatic acid 
and so, in the physiological situation, there is only a 
limited time period within which PKC can become activated. 
Preventing breakdown of diacylglycerol or its synthetic 
analogues by the use of diacylglycerol kinase inhibitors 
would result in an elevated level of diacylglycerol and 
cause a more sustained activation of PKC. The use of 
diacylglycerol kinase inhibitors has been employed to study 
prolonged activation of PKC (Chataway & Barritt, 1988).
The other difference between PMA and DOG is that the 
degree of inhibition of enzyme activity is different for the 
two compounds. PMA was found to be capable of inhibiting 
enzyme activity to 50% of control, whereas DOG only 
inhibited enzyme activity to 70% of control. The 
differences in effect between the two compounds in this case 
again probably reflects the fact that DOG is much more 
rapidly broken down than PMA, resulting in a low intra­
cellular concentration of DOG.
Phorbol esters are known to be capable of activating 
PKC independently of calcium (Donelly & Jensen, 1983) and 
PKC activated in the absence of calcium can still function 
in the same way as PKC activated via the usual inositol 
phospholipid turnover pathway (Kishimoto et al,1983). 
Diacylglycerol, and its synthetic analogues, have a specific 
requirement for calcium and phospholipid in order to fully
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activate PKC (Nishizuka, 1984b).
Our experiments using intact hepatocytes should have 
contained adequate reserves of intracellular calcium to 
enhance DOG-mediated activation of PKC, without the need to 
supplement the medium with calcium, and the most probable 
explanation for the difference in effect between PMA and DOG 
is the rapid degradation of DOG within the cell.
4.3(c) Effect of Vasopressin upon hepatic steroid 
metabolism.
The hormone vasopressin was investigated in our study 
at both a physiological concentration (lOOnM) and a 
supraphysiological concentrations (lOOpM). Incubation of 
intact hepatocytes with both concentrations once again 
produced an inhibition of enzyme activity (figures 20 and 
21) in a manner analogous to that seen with PMA (figure 12 & 
13).
Analogous effects of PMA and vasopressin have been 
previously reported in hepatocytes, eg they both block 
ax-mediated effects in hepatocytes (Garcia-Sainz et al,
1987) and they both have antiketogenic effects (Nomura et 
al, 1987).
Some of the effects of vasopressin are reported to be 
mediated by activation of PKC (Blackmore et al, 1986a; Cabot 
et al, 1988a). It has been reported that vasopressin, upon 
activation of a 1 receptors stimulates inositol phospholipid 
turnover, resulting in production of
inositol-1,4,5-trisphosphate and diacylglycerol, which cause 
an elevation of intracellular calcium levels and activation
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of PKC respectively (Nishizuka, 1984b). More recent 
evidence has suggested that vasopressin can also act in a 
manner which differs to the usual pathway, involving 
inositol phospholipid turnover. Tijburg et al (1987b) 
reported that vasopressin can enhance biosynthesis of 
phosphatidylethanolamine and it has also been proposed that 
phosphatidylethanolamine can activate PKC (Asaoka et al, 
1988). Phosphatidylethanolamine is thought to replace 
phosphatidylserine in order to activate PKC. Another 
potential consequence of vasopressin acting upon inositol 
phospholipid turnover, is that phosphatidylinositol 
-4,5-bisphosphate (PIP2 ), which is produced during the 
turnover cycle, has also been found capable of activating 
PKC (Chauhan & Brockerhoff, 1988). It appears that PIP2 
confers a narrower substrate specificity upon PKC than 
diacylglycerol, and PIP2 may antecede diacylglycerol as the 
PKC activator. A difference between vasopressin's and PMA's 
effects is that both concentrations of vasopressin appear to 
exert a biphasic effect upon the inhibition of steroid 
metabolising enzymes activity. Inhibitions of enzyme 
activity with vasopressin are seen at 20 and 40 minutes, 
with a return toward control activities in the intervening 
time periods. This suggests that PKC is subject to a cyclic 
pattern of activation in the presence of vasopressin. The 
biphasic effect of vasopressin has been reported previously 
(Hermon et al, 1986) and it appears that diacylglycerol, 
produced by inositol phospholipid turnover, is the rate 
limiting step in the early activation of PKC, whilst 
calcium, mobilised from intracellular stores by
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inositol-1,4,5-trisphosphate, may become the rate limiting 
step once diacylglycerol is metabolised. This hypothesis 
fits well with our observations. Both vasopressin and DOG 
produced inhibitions in enzyme activity at 20 minutes, which 
quickly wore off. This effect could conceivably be the 
diacylglycerol-controlled step, the loss of effect 
representing metabolism of diacylglycerol by diacylglycerol 
kinase. The later reduction seen with vasopressin at 40 
minutes, but not with DOG, could be the calcium-controlled 
activation step. It is well known that high intracellular 
levels of calcium can activate PKC, independently of a need 
for phospholipid (O'Flaherty & Nishihira, 1987), and 
vasopressin by producing inositol-1,4,5-trisphosphate, could 
easily elevate calcium levels to the pM concentrations 
required to activate PKC. Therefore, it appears that 
vasopressin can exert a dual regulatory control upon PKC in 
order to inhibit the activity of steroid metabolising 
enzymes.
4.3(d) Effect of A23187 upon hepatic steroid metabolism.
Incubation of intact hepatocytes with the calcium 
ionophore A23187 alone (figure 22) showed that this compound 
had no effect upon the activities of the enzymes 
metabolising 4-androstene-3,17-dione. A23187 is known to
act by increasing intracellular calcium levels and although 
PKC is known to be activated by high intracellular calcium 
(Kishimoto et al, 1983), the concentration of A23187 we 
employed (lOOnM) may not have been enough to raise intra­
cellular calcium levels sufficiently to activate PKC. The
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lack of effect with A23187- has been reported previously in 
our laboratory (Hussin et al, 1988).
Combining A23187 and PMA together (figure 22) showed 
that in contrast to A23187 acting alone, the combination of 
the two compounds produced a marked inhibition of enzyme 
activity. The degree of inhibition with PMA and A23187 in 
combination was greater than for PMA acting alone (figure 
12). Treatment with the combination produced inhibition to 
30% of control, whilst PMA acting alone produced maximum 
inhibitions to 50% of control. The more pronounced 
inhibition with the combination of PMA and A23187 suggests 
that while A23187 alone is incapable of inhibiting enzyme 
activity, once A23187 is acting in the presence of PMA there 
is a synergistic effect between the two compounds. 
Synergistic effects between phorbol esters and ionophores 
are well documented on diverse cell functions, eg glycogen 
phosphorylase is synergistically affected by PMA and A23187 
(Fain et al, 1984) and interleukin-2 secretion from human 
peripheral blood lymphocytes is synergistically enhanced by 
PMA and A23187 (Conradt et al, 1988). The involvement of 
PKC in these synergistic effects has been implicated by 
experimental evidence (White and Metzger, 1988; Seiss and 
Lapetina, 1988) and so it is reasonable to propose that, in 
our hepatocyte system, PMA acts to cause translocation of 
PKC from cell cytosol to the plasma membrane, while A23187 
increases the intracellular calcium concentration to 
facilitate PKC activation in the presence of the phorbol 
ester and endogenous phosphatidylserine. The rise in 
intracellular calcium levels produced by A23187, although
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not high enough to activate PKC alone, would be more than 
adequate to activate PKC in the presence of the phorbol 
ester, bearing in mind that one of the functions of PMA upon 
PKC is to lower its requirement for calcium.
4.3(e) Effect of Angiotensin II upon hepatic steroid 
metabolism.
The final compound we investigated with proposed 
actions through PKC, was angiotensin II (Figure 23). 
Incubation of intact hepatocytes with angiotensin II 
produced an unexpected, but significant, increase in the 
activity of the enzymes metabolising 4-androstene-3,17- 
dione. This was the first, and only, time we saw a 
stimulation of enzyme activity.
Phorbol esters and angiotensin II have been reported to 
have similar effects upon hepatic steroid-metabolising 
enzymes, McAllister and Hornsby (1988) reported that PMA and 
angiotensin II could inhibit forskolin-induced increases in 
3p-hydroxysteroid dehydrogenase and 7a-hydroxylase 
activities. In contrast to this observation, Garcia-Sainz & 
Hernandez-Sotomayor (1987) reported that, while vasopressin, 
angiotensin II and PMA all inhibited stimulation of 
ureogenesis induced by a 1 activation in hepatocytes, the 
effects of vasopressin and PMA could be blocked by PKC 
inhibitors while those of angiotensin II were unaffected by 
PKC inhibitors. This suggests that PMA and angiotensin II 
can act through both similar and dissimilar pathways to 
produce the same effect. The fact that we have seen a 
stimulation of enzyme activity with angiotensin II and an
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inhibition with PMA suggests that these different effects 
are mediated by separate pathways.
Effects of angiotensin II in hepatocytes are mediated 
by receptor activated processess, unlike phorbol esters 
which act directly within the cell membrane. Some of these 
receptor-mediated effects of angiotensin II are proposed to 
be due to an enhanced mRNA accumulation (Ben-Ari and 
Garrison, 1988) and so it may be that the stimulatory 
effects we are seeing with angiotensin II are due to mRNA 
production.
Bouscarel and co-workers have studied angiotensin II 
receptors extensively and have proposed the following 
hypothesis: hepatocytes contain a homogenous population of
angiotensin II receptors that are coupled to two different 
biological effects, apparently mediated by different G 
proteins (Bouscarel et al, 1988b). The two biological 
effects of activating angiotensin II receptors are an 
increase in intracellular calcium levels, which would 
facilitate activation of PKC, and an enhancement of 
agonist-induced cyclic AMP accumulation, which would 
facilitate activation of protein kinase A (PKA). Hence, the 
two main intracellular signalling pathways appear to be 
subject to influence from angiotensin II receptors. It has 
previously been shown in our laboratory that 
supraphysiological concentrations of cyclic AMP can cause a 
stimulation in the activity of the enzymes metabolising 
4-androstene-3,17-dione in a similar manner and over the 
same time as we have seen here using angiotensin II 
(Berry & Skett, 1988b). This would support an effect of
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angiotensin II mediated by- an enhancment of cyclic AMP 
accumulation.
Bouscarel et al (1988a) further suggested that 
down-regulation of angiotensin II receptors induced by their 
agonist is homologous and does not involve the inhibitory 
guanine-nucleotide binding protein, Ni, calcium or PKC. It 
appears that the angiotensin II receptor can regulate two 
different messengers, calcium or cyclic AMP, depending upon 
the mode of activation of the receptor.
We propose that in our hepatocyte model, in this 
particular study, angiotensin II receptor activation 
selectively produces cyclic AMP within the cell, which then 
acts to stimulate the activity of the enzymes metabolising 
4-androstene-3,17-dione. This effect may also involve de 
novo protein synthesis, as it has been shown that high 
concentrations of cyclic AMP produced their stimulatory 
effect upon enzyme activity in a protein-synthesis-dependent 
manner (L. Berry, Ph.D. thesis, 1988). It may be that the 
production of cyclic AMP in some way represses the calcium 
limb of the angiotensin II response, thus preventing PKC 
activation and accounting for the absence of any inhibitory 
effect of angiotensin II upon 4-androstene-3,17-dione 
metabolising enzymes. It is known that cyclic AMP can 
inhibit the action of phorbol esters in some cells (Goto et 
al, 1988).
It has been reported (Summers et al, 1988) that 
activation of PKC can increase the initial rate of cyclic 
AMP synthesis and so another possible hypothesis for 
angiotensin II effects is that activation of PKC by
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angiotensin II could enhance cyclic AMP synthesis and 
production of cyclic AMP by the two pathways regulated by 
angiotensin II could cause a synergistic effect and produce 
the marked stimulation in enzyme activity which we observe.
4.3(f) Conclusions to section 4.3.
Activation of protein kinase C in intact rat 
hepatocytes, was found to cause a time-dependent inhibition 
of the activity of the enzymes metabolising the steroid 
substrate 4-androstene-3,17-dione, apart from the hormone 
angiotensin II. The reductions in activity seen at 20 and 
40 minutes suggest that PKC has a biphasic effect upon 
enzyme activity, which is regulated by diacylglycerol 
production initially with the later effect more dependent 
upon calcium. The loss of effect with vasopressin after 40 
minutes is probably due to calcium sequestration back into 
intracellular stores, while the loss of effect with PMA is 
probably due to a down-regulation of PKC.
4.4 Activation of protein kinase C by 
4p-Phorbol-12-myristate-13-acetate.
Protein kinase C (PKC) is reported to be the 
intracellular receptor for phorbol esters in a variety of 
tissues and cell lines, eg brain (Baraban, 1987; Shearman et 
al, 1987), spleen, retina, thymus and intestine (Yoshida et 
al, 1988), hepatocytes (Garcia-Sainz et al, 1986), BC3H-1 
myocytes (Cooper et al, 1987) and pituitary cells (Ramsdell 
et al, 1986).
Before we can attribute the inhibitory effect of
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4p-phorbol-12-myristate-13-acetate (PMA) upon hepatic 
steroid metabolism to an activation of PKC, it was necessary 
to confirm that PKC could become activated in the presence 
of PMA in our hepatocyte model. The method of Pelech et al 
(1986) was employed for this purpose. PKC is known to 
phosphorylate a variety of protein substrates which are used 
as intracellular markers of PKC activation. One of the 
commonest proteins used to identify phosphorylation by PKC 
are the histones (Jakes et al, 1988a; Brocklehurst & Hutton, 
1984; Ono et al, 1988a) and the assay we used determines 
phosphorylation of histone HI. The assay showed (figure 24) 
that as the concentration of phorbol ester was increased, a 
translocation of PKC occured, reflected by a decrease in 
activity of PKC in the soluble fraction, which represents 
the cell cytosol, and an increase in activity in the 
particulate fraction, which represents the cell membrane, to 
which PKC becomes bound in order to become activated. 
Translocation of PKC from the soluble to the particulate 
fraction is taken as an indication that the enzyme has 
become activated (Portilla et al, 1988; Vegesna et al, 
1988a). The maximum activity of PKC in the particulate 
fraction was seen with lOnM PMA and this concentration 
correlates well with concentrations of PMA which we earlier 
found were able to reduce steroid metabolism (section 4.3: 
50nM and InM). The loss of activity of PKC from the soluble 
fraction and the concomitant increase in activity in the 
particulate fraction, suggests that the majority of 
activated PKC found in the particulate fraction has come 
from the soluble fraction. The soluble fraction represents
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the storage area for PKC in the quiescent cell.
The above results indicate that PMA is capable of 
activating PKC in our hepatocyte model and it is presumably 
via activation of PKC that the inhibitory effects upon 
steroid metabolism are mediated. The optimal concentration 
of PMA required for activation of PKC in this assay was 
lOnM.
4.5 The role of protein kinases and protein synthesis in 
mediating the effects of 4p-Phorbol-12-myristate-13-acetate 
upon steroid metabolism.
Activation of protein kinase C (PKC) with either 
phorbol esters or agonists is known to result in the 
phosphorylation of a variety of protein substrates which 
then mediate the intracellular effect of PKC. Two proteins 
used as intracellular markers of PKC activation are an 
80 Kd protein (Malvoisin et 31,1987; Blackshear et al, 1987) 
and a 40 Kd protein (Chida et al, 1988a; Vila and Weber, 
1988). PKC is also known to phosphorylate certain liver 
enzymes such as glycogen synthetase (Arino and Guinovart,
1986) and pyruvate kinase (Hsu et al, 1987). In addition to 
phosphorylating specific proteins and hepatic enzymes,
Pyerin et al (1987) reported that a variety of rat liver 
cytochrome P450 isozymes were phosphorylated by PKC. The 
same group also reported that activation of the cyclic 
AMP-dependent protein kinase (PKA) resulted in 
phosphorylation of cytochrome P450 isozymes, and there was 
some interaction between PKC and PKA in mediating 
phosphorylation of these cytochrome P450 isozymes. The role
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of protein kinases in mediating effects upon hepatic steroid 
metabolism was, therefore, carefully examined.
Phorbol esters, because of their mitogenic properties, 
can exert some of their actions via an enhancement of gene 
expression (Wu et al, 1988; Deutsch et al, 1988; Lindstein 
et al, 1988) with these effects occuring at both the 
transcriptional and translational level. The possibility 
that protein synthesis may be involved in the effect of PMA 
upon hepatic steroid metabolism in the present study was 
therefore, also investigated.
4.5(a) Agents
(i) Protein kinase inhibitors.
PKC inhibitors have been used previously but these 
inhibitors have suffered from problems of selectivity and 
side-effects. Staurosporine is a widely used inhibitor of 
PKC (Matsumoto and Sasaki, 1989; Sako et al, 1988) but 
staurosporine is relatively non-specific and also inhibits 
tyrosine kinases as well as PKC (Smith et al, 1988).
Another inhibitor of PKC is the endogenous phospholipid 
sphingosine (Merrill & Stevens, 1989; Kolesnick & Clegg,
1988) but this again suffers from selectivity problems 
(Krishnamurthi et al, 1989). A recently developed class of 
kinase inhibitors, the K252 compounds, have been found to 
show a great potential as protein kinase inhibitors.
K252 compounds are a group of substances derived from 
microbial origin, from the species Nocardiopsis of strain 
K252 (Kase et al, 1986). The first compound isolated was 
K252a, which was found to be an indole carbazole compound.
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Initially, K252a was shown-to be active against PKC, and it 
inhibited PKC with an IC50 of 32.9nM and a Ki of 25nM (Kase 
et al,1986). K252a was subsequently reported to be capable
of inhibiting both cyclic AMP-dependent protein kinase 
(PKA), with a Ki of 18nM, and cyclic GMP-dependent protein 
kinase (PKG), with a Ki of 20nM (Kase et al, 1987). It 
appears then that K252a is a general, non-selective 
inhibitor of both cyclic nucleotide-dependent and cyclic 
nucleotide-independent protein kinases.
Nakanishi and his co-workers (1986) found that a 
related microbial strain of Nocardiopsis, K290, also
possessed the ability to inhibit PKC, and K290 gave rise to 
a series of compounds termed K252b, c and d. These 
compounds were all found to possess PKC blocking activity, 
but K252b was found to be the most potent, with an IC50 of 
38.3nM. The IC50 for K252c and K252d were 214nM and 337nM 
respectively. Upon structural analysis of K252b, it was 
discovered that it was the 9-carboxylic acid derivative of 
K252a, previously identified by Kase et al (1987). K252b
differed from K252a in that it was relatively specific 
against PKC, with minimal actions toward PKA and PKG. K252b 
has a Ki for PKC of 20nM, whereas its Ki for PKA is 90nM and 
Ki for PKG is lOOnM (Kase et al, 1987). We used K252b at a 
concentration of 20nM so that it would act selectively to 
block PKC and have minimal activity against PKA and PKG.
Upon chemical modification of K252a, two further 
derivatives were discovered, both of which possessed kinase 
blocking activity. KT5720 was found to be the 9-hexyl ester 
derivative of K252a and with a Ki of 60nM for PKA is a
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selective inhibitor of this kinase (Kase et al, 1987). The 
other derivative is KT5822, which was found to be the 
9-methoxy derivative of K252a, and with a Ki of 2.4nM was 
found to selectively inhibit PKG (Kase et al, 1987).
All of these protein kinase inhibitors act by 
competing with intracellular ATP for the active site on the 
respective kinase (Kase et al, 1987) and this action is 
identical to that reported for the inhibitory action of the 
PKC inhibitors staurosporine, quercetin and the 
isoquinoline sulfonamide derivative, H7, (Nakadate et al,
1988). One drawback to using the K252 compounds is that 
they become relatively non-selective at high concentrations 
and to take account of this, we employed the inhibitors at a 
concentration equivalent to their Ki for their respective 
kinases. To eliminate any possible direct effect of the 
kinase inhibitors against hepatic monooxygenase activity, 
test samples were compared to control samples which had been 
treated with inhibitor alone. It was found that the kinase 
inhibitors themselves exerted little or no direct effect 
upon the hepatic monooxygenases, when the inhibitor-treated 
cells were compared to untreated control cells.
Kase et al (1987) established the inhibitory potencies 
of K252 compounds using in vitro models and they did not 
determine the effects of the inhibitors upon intact cells. 
Our preliminary studies showed that K252 compounds were 
inactive in our hepatocyte model but studies with 
electropermeabilised cells established that once the cells 
were permeabilised, the K252 compounds were highly effective 
(L. Berry, personal communication). The electroperm-
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eabilisation parameters we- employed (1000V for 5 pulses) 
have been previously standardised and have been found to 
allow access of compounds into the cell without causing 
adverse effects upon cell viability or cytochrome P450 
levels (L. Berry, Ph.D. thesis). The problem of cell access 
with the K252 compounds may be one of the disadvantages to 
using these compounds to investigate physiological 
processess.
(ii) Cycloheximide.
Cycloheximide is a glutaramide antibiotic and it 
inhibits protein synthesis at the translational level.
Peshka (1971) reported that cycloheximide may act by 
inhibiting both the initiation of protein synthesis and 
polypeptide chain elongation by interaction with the 60S 
ribosomal subunit.
A disadvantage to the use of cycloheximide in 
investigating hepatic monooxygenase activity is that general 
non-selective inhibition of protein synthesis will occur and 
this may result in a loss of the total cell cytochrome P450 
level. The loss of cytochrome P450 would have profound 
effects upon the activity of monooxygenases. To combat this 
effect of cycloheximide, we compared test cells treated with 
cycloheximide to control cells which had received 
cycloheximide alone, thereby overcoming the potential effect 
of cycloheximide upon hepatic enzyme turnover.
The effect of cycloheximide was investigated in 
electropermeabilised cells, again to ensure that 
cycloheximide would penetrate the cell and any effect of
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cycloheximide was, therefore, a consequence of an 
intracellular action.
4.5(b) Effect of K252a.
The effect of the non-selective kinase inhibitor K252a 
is shown in figure 29. It can be seen that PMA acting alone 
was able to inhibit steroid metabolism in its usual manner, 
which we have seen and described earlier (section 4.3(a)).
When PMA and K252a were added together, it could be 
seen that PMA was still capable of causing inhibition of 
hepatic steroid metabolism in the same way as PMA acting 
alone. This suggests that in our isolated rat hepatocyte 
system, K252a was not able to inhibit the action of PMA, 
which is acting presumably through protein kinase C (PKC).
The lack of effect with K252a was unexpected, as we 
were using the compound at its Ki and also the cells had 
been electropermeabilised to ensure access of K252a into the 
hepatocyte. Due to the lack of effect with K252a we are 
unable to provide any definite theories as to the action of 
this compound upon phorbol ester-mediated inhibition of 
hepatic steroid metabolising enzyme activity.
4.5(c) Effect of KT5720.
KT5720, the selective inhibitor of PKA, produced the 
effect shown in figure 30. KT5720 was found to have no
detectable effect upon the action of PMA upon hepatic 
steroid metabolism. PMA was equally effective both in the 
presence and absence of KT5720.
This confirms our previous suspicion that activation of
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PKA plays no role in mediating PMA effects upon steroid 
metabolism. The inhibitory effect of PMA appears to be 
exerted independently of cyclic AMP production and PKA 
activation.
4.5(d) Effect of K252b.
Addition of the selective PKC inhibitor K252b, as shown 
in figure 31, was found to cause a virtually complete 
blockade of PMA effects and in the presence of K252b, the 
activities of the enzymes are returned to control levels.
It would appear, therefore, that the actions of PMA upon 
hepatic steroid metabolism are exerted directly through 
activation of PKC.
The results show that some of the enzymes metabolising 
4-androstene-3,17-dione seem to be more susceptible to 
modulation by PKC than others. PMA was still able to cause 
slight inhibitions in activity in the presence of K252b, 
although not as efficiently as for PMA acting alone.
K252b appears to be selective for PKC in our 
hepatocyte model, and this effect is in keeping with the 
idea that PKC is the intracellular receptor for phorbol 
esters (Niedel et al, 1983).
4.5(e) Effect of cycloheximide.
The use of cycloheximide (figure 28) indicates that, as 
well as having a dependency upon PKC, the effect of PMA also 
has a requirement for protein synthesis. Cycloheximide was 
found to effectively block the actions of PMA upon all of 
the enzymes metabolising 4-androstene-3,17-dione.
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The effect of cycloheximide was rapid in onset, the 
actions of PMA could be blocked within 10 minutes, 
suggesting that the protein inhibited by cycloheximide is 
subject to rapid turnover and its synthesis appears to be 
completely and irreversibly blocked by cycloheximide. The 
search for such a protein, with a rapid turnover and fast 
onset of action, has been conducted and there are a few 
possible candidates.
Angel et al (1987b) reported that phorbol ester- 
inducible genes contain a common cis element which is 
recognised by a PMA-modulated trans-acting factor. Angel 
and his group proposed that this element is transcription 
factor AP-1. Transcription factor AP-1 appears to be at the 
receiving end of a complex pathway responsible for 
transmitting the effects of phorbol ester tumor promoters 
from the plasma membrane to the transcriptional machinery of 
the cell. It is possible that cycloheximide is inhibiting 
the synthesis of transcription factor AP-1 in our hepatocyte 
system, and blockade of synthesis of this protein causes the 
blockade of PMA effect.
Another possible candidate for cycloheximide action are 
the c-myc and c-fos proteo-oncogenes. It is known that PKC 
activation, with phorbol esters, can stimulate the 
accumulation of mRNA for both c-myc and c-fos (Blackshear et 
al, 1987; Stumpo et al, 1988), and most studies seem to 
implicate the c-fos gene as the more important transcript.
A c-fos binding factor has been proposed as the essential 
mediator of c-fos expression by PKC (Stumpo et al, 1988) and 
it is possible that the c-fos gene is necessary for the
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effect of PMA upon hepatic- steroid metabolism and this 
protein is inhibited by cycloheximide.
The results with cycloheximide suggest that the action 
of PMA upon hepatic steroid metabolism are dependent upon 
protein synthesis. Although we have not determined the 
identity of the actual protein inhibited by cycloheximide, 
the literature suggests that either transcription factor 
AP-1 or the c-myc/ c-fos proteo-oncogenes may be potential 
candidates. The role of the genes responsible for phorbol 
ester-mediated effects are still being investigated and 
extensive work, outwith the scope of this thesis, is
necessary before we could confidently predict the protein
c
responsible for mediating PMA eff^ts upon hepatic steroid 
metabolism.
4.5(f) Conclusion to section 4.5.
Using selective protein kinase inhibitors and the 
protein synthesis inhibitor cycloheximide, we have shown 
that the effects of the phorbol ester PMA upon hepatic 
steroid metabolism are mediated solely by activation of PKC, 
no other kinase* appears to be affected by PMA. This result 
enhances the idea that PKC is the only intracellular 
receptor for phorbol esters. The effect of PMA also 
requires protein synthesis, although the identity of the 
protein or proteins remains to be established.
It is possible that once activated, PKC has subsequent 
effects upon gene expression and these genes produce the 
effects upon hepatic steroid metabolism. This idea is 
further expanded in section 4.9.
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4.6 Mechanisms of action o-f 4p-Phorbol-12-myristate-13- 
acetate.
Having determined that the active phorbol ester PMA 
could exert inhibitory effects upon hepatic steroid 
metabolism, we next attempted to elucidate the underlying 
mechanism of this action. The first area of investigation 
was upon PMA action on various components of the NADPH/ 
cytochrome P450 enzyme system. The key enzymatic components 
of this mixed function monooxygenase system are the
I
flavoprotein NADPH-cytochrome c(P450) reductase and 
cytochrome P450 itself. NADPH-cytochrome c reductase has 
been reported to be a phosphorylatable substrate of PKC, 
activated by PMA (Tamoto et al, 1989) and phosphorylation of 
specific cytochrome P450 isozymes by PKC has also been 
reported (Pyerin et al, 1987). We hoped to extend, or at 
least confirm, these observations in our own study.
4.6(a) Effect of PMA upon the cofactor NADPH.
One of the mechanisms by which PMA may be acting is by 
affecting the availability of the cofactor NADPH. NADPH is 
essential in cytochrome P450-mediated reactions, and it acts 
as the electron donor for hepatic monooxygenases. The 
activity of the cytochrome P450 enzyme system in isolated 
hepatocytes depends upon an in vivo supply of NADPH and so 
we tested the possibility that the changes in enzyme 
activity which occur with PMA were due to a change in the 
supply of NADPH.
Figure 25 shows the effect of PMA acting in the 
presence of excess NADPH. It can be seen that
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homogenisation of the hepatocytes, following incubation with 
PMA, and the addition of excess cofactor, NADPH, had no 
effect on either the rate or magnitude of PMA's inhibition 
of steroid metabolism. PMA still acted in the same way as 
when added alone to the hepatocytes (figures 12 and 13).
This indicates that the inhibitory effects of PMA are not 
dependent upon the availability of NADPH.
As the availability of NADPH did not appear to be 
involved in the effect of PMA, we tested the possibility 
that the rate of degradation of NADPH may be important in 
controlling PMAs effects. NADPH degradation by NADPH 
oxidase may be a limiting factor in controlling the rate of 
cytochrome P450-mediated reactions, and it is possible that 
PMA acting upon NADPH oxidase may affect the activity of 
cytochrome P450-dependent reactions. The results indicate, 
however, that the rate of degradation of NADPH in both 
control and PMA-treated samples remains at a constant level 
and there is no significant difference between the rate of 
loss of NADPH between the two samples (figure 26). It 
appears then, that NADPH oxidase is not affected in any way 
by PMA and consequently, the rate of loss of NADPH is not 
affected by PMA.
The above result indicates that neither the 
availability nor the rate of loss of the cofactor NADPH are 
involved in PMA's inhibition of hepatic steroid metabolism.
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4.6(b) Effect of PMA upon NADPH cytochrome c (P450) 
reductase.
NADPH cytochrome c (P450) reductase is a flavoprotein 
present in the microsomal fraction of the liver and it acts 
by transferring the necessary reducing equivalents from 
NADPH to cytochrome P450 during drug metabolising reactions 
as determined by the equation
e~ e~
NADPH ---> NADPH cytochrome c --- > Cytochrome P450
reductase
NADPH cytochrome c reductase has been reported as a 
substrate of activated PKC (Tamoto et al, 1989; Steele and 
Virgo, 1988) and phosphorylation of the enzyme is reported 
to cause activation. We measured the activity of NADPH 
cytochrome c reductase because by determining the reduction 
of cytochrome c, we can directly determine the reduction of 
cytochrome P450 itself, on the principle of the above 
equation. Reduction of cytochrome P450 directly is 
difficult to measure experimentally, but by measuring 
reduction of cytochrome c we can obtain an estimate of the 
reduction of cytochrome P450 itself. Cytochrome c is used as 
an artificial electron acceptor in this instance.
The principal of the method is that both the oxidised 
(ferric) and reduced (ferrous) form of cytochrome c 
have characteristic absorption spectra. The difference 
between the ferrous and ferric spectra is that the reduced 
(ferrous) form absorbs at 550nm, while the oxidised (ferric) 
form does not. Hence, activity of NADPH cytochrome c 
reductase can be conveniently determined by measuring
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absorption at 550nm as a function of time (Philips and 
Langdon, 1962).
The results show (figure 27) that treatment of 
hepatocytes with PMA had no effect upon the activity of 
NADPH cytochrome c reductase. The activity of the enzyme 
declined gradually after 20 minutes, but both control and 
PMA-treated samples showed a decline in activity at the same 
rate suggesting that this was not a direct effect of PMA.
The above findings imply that in the isolated rat 
hepatocyte, NADPH cytochrome c reductase is not a target for 
PMA and from this, we can infer that PMA does not affect the 
rate of reduction of cytochrome P450 in order to exert its 
inhibitory effect upon hepatic steroid metabolism.
4.6(c) Effect of phosphorylation of cytochrome P450.
It has been previously reported (Pyerin et al, 1987) 
that various cytochrome P450 isozymes are substrates for 
phosphorylation by both PKC and cyclic AMP-dependent protein 
kinase (PKA) in vitro. Some of the isozymes appeared to be 
more susceptible than others to phosphorylation and the 
kinases themselves appeared to selectively phosphorylate 
different isozymes. Rat cytochrome PB3a (P450IIB1) was 
reported (Pyerin et al, 1987) to be a target for 
phosphorylation by both PKA and PKC, rat cytochrome P450 
MC-lb (P450IA1) and rat cytochrome P450 UT-1 (P450IIA1) were 
reported not to be phosphorylated by either kinase and rat 
cytochrome P450 PB2c (P450IIC11) was reported to be 
phosphorylated only by PKC.
We investigated a more physiological., in vivo, system
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to try to determine whether or not any of the cytochrome 
P450 isozymes which were proposed substrates for these 
kinases, underwent phosphorylation in the presence of PMA to 
try to determine if phosphorylation of cytochrome P450 may 
be a mechanism by which PMA inhibited steroid metabolism in 
isolated rat hepatocytes.
When we examined incorporation of 32P into cytochrome 
P450 PB 2c (P450IIC11), the isozyme thought to be 
responsible for up to 90% of the hydroxylation of 
4-androstene-3,17-dione at the 16a position (Waxman, 1984), 
we found that we were unable to detect any incorporation of 
32P into immunoprecipitated cytochrome P450 PB2c (P450II 
Cll). Neither the control hepatocytes nor those incubated 
for 1 hour with 50nM PMA (figure 33) showed any 
incorporation of 32P. Cytochrome P450 PB3a (P450IIB1), a 
reported substrate for PKC, and cytochrome P450 MC-lb 
(P450I Al) and cytochrome P450 UT-1 (P450II Al), all failed 
to show any incorporation of 32P, again after 1 hour 
treatment with 50nM PMA prior to immunoprecipitation (figure 
33). The immunoprecipitated cytochrome P450s were compared 
to whole cell samples, which did show 32P incorporation into 
both control and PMA-treated samples.
The above findings imply that direct phosphorylation of 
cytochrome P450 isozymes by PKC is not a physiological 
effect, which contradicts the earlier findings of Pyerin et 
al (1987).
It could be argued that our immunoprecipitation 
technique was at fault and we were not actually precipitat­
ing cytochrome P450 isozymes, but some other proteinaceous
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component. Further experimental evidence, however, tends to 
refute this hypothesis;
(a) The supernatant used for immunoprecipitation was 
assessed spectrophotometrically before being treated with 
the antibodies, and we were able to detect cytochrome P450 
in the supernatant, by the method of Omura and Sato (1962b).
(b) The presence of a large, solitary protein band of 
apparent molecular weight 40,000 - 50,000D on the SDS gels 
indicates that the isolation process has yielded a protein 
with a comparable molecular weight to that of cytochrome 
P450.
(c) Cytochrome P450 is a haem-containing flavoprotein and by 
assessing the amount of haem present in each precipitate 
(Table 17) we can see that haem is present in our 
immunoprecipitates and consequently it is probable that 
cytochrome P450 itself is also present, as haem is an 
integral component of cytochrome P450. The lower values for 
the amount of haem present in the isozymes compared to the 
whole cell samples is a reflection of the fact that the 
immunoprecipitates contain only one form of cytochrome P450, 
while the whole cell samples express the complete range of 
cytochrome P450 isozymes.
This evidence implies that we have successfully 
immunoprecipitated the relevant cytochrome P450 isozymes, 
using our methods.
1 5 7
As a further confirmation that there was no 32P 
incorporation into the cytochrome P450 immunoprecipitates, 
the precipitates were directly counted. The whole cell 
samples showed a high level of counts (Table 18) although 
there was no significant difference between PMA-treated and 
control samples, suggesting that PMA had not enhanced 32P 
incorporation into the cells. The immunoprecipitates showed 
very low counts in comparison to the whole cell samples, but 
once again there was no difference between control and 
PMA-treated samples.
As well as our own data with the phosphorylation of 
cytochrome P450 isozymes, additional evidence exists which 
implies that phosphorylation of cytochrome P450 isozymes may 
not be the underlying mechanism of PMA-mediated, PKC- 
dependent inhibition of steroid metabolism:
(i) Pyerin et al (1987) reported that cytochrome P450 UT-1 
(P450IIA1), which mediates 7a-hydroxylation of 
4-androstene-3,17-dione (Waxman et al, 1987; Nagata et al,
1986) was not phosphorylated by either PKA or PKC. We have 
reported that activation of PKC with PMA causes an 
inhibitory effect upon the activity of this enzyme in 
isolated hepatocytes and it has also been reported that 
activation of PKA with cyclic AMP also produced an 
inhibition of activity of this ensyme (L. Berry, Ph.D. 
thesis, 1988).
(ii) In our earlier discussion (section 4.3) we reported
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that all of the enzymes metabolising 4-androstene-3,17-dione 
were inhibited in the presence of PMA. The enzymes 
5a-reductase and 17-hydroxysteroid dehydrogenase do not 
contain cytochrome P450 as integral components (Golf and 
Graef, 1978) and yet they are inhibited in exactly the same 
manner as the cytochrome P450-containing enzymes, 
7a-hydroxylase, 6f3-hydroxylase and 16a-hydroxylase. Enzyme 
inhibition, therefore, cannot be attributed to 
phosphorylation of cytochrome P450 for these cytochrome 
P450-independent enzymes.
4.6(d) Conclusion to section 4.6.
In the present study, we have shown that the inhibition 
of hepatic steroid metabolising enzymes, mediated by 
activation of protein kinase C with the phorbol ester, PMA, 
appears to be mediated independently of any change in the 
availability or rate of loss of the cofactor NADPH, without 
a direct effect upon the reduction of cytochrome P450 itself 
or by a direct phosphorylation of cytochrome P450 isozymes. 
PKC can apparently mediate its inhibitory effect entirely 
without the involvement of the NADPH cytochrome P450 drug 
metabolism enzyme system.
4.7 Protein Phosphorylation.
Many of protein kinase C's (PKC) intracellular actions 
are reported to occur as a consequence of protein 
phosphorylation. A variety of proteins have been identified 
as PKC substrates in a diverse range of cells, eg the PKC 
intracellular marker proteins 40 Kd, 47 Kd and 80 Kd are
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phosphorylated in BC3-H1 myocytes (Vila et al, 1989), a 
42 Kd Class 1 heavy chain protein is a substrate in human B 
lymphoblastoid cells (Peyron and Fehlman, 1989), and the EGF 
receptor (Davis, 1988). These phosphorylations typically 
occur at serine and threonine residues within the protein 
(Jakes et al, 1988a; Soderling et al, 1986).
We investigated phosphorylation of proteins within 
isolated rat hepatocytes, to try to identify a precise 
protein or proteins which may be responsible for the effect 
of the phorbol ester upon hepatic steroid metabolism.
The phosphorylation study utilised (^32P)ATP as a 
radiolabel, which was preincubated with the hepatocytes for 
15 minutes at 4°C to allow intracellular pools of ATP to 
become equilibrated with the label. Two main studies were 
conducted, the first of which was a time course study to 
investigate changes in phosphorylation with time, and the 
second study employed the specific PKC inhibitor K252b 
(section 4.5 (d) ) to see if inhibition of the kinase 
affected protein phosphorylation.
The time course study, results of which are depicted in 
figure 35, showed that although we could detect a vast array 
of proteins on the SDS gel, analysis of the corresponding 
autoradiogram failed to show any incorporation of 32P into 
these proteins. Modification of experimental technique and 
repetition of the experiment still failed to show any 
incorporation of 32P into any protein.
Investigation into the incorporation of 32P into 
proteins in the presence of the PKC inhibitor, K252b, also
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failed to show any incorporation of 32P into any protein. 
This implies that any protein phosphorylation which may be 
occuring happens outwith the time period of our assay.
These results suggest that phosphorylation of proteins 
may not be involved in mediating the effects of phorbol 
esters upon hepatic steroid metabolism. This hypothesis 
seems unlikely when we consider that phorbol esters act via 
activation of PKC and the sole action of PKC is to cause 
protein phosphorylation.
An alternative, and more credible, hypothesis is that 
any protein phosphorylation which may be occuring is 
occuring very rapidly, in the time before we have taken our 
first sample at 5 minutes. Phorbol esters are known to be 
capable of phosphorylating proteins within seconds, through 
activation of PKC, (Blackshear, 1988; De Graan et al, 1988) 
and these proteins are also rapidly dephophosphorylated. It 
may be that this rapid phosphorylation/dephosphorylation has 
occurred during the first 5 minutes of the time course and 
the intracellular protein profile has returned to normal by 
the time we begin to determine phosphorylation patterns. To 
test this hypothesis, a shortened time course study should 
have been conducted, but such an experiment was not 
performed here.
A third reason why we may not be able to detect any 
change in phosphorylation could be proposed on the knowledge 
that phosphoproteins exist within the cell. Of the 1000 or 
so phosphoproteins which appear to exist, 120 are proposed
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to be phosphorylated in response to active phorbol esters, 
such as PMA (Blackshear, 1988). Exactly how many of these 
phosphoproteins are true substrates for PKC or are the 
result of secondary phosphorylation is not clear.
On the strength of the above results we can only 
speculate as to the precise mechanism by which PMA and 
subsequent activation of PKC, inhibits steroid metabolism 
through protein phosphorylation. It is possible, although 
not proven, that PMA activates PKC very rapidly, within 
seconds, and the activated PKC then induces phosphorylation 
of the proteins responsible for mediating effects upon 
steroid metabolism. This potential phosphorylation may 
occur too rapidly for us to detect with our techniques, but 
although the actual phosphorylation may be rapid, the effect 
upon steroid metabolism appears to be sustained for up to 1 
hour, perhaps via a secondary effect of the rapidly 
phosphorylated protein.
The integral details of PKC-mediated effects, therefore 
remains to be determined, but it may involve a form of 
cascade system which is regulated by the rapidly 
phosphorylated substrate proteins for PKC.
4.8 Approaches to the study of protein kinase C involvement 
in intracellular effects.
We have employed the tumor-promoting phorbol ester PMA 
in this study, assuming previous evidence to be correct, and 
that phorbol esters act exclusively through protein kinase C 
(PKC). Although phorbol esters activate PKC both in vivo
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and in vitro, because of their mitogenic properties and 
because they do not necessarily reflect a true physiological 
situation, several criteria must be fulfilled and borne in 
mind when using phorbol esters to probe PKC-mediated effects 
within an experimental system.
4.8(a) Can we attribiute a biological phenomenon to 
activation of protein kinase C?
For certain short term responses, the answer to this 
question is almost certainly yes. For example, incubation 
of 3T3-L1 adipocytes upon exposure to PMA or 
dioctanoylglycerol, both of which activate PKC, for 30 
minutes was found to enhance mRNA accumulation of the c-fos 
proteo-oncogene (Blackshear, 1988), PMA can inhibit 
tumor-necrosis factor activity within 15-60 minutes of 
treatment (Johnson & Baglioni, 1988) and also, PMA 
preincubation for 30-180 seconds inhibits EGF-stimulated 
production of inositol-1,4,5-trisphosphate and subsequent 
increases in intracellular calcium (Johnson & Garrison,
1987).
For these short term studies, it is generally accepted 
that, if a process can be stimulated by phorbol esters with 
the appropriate stereospecificity for PKC and also by 
appropriate diacylglycerols (synthetic or natural), then the 
biological phenomenon which is observed is a consequence of 
activation of PKC.
The studies we have performed were of no more than 120 
minutes duration and we observed similar effects with 
biologically active PMA, the synthetic diacylglycerol
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1 ,2-dioctanoylglycerol and- also vasopressin, which acts to 
stimulate inositol phospholipid hydrolysis to produce 
endogenous diacylglycerol. As we see the same effect 
regardless of the manner in which we activate PKC, we have 
therefore fulfilled the criteria for activation of PKC 
within a short term incubation to produce a biological 
phenomenon.
The issue becomes more complicated, however, when 
longer term effects of phorbol esters are studied. The 
problem arises in that long-term treatment of cells with 
phorbol esters results in down-regulation of PKC and this 
down-regulation typically takes between 3 and 24 hours 
(Cherqui et al, 1987; Bouscarel et al, 1988c; von Reucker et 
al, 1988).
The phenomenon of down-regulation appears to be 
reversible, at least if a phorbol ester is used which can be 
eliminated from the cells by extensive washing. Phorbol 
dibutyrate is such a phorbol ester and although incubation 
with phorbol dibutyrate causes a 90% decrease in specific 
PKC activity in both soluble and particulate fractions of 
the cell, washout of phorbol dibutyrate and reincubation in 
normal culture medium restores PKC activities in both 
fractions to near pretreatment levels after 48 hour 
incubation (Blackshear, 1988).
The effect of down-regulation does not appear to 
involve significant changes in the levels of PKC mRNA 
(Makauske et al, 1986). Most evidence suggests that 
exposure of cells to phorbol esters leads to a translocation 
of PKC to the particulate fraction, followed by an increased
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rate of destruction of the- bound PKC. The rate of 
biosynthesis of mRNA or protein is not strikingly affected 
and these continue at a slow rate to replace PKC if the 
phorbol ester stimulus is removed.
The problems in assessing long term activation of PKC 
are summarised below and should be borne in mind when 
conducting such a study;
(1) Down-regulation of PKC occurs in many cells in response 
to phorbol esters, therefore, are the long-term effects of 
phorbol esters a consequence of PKC activation or a 
consequence of its disappearance?
(2) Synthetic diacylglycerols are metabolised rapidly by 
most cells and phorbol esters themselves can be broken down 
eventually, especially by hepatocytes and liver cells.
(3) Phorbol esters appear to be toxic to some cells, eg K562 
and leukemic HL60, in long-term incubation studies.
(4) Active phorbol esters cause an "unnatural11 permanent 
association of cytosolic PKC to the particulate fraction.
(5) Long term treatment with phorbol esters may lead to both 
down-regulation and constitutive activation of any remaining 
PKC.
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4.8(b) Does a specific agonist activate protein kinase C in 
an intact cell?
Two major criteria have been used to demonstrate that 
protein kinase C (PKC) is being activated in intact cells;
(i) Protein phosphorylation.
The increased phosphorylation of specific substrates of 
PKC within cells is a widely used approach to investigate 
the involvement of PKC in an observed effect. Recognised 
substrates include the EGF receptor (Davis, 1988), an 
80 Kd protein regarded as a major intracellular marker of 
PKC action (Brooks et al, 1987; Rodriguez-Pena et al, 1986; 
Erusalimsky et al, 1988) and a 40 Kd protein, also an 
intracellular marker for PKC (Kroll et al, 1988; Nishizuka 
et al, 1988).
Within the past ten years, a vast body of evidence has 
accumulated concerning potential substrates for PKC. 
Nishizuka and his colleagues have extensively researched PKC 
phosphorylatable substrates (Nishizuka, 1984a;
Nishizuka, 1984b; Takai et al, 1984) and their data is 
widely used as the basis for determining whether protein 
phosphorylation is a consequence of PKC activation.
In this study, we attempted to determine whether or not 
protein phosphorylation was occuring to try to identify a 
protein which may be related to the effect we observed upon
A,
hepatic steroid metabolism subequent to activation of PKC. 
However, all our attempts to show protein phosphorylation 
were unsuccessful, despite modification of experimental 
technique and extensive repetition of the experiments. This
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may imply that protein phosphorylation is not an important 
factor in mediating the effect of activated PKC, but this is 
unlikely as discussed earlier (section 4.7).
Although protein phosphorylation is reported to be the 
most effective method of investigating PKC action, several 
problems do occur when conducting protein phosphorylation 
experiments. One problem is that it is important to ensure 
that protein phosphatases are inhibited, to prevent any 
non-specific phosphorylation. We used p-glycerophosphate to 
ensure any phosphatases would be inhibited, so we have 
accounted for this effect in our cells. Another factor 
which must be considered, but which is more difficult to 
prevent, is that secondary or tertiary kinases 
have become activated once PKC is activated. Finally, 
although a protein may be a substrate for PKC in cell-free 
systems, this does not necessarily imply that the protein 
will be phosphorylated in intact cells, which will be 
subject to the action of phosphatases and other kinases as 
mentioned above.
Hence, although protein phosphorylation is a useful 
method for investigating the action of PKC in an intact 
cell, there are still an array of difficulties which can 
complicate the interpretation of results.
(ii) Protein kinase C translocation.
Another method used to evaluate the involvement of PKC 
in an effect is to look for evidence that "translocation11 of 
PKC has occurred from the soluble to the particulate 
fraction of the cell. Translocation usually refers to
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agonist-induced association of the kinase with the whole 
cell particulate fraction, although it very occasionally is 
used to refer to a decrease in membrane-associated kinase 
and an increase in cytosol-associated kinase. Translocation 
of kinase from the cell membrane to the cell nucleus has 
been demonstrated (Cambier et al, 1987).
In this study, we successfully showed (section 4.4) 
that in the presence of the active phorbol ester PMA, there 
was a dramatic shift in the location of PKC, with an 
increase in membrane-associated activity and a decrease in 
the soluble kinase activity. Therefore, we feel satisfied 
that activation of PKC has occurred in the presence of an 
agonist, and that activation of PKC is responsible for the 
effect upon hepatic steroid metaboliism.
4.8(c) Which effects of an agonist are mediated through 
protein kinase C-dependent and which by protein kinase 
C-independent events ?
To answer this question, it would be advantageous to 
possess cell lines which lack protein kinase C (PKC), but 
such cell lines do not exist. The closest to a PKC-free 
cell is when a cell has had its levels of intracellular PKC 
down-regulated by prolonged treatment with phorbol esters. 
Even if PKC-free cell lines were available, they would not 
be useful for evaluating PKC-independent processes in other 
cell lines.
The two main approaches to determine if a process is 
dependent upon PKC are to use inhibitors of PKC or to induce 
down-regulation of the kinase. As we did not perform
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long-term studies, down-regulation of PKC was not 
investigated in this study. PKC inhibitors, however, were 
employed.
Inhibitors of kinase action in the past have been 
plagued by problems of selectivity, which we appear to have 
been able to overcome by the use of the relativly specific 
set of inhibitors derived from Nocardiopsis, according to 
the methods of Kase and his group (1987). The use of these 
inhibitors suggests that the actions of phorbol esters upon 
hepatic steroid metabolism are exerted entirely through 
activation of PKC. No other kinase or combination of 
kinases appears to be involved in the phorbol ester effect.
The inhibitors we employed here will hopefully become 
more widely used in the future to aid determination of 
kinase involvement in different intracellular effects.
4.8 (d) Conclusion to section 4.8.
The purpose of this section of the discussion was to 
bring to light some of the problems which are associated 
with the investigation of protein kinase C involvement in 
signal transduction. It can be seen that various criteria 
must be fulfilled in order to implicate PKC with an observed 
biological phenomenon. We have managed to satisfy some of 
these criteria in this study, with respect to activation of 
protein kinase C during a short-term incubation, the ability 
to translocate the kinase upon exposure to a known agonist 
from the soluble to the particulate fraction of the cell 
and, with the use of inhibitors, we have further evidence 
that activation of protein kinase C is a major factor in
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causing inhibition of hepatic steroid metabolism. The one 
criterion we have failed to fulfill is that of demonstrating 
protein phosphorylation, but reasons for this discrepancy 
have been proposed.
4.9 Mechanism of action by which activated protein kinase C 
may regulate steroid metabolism at the intracellular level.
This study into the control of hepatic steroid 
metabolism has shown that there appear to be two 
consequences of activating protein kinase C (PKC). The 
first and major effect is that activation of PKC through the 
use of biologically active phorbol esters, synthetic 
diacylglycerols or hormones, produces a marked inhibition in 
the activity of the enzymes responsible for metabolising the 
steroid substrate 4-androstene-3,17-dione, an effect which 
is apparently dependent upon protein synthesis. The other 
effect, which does not appear to be as important as the 
inhibitory effect, was seen only with the hormone 
angiotensin II and this was a stimulation in the activity 
of the enzymes metabolising 4-androstene-3,17-dione. The 
method by which each effect occurs will be considered 
separately.
4.9 (a) Inhibition of hepatic steroid metabolism.
An interesting finding from this study is that 
activation of PKC, which was probed by the use of the 
tumor-promoting, biologically active phorbol ester 
4p-phorbol-12-myristate-13-acetate (PMA), appears to inhibit 
hepatic steroid metabolism in a manner which is independent
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of any effect or direct involvement of the NADPH/cytochrome 
P450 enzyme system. Although this effect appears unusual 
when we consider that most regulation upon hepatic 
monooxygenases is through this system, the idea becomes more 
acceptable when we realise that there are very few reports 
about inductive or degradative effects on cytochrome P450 
levels in isolated rat hepatocytes, mediated by activation 
of PKC. Inductive effects upon cytochrome P450 levels have 
been widely reported for cyclic AMP acting through protein 
kinase A (Dokas & Kleinsmith, 1971; Johnson & Allfrey, 1972) 
and the effect of cyclic AMP is thought to be due to a 
stabilisation of post-translational events in an analagous 
manner to the effects reported for phenobarbitone and
3-methylcholantherene. Degradative effects of PKC upon 
cytochrome P450 are unknown at this time, although there is 
evidence that PKC may play a role in inhibiting induction of 
basal levels of cytochrome P450 (Steele & Virgo, 1988).
Direct effects of activating PKC upon levels of 
cytochrome P450 were not determined in this study, but the 
lack of reported effects of activated PKC upon cytochrome 
P450 implies that this is not the main way by which PKC 
affects hepatic function.
Activation of PKC, by phorbol esters, has been reported 
to cause the inhibition of some hepatic enzymes, such as 
pyruvate kinase (Soderling et al, 1986), glycogen synthetase 
(Ahmed et al, 1984) and the glucose transporter (Allard et 
al, 1987). These inhibitions of enzyme activity appear to 
occur as a consequence of phosphorylation of the enzymes, 
although enzyme inhibition can also occur as a consequence
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of inhibition of gene expression. Activation of PKC was 
found to inhibit the gene expression of phosphoenolpyruvate 
carboxykinase (Chu et al, 1987; Chu & Granner, 1986). The 
absence of any detectable phosphorylation after activation 
of PKC in this study suggests, that the effect of activated 
PKC to inhibit steroid metabolism may occur through an 
effect upon gene expression.
The half-life of the enzymes metabolising 4-androstene 
-3,17-dione are approximately 48 hours and it is unlikely 
that these enzymes are subject to acute effects upon gene 
expression effects. The effect upon steroid metabolism 
which we observe is a rapid effect, inhibition of enzyme 
activity can be seen after 5 minutes of treatment with PKC 
agonists. This implies that a rapidly turning over protein 
is the site of action for gene expression modulation.
As mentioned earlier (section 4.5 (e)) the use of 
cycloheximide suggests that inhibition of protein synthesis 
is occurring. We proposed several candidates for this 
inhibition by cycloheximide, including trans-acting factor 
AP-1 and the c-myc and c-fos proteo-oncogenes. A role for 
PKC in mediating an effect upon gene transcription to 
ultimately inhibit steroid metabolism seems more realistic 
when we consider a recent report by Deutsch and his group 
(1988). This group further extended the concept that 
activation of both protein kinase A (PKA) and PKC could 
stimulate gene expression by way of interactions of specific 
proteins with DNA control elements.
It is known that many genes are transcriptionally 
regulated by cyclic AMP and these genes contain a conserved
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sequence in the 5 '-flanking region that is identical or 
highly similar to the palindromic octamer TGACGTCA, the 
so-called cyclic AMP-responsive element (cAMP-RE)(Silver et 
al, 1987). A very similar symmetrical heptameric motif, 
TGACTCA (the PMA-responsive element, PMA-RE), or close 
relatives thereof, has been identified in many genes 
transcriptionally activated by phorbol esters (Angel et al, 
1987a; Angel et al, 1987b; Lee et al, 1987). It was shown 
(Montminey et al, 1986) that a protein called CREB bound 
preferentially to the 8 base pair (bp) cAMP-RE, while a 
nuclear protein AP-1, mentioned above as a possible target 
for cycloheximide action, with a molecular weight of 44-47kD 
on SDS-PAGE, could bind to the related 7 bp PMA-RE (Angel et 
al, 1987b; Lee et al, 1987). It is likely, therefore, that 
the transcriptional activities of the cAMP-RE and the PMA-RE 
consensus sequences are mediated by protein phosphorylation, 
initiated by the respective signal transduction events of 
adenylate cyclase activation to produce cyclic AMP and 
inositol phospholipid hydrolysis to produce diacylglycerol.
Because of the close similarity in consensus sequence 
between the two base pair motifs, the parallels in mechansim 
of action and the fact that the two transduction systems can 
interact at several levels (Imagawa et al, 1987; Emoto et 
al, 1988; Choi & Toscano, 1988), the capability of either 
consensus motif to respond to either second messenger analog 
was investigated (Deutsch et al, 1988). It was found that 
the functional properties of the related DNA elements could 
be dissociated by the addition or subtraction of a single 
base pair and that different DNA binding proteins interact
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with the 8bp or 7bp sequences.
It was found that PMA and cyclic AMP could respond 
synergistically on the 7bp motif (PMA-RE) but not on the 8bp 
motif (cAMP-RE). This implies that the two signal 
transduction systems converge at one of several levels, some 
of which have the following precedents;
(i) Activation of PKC (for example by phorbol esters) 
enhances cyclic AMP accumulation (Ritvos et al, 1987) 
perhaps by way of phosphorylation of an inhibitory G protein 
(Pyne et al, 1989; Gordeladze et al, 1988), phosphorylation 
of a stimulatory G protein (Summers & Cronin, 1988) or 
phosphorylation of the catalytic subunit of adenylate 
cyclase (Choi & Toscano, 1988; Summers et al, 1988).
(ii) Cyclic AMP activates PKC or translocates it to the 
nucleus (Cambier et al, 1987)
(iii) PKA and PKC phosphorylate the same protein, for 
example AP-1
(iv) Different proteins at the end of the PKA- and 
PKC-mediated phosphorylation cascades, for example CREB and 
AP-1, can bind to the 7bp motif (PMA-RE).
The ability of cyclic AMP alone to activate the 7bp 
motif (PMA-RE) but not for PMA to activate the 8bp motif 
(cAMP-RE) favours mechanisms i,ii and iii above. It has 
been reported, however, that the 7bp and 8bp motifs appear
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to bind different proteins* (Deutsch et al, 1988) and this 
favours model iv, although distinctly phosphorylated 
versions of the same protein may have different molecular 
masses. Clearly, these two potent DNA motifs, differing by 
lbp have different transcriptional and protein binding 
properties, but they share the property of cyclic AMP 
responsiveness, reflecting the complex interaction between 
these parallel signal transduction pathways.
Hence, an effect upon gene expression appears to be the 
most satisfactory explanation for activation of PKC causing 
inhibition of hepatic steroid metabolism. Based on the 
above literary evidence, we propose the following hypothesis 
for PKC-mediated inhibition of hepatic steroid metabolism.
Activation of PKC, either by phorbol esters, synthetic 
diacylglycerol or vasopressin, promotes a rapid activation 
of PKC as a consequence of translocation of the kinase to 
the cell membrane. Once activated, PKC causes a very rapid 
protein phosphorylation, which could possibly be a 
site-specific phosphorylation upon the trans-acting factor 
protein AP-1, which has been identified as a substrate for 
PKC. This phosphorylation is so rapid that it has occurred 
before we have begun to take samples in our phorphorylation 
study, and is probably the reason why we did not observe a 
change in the phosphorylation profile of the cell in the 
presence of phorbol ester.
Phosphorylation of AP-1 causes it to become activated , 
in a way which is unclear at the present time, but the 
activation prompts the binding of AP-1 to the 7bp motif 
TGACTCA, the so-called phorbol ester-responsive element
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(PMA-RE). Once the AP-1 f-actor and PMA-RE are coupled 
together, protein translation occurs, and the resulting 
proteins then act upon the enzymes metabolising 
4-androstene-3,17-dione to inhibit the activity of these 
enzymes. The synthesis of these unidentified proteins 
appears to be the site of action for cycloheximide, and it 
seems that cycloheximide acts in intact cells at a 
post-translational site to modify proteins produced from 
translation induced by AP-1. This hypothesis for the site of 
action of cycloheximide is supported by the evidence that 
the induction response of the 7bp motif (PMA-RE) to PMA is 
resistant to cycloheximide (Imbra & Karin, 1986; Imbra & 
Karin, 1987; Angel et al, 1987a) and also the increase in 
AP-1 activity is resistant to cycloheximide (Angel et al, 
1987b). The translation proteins which are produced by 
activation of PKC do not appear to be cytochrome P450 itself 
or the enzymes responsible for mediating steroid metabolism. 
They appear to be an, as yet, unidentified protein or set of 
proteins which can exert inhibitory actions upon the 
activity of hepatic steroid metabolising enzymes. The 
precise manner by which this inhibition is produced remains 
to be elucidated.
4.9 (b) Stimulation of hepatic steroid metabolism.
The only time stimulation of hepatic steroid metabolism 
was observed was when we employed the hormone angiotensin 
II. Angiotensin II is known to exert intracellular effects 
via activation of PKC (Garcia-Sainz et al, 1986; McAllister 
& Hornsby, 1988; Pfeilschifter, 1988) and also independently
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of PKC (Garcia-Sainz & Hemandez-Sotomeyor, 1986; Bouscarel, 
1988a). Some of the effects of angiotensin II are thought 
to be mediated by changes in cyclic AMP accumulation and it 
has been reported that high intracellular levels of cyclic 
AMP can cause a stimulation of hepatic steroid metabolism 
(L. Berry, Ph.D. thesis, 1988) in a similar manner to that 
which we have seen here with angiotensin II.
Angiotensin II has also been reported to act by 
increasing mRNA accumulation within the cell (Ben-Ari 
& Garrison, 1988).
It is conceivable that the increase in steroid 
metabolism which we observe with angiotensin II is due to an 
induction of cytochrome P450 levels. However, this 
hypothesis seems unlikely when we remember that 
4-androstene-3,17-dione is metabolised by both cytochrome 
P45O-dependent and cytochrome P45O-independent enzymes, and 
the activity of all the enzymes metabolising
4-androstene-3,17-dione are affected in a similar manner by 
angiotensin II. Also, induction of cytochrome P450 was only 
seen with supraphysiological concentrations of Cyclic AMP, 
and the concentration of angiotensin II which we employed 
(lOOnM) would not elevate intracellular cyclic AMP to 
anywhere near these concentrations, because cyclic AMP would 
be rapidly degraded by cyclic AMP phosphodiesterase.
The effect of angiotensin II to stimulate hepatic 
steroid metabolism can be most satisfactorily explained, 
again, by an effect upon gene expression.
It will be remembered from the above section (4.9(a)), 
that cyclic AMP can bind to both the 7bp motif (PMA-RE) and
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the 8bp motif (cAMP-RE) and it can have synergistic actions 
when it binds to the 7bp motif. As angiotensin has effects 
upon both cyclic AMP levels, which will activate PKA, and 
calcium levels, which will facilitate activation of PKC, the 
marked stimulatory effect of angiotensin II can be proposed 
to occur as follows.
Occupation of angiotensin II receptors can activate 
either PKA or PKC alone or possibly both together, in a 
manner which is regulated by the receptors themselves in a 
complex, and unexplained manner, based on the evidence of 
Bouscarel et al (1988b). The activated kinases then 
phosphorylate their selective transduction proteins, either 
CREB (Montminey et al, 1986) for PKA or AP-1 (Angel et 
al, 1987b) for PKC. These phosphorylated, and activated 
proteins, then bind to their respective base pair motifs and 
induce protein translation. The proteins produced in the 
presence of angiotensin confer a stimulatory effect upon the 
enzymes metabolising 4-androstene-3,17-dione. Whether or 
not the synthesis of these proteins can be inhibited by 
cycloheximide was not determined in this study.
The reason we see such a marked stimulation with 
angiotensin II may be accounted for, based on the fact that 
angiotensin II induces the production of cyclic AMP, which 
has the ability to bind to either the 8bp cAMP-RE or the 7bp 
PMA-RE. If cyclic AMP binds to both motifs at once, a 
synergistic effect upon protein transduction will occur, 
possibly as a result of both motifs phosphorylating AP-1, 
and ultimately producing the marked stimulation which we 
observe.
1 7 8
An investigation into* the effect of angiotensin II 
acting in the presence of the selective PKA inhibitor KT5720 
(section 4.5(c)) would be advantageous in order to probe an 
involvement of PKA in angiotensin II action to stimulate 
hepatic steroid metabolism.
It is equally possible that PKC activated by 
angiotensin II selectively produced proteins which 
stimulated the activity of the hepatic steroid metabolising 
enzymes, whilst activation of PKC by phorbol esters, 
synthetic diacylglycerols or vasopressin induces a selective 
production of inhibitory proteins. Such a selective 
production of inhibitory or stimulatory proteins through the 
actions of the different DNA motifs remains to be 
estabilished.
4.9 (c) Conclusion to section 4.9
In this section we have tried to elucidate the precise 
intracellular mechanism by which activation of PKC can 
either inhibit or stimulate steroid metabolism in isolated 
rat hepatocytes. By dissecting out some of the various ways 
by which PKC is known to act, such as protein phosphoryla­
tion and enhancement of gene expression, we arrived at the 
hypothesis that activation of PKC produces proteins, through 
an enhancement of gene transcription, which appear to 
possess the ability to modulate the activity of hepatic 
steroid metabolising enzymes, in a manner which remains to 
be clarified.
The issue becomes more complicated in the case of the 
hormone angiotensin II, which appears to possess the ability
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to modulate steroid metabo-lising enzyme activity through a 
pathway which involves an interaction between both PKA and 
PKC cascade systems. The processes by which such a cascade 
interaction may be regulated can only be speculated upon at 
the present time.
The proteins produced by an enhancement of gene 
expression do not appear to be the enzymes metabolising 
4-androstene-3,17-dione themselves, cytochrome P450 or other 
proteinaceous components of the hepatic monooxygenase 
system. To determine the nature of these proteins is an 
exciting future prospect.
4.10 Physiological implications
The results of this study have shown that activation of 
the phosphorylating enzyme, protein kinase C (PKC), by 
hormones known to induce inositol phospholipid turnover can 
produce marked inhibitory or stimulatory effects upon 
hepatic monooxygenases. The involvement of PKC in these 
effects is implicated by the fact that a variety of 
compounds, which are known to act either completely or at 
least partly, through activation of PKC all produce the same 
effect. The predominant effect upon activation of PKC is to 
cause inhibition of the activity of hepatic monooxygenases.
In vivo effects of various hormones have already been 
suggested to be a consequence of activating PKC. Vasopress­
in can act through PKC to inhibit ureogenesis in hepatocytes 
(Garcia-Sainz & Hernandez-Sotomayor 1987), it can 
inactivate glycogen synthetase (Blackmore et al, 1986) and 
it can induce the hydrolysis of various cellular
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glycerophospholipids (Cabot et al, 1988). The involvement 
of PKC has been implicated in the actions of other hormones 
such as thyroid stimulating hormone (Ginsberg et al, 1988), 
gonadotropin releasing hormone (McArdle et al, 1988), 
parathyroid hormone (Yamaguchi et al, 1988), 
adrenocorticotrophic hormone (ACTH) (Reisine & Zatz, 1987), 
insulin (Acevedo et al, 1989; Cooper et al, 1987), the 
interleukins (Baumann et al, 1988), and prolactin (Buckley 
et al, 1988).
The inhibitory effects of vasopressin mentioned above 
suggest that activation of PKC and its subsequent intracell­
ular effects are one of the main ways of controlling hepatic 
monooxygenase activity within the liver.
Direct inhibition of hepatic monooxygenases by the 
activation of PKC has not been widely reported and such 
reports which exist are contradictory. Inhibitory effects 
upon hepatic monooxygenases in the past have been attributed 
to changes in cyclic AMP levels either directly or 
indirectly (Irvine et al, 1986; Heyworth et al, 1984c).
Glucagon, however, has previously been reported (Hussin 
et al, 1988) to mediate stimulation of phosphatidylinositol-
4,5-bisphosphate (PIP2 ) hydrolysis, which results in 
activation of PKC, and this is thought to be the process by 
which glucagon inhibits steroid metabolism. Inhibitory 
effects upon hepatic monooxygenases due to hormonal 
activation of PKC will hopefully be closely investigated in 
the future.
Although reports in the past have suggested that cyclic
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AMP and protein kinase A (PKA) are important for mediating 
effects upon hepatic monooxygenases, this study and previous 
work in our laboratory implies that inhibition of hepatic 
steroid metabolism can be directly affected by activation of 
PKC (present study) and also susequent to activation of PKC 
by activated PKA (L. Berry, Ph.D. thesis, 1988). It appears 
that cyclic AMP alone is unable to mediate inhibitory 
effects upon hepatic steroid metabolism and PKA has to 
activate PKC in order to mediate an inhibitory effect. 
Whether or not PKA directly activates PKC to cause this 
effect or perhaps has some unknown effect upon PKC remains 
to be determined.
Another finding from this study was that activation of 
PKC by different agonists (section 4.3) had no effect upon 
the sexually differentiated enzyme profile from either male 
or female rats and the effect upon inhibition of all steroid 
metabolising enzymes occurred non-specifically in rats of 
either sex. This implies that activation of PKC is not the 
mechanism by which the postulated in vivo feminising factor, 
now thought to be growth hormone (Guzelian et al, 1988) 
exerts its effects. Indeed, growth hormone is thought to 
act directly upon hepatocytes to feminize the cytochrome 
P450 phenotype, without a requirment for any transduction 
system. The action of growth hormone to feminise cytochrome 
P450 phenotype is thought to require hormonal influence and 
it has recently been shown that a combination of growth 
hormone, thyroxine and dexamethasone can mediate 
feminisation of male rat steroid metabolism (P. Gulati, 1989 
in press). The combination of these hormonal factors is the
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probable cause of feminisa-tion, but the ultimate effect 
appears to be independent of PKC (French et al, 1989).
Although PKC is a recognised mediator of intracellular 
hormonal effects, both in the liver and throughout the body, 
its role in mediating changes in steroid metabolism has not 
been previously reported. The prospect of fully elucidating 
the mechanism for regulation of hepatic monooxygenases by 
PKC is one to look forward to.
4.11 Pharmacological implications.
Although inductive effects of compounds such as 
phenobarbitone (Hutterer et al, 1975) and
3-methylcholanthrene (Byus et al, 1976) have been attributed 
to an enhancement of cyclic AMP accumulation and/or 
activation of protein kinase A (PKA), such a role for 
protein kinase C (PKC) activation and turnover of inositol 
phospholipids has not been proposed. As the two cascade 
systems are subject to interregulation, it may be that an 
involvement of PKC in induction is being masked by an 
overriding action of PKA, or it may be that PKA and PKC act 
in close concert to produce subsequent effects upon 
induction.
It has been reported that phenobarbitone can inhibit 
PKC activation in rat brain (Chauhan & Brockerhoff, 1987) 
and it is possible that PKC acts in vivo to suppress 
induction of cytochrome P450, but once PKC is inhibited,
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induction then occurs as ar consequence of activation of PKA. 
The relevance of such a suppression of induction of 
cytochrome P450 remains to be determined.
The evidence of Pyerin and his group (1987) indicating 
that different isozymes of cytochrome P450 can be 
preferentially phosphorylated by either PKA or PKC is also 
another area in which a more extensive investigation is 
required.
4.12 General conclusions.
This study has shown, that in isolated rat hepatocytes, 
stimulation of the signal transduction system which 
ultimately activates the enzyme protein kinase C (PKC), 
produces a distinctive effect upon the activity of hepatic 
steroid metabolising enzymes. Activation of PKC with a 
variety of different agonists produces the same effect upon 
steroid metabolising enzymes, implying that activation of 
PKC is an important in vivo modulator of hepatic 
monooxygenase activity. The effect produced on the steroid 
metabolising enzymes is either a predominant inhibition of 
enzyme activity or a less important stimulation. The 
ultimate effect appears to depend upon the forces 
controlling signal transduction.
Inhibition occurs as a consequence of directly 
activating PKC and inhibition of steroid metabolising enzyme
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activity appears to be a property of agonists which mediate 
their intracellular actions solely through the PKC 
transduction pathway. The inhibitory effect upon steroid 
metabolising enzymes may be produced after modulation of 
gene expression by activated PKC.
Stimulation of steroid metabolising enzymes occurs in 
the presence of a hormone which can exert actions through 
both transduction systems, angiotensin II being the example 
we have used. In order to produce a stimulation of steroid 
metabolising enzyme activity, a complex interaction system 
appears to be at work between the two cascade systems and it 
is this interaction, which is as yet unclarified, which 
determines how the stimulation occurs. It is probable that 
gene expression is also a controlling factor in producing 
this stimulation.
We propose that activation of the signal transduction 
pathway responsible for controlling the activation of the 
enzyme protein kinase C is an important intracellular 
mechanism by which hormones can modulate the activity of 
hepatic monooxygenases.
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